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Bronchiectasis is a common chronic debilitating respiratory condition. Patients suffer 
daily cough, excess sputum production and recurrent chest infections because of 
inflamed and permanently damaged airways. The pathogenesis of bronchiectasis is 
poorly understood. Pulmonary pathology shows excess neutrophilic airways 
inflammation, but despite this over two thirds of patients are chronically infected with 
potential pathogenic microorganisms. The acute inflammatory response is a protective 
mechanism that is evolved to eliminate invading organisms and should ideally be self-
limiting and lead to complete resolution. The driver for persistent neutrophilic airway 
inflammation in bronchiectasis is unknown, but infection is considered to play a 
major role.  
 
AIMS 
The main aims of this thesis were to: (i) Characterize neutrophils in the serum and 
airways in bronchiectasis in the stable state and during exacerbations; (ii) Cohort 
study to establish if LXA4 deficiency correlates with disease severity (iii) 
Characterize lipids in bronchiectasis airways and peripheral blood to establish the 
correlation of LXA4  to disease severity; (iv) To investigate a potential mechanism for 
low levels of LXA4 in bronchiectasis, lipoxin biosynthetic genes expression will be 
measured; (v) Assess the anti-inflammatory and pro resolution effect of LXA4 on 
neutrophils and monocyte derived macrophages from healthy volunteers; (vi) Assess 
the anti-inflammatory and pro resolution effect of LXA4 on neutrophils during 
exacerbations in bronchiectasis and community acquired pneumonia. 
 
Methods 
(I) To establish the serum neutrophil subtype in stable state and following antibiotic 
treatment in patients with bronchiectasis, the following studies were done.  
Inclusion criteria: Patients aged 18-80 were recruited. All had an established 
radiological diagnosis of bronchiectasis (CT of the chest). Patients had clinically 
significant bronchiectasis, aetiology being either idiopathic or post infection.     
Exclusion Criteria: current smokers or ex-smokers of less than 1 year; >20 pack year 
history; cystic fibrosis; active allergic bronchopulmonary aspergillosis; active 
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tuberculosis; poorly controlled asthma; severe COPD requiring nebulised 
bronchodilators or long term oxygen therapy; patients on aspirin or leukotriene 
inhibitors, pregnancy or breast feeding, active malignancy.  
 
A. 6 patients with mild bronchiectasis, 6 patients with severe bronchiectasis and 6 
healthy volunteers were recruited. Serum and airways neutrophils were subsequently 
isolated. Neutrophil apoptosis, CD11b and CD62L expression, myeloperoxidase 
release, superoxide generation, phagocytosis and killing of GFP labeled bacteria were 
assessed. 
 
B. To compare serum with airways neutrophils function, bacterial phagocytosis and 
killing of GFP labeled bacteria was done, with both serum and airways neutrophils. 
Samples were obtained from the above group of patients.  
 
C. To establish neutrophil function following antibiotic treatment, 6 bronchiectasis 
patients at the beginning (day1) and the end (day14) of intravenous antibiotic therapy 
for an exacerbation were studied. As a control group, 6 community acquired 
pneumonia patients at the beginning (day1) and the end (day 5) of intravenous 
antibiotic therapy for infection were studied. Induced sputum and peripheral blood 
was taken at day1 and 5, where able. Phagocytosis and killing of GFP labeled bacteria 
was assessed and the two groups compared.  
 
(II) To address if lipoxin A4 deficiency correlates with disease severity, a cohort study 
was done in bronchiectasis patients. 169 patients were recruited and followed up for 1 
year. Assessments done were Bronchiectasis severity index, systemic inflammatory 
markers (white cell count, ESR and c-reactive protein), Forced Expired Volume in 
1sec, Forced Vital Capacity and its ratio, antibiotic courses in 1 year, hospital 
admissions in 1 year, sputum microbiology, quality of life assessments by Leicester 
Cough Questionnaire and St. Georges Respiratory Questionnaire, interleukin 8, 
myeloperoxidase, neutrophil elastase and leukotriene B4 (from sputum).  
 
(III) To assess effect of lipoxin on disease severity, 6 healthy volunteers, 10 patients 
with mild disease, 15 with moderate and 9 with severe disease were recruited. Disease 
severity was calculated as per the bronchiectasis severity index. All participants had 
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60mls of blood taken and underwent a bronchoscopy. Two segments of the lungs 
were washed out from bronchiectasis patients, an area affected by bronchiectasis and 
an area unaffected by bronchiectasis. This led to patients acting as their own internal 
control. Serum and airways neutrophils (from both segments) were subsequently 
isolated. 
Assessments done were systemic inflammatory markers (white cell count, ESR and c-
reactive protein), serum lipoxin A4 and the cathelicidin LL-37, Forced Expired 
Volume in 1sec, Forced Vital Capacity and its ratio, transfer factor for carbon 
monoxide, antibiotic courses in 1 year, hospital admissions in 1 year and sputum 
microbiology. Phagocytosis and bacterial killing were assessed by both serum and 
airways neutrophils. From bronchoalveolar lavage fluid (BALF), I measured 
myeloperoxidase and neutrophil elastase. For both serum and BALF, lipidomics were 
obtained. 
 
(IV) To address the impact of anatomic compartment, gene expression was measured 
in from endobronchial brushings from the same cohort of bronchiectasis patients and 
controls as above, where samples were available. qPCR was performed for the 
following eicosanoid biosynthetic genes- 5 Lipoxygenase (LOX), 15 LO-A, 15LO-B 
and leukotriene (LT) A4 hydrolase. 
 
 (V) To assess the anti inflammatory and pro resolution effect of LXA4 on neutrophils 
and monocyte derived macrophages from healthy volunteers, freshly isolated PMN 
will be treated with LXA4 or vehicle control. Spontaneous apoptosis was measured. 
fMLF and cytochalasin B was added and the inflammatory response assessed 
measuring myeloperoxidase (MPO), free neutrophil elastase (NE), CD11b, CD18 and 
CD62L. Human monocytes and PMNs were isolated from bronchiectasis patients. 
Following differentiation, LXA4 treated or control adherent, washed MDMs will be 
incubated with apoptotic stained PMNs. Efferocytosis was analyzed by flow 
cytometry. 
 
(VI) To establish the effect of Lipoxin A4 on neutrophil function following antibiotic 
treatment, the same study group used to evaluate aim 1 was taken. As a control group, 
6 community acquired pneumonia patients at the beginning (day1) and the end (day 5) 
of oral or intravenous antibiotic therapy for infection were studied. Induced sputum 
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and peripheral blood was taken at day1 and 5, where able.  
Phagocytosis and killing of GFP labeled bacteria and the effect of Lipoxin A4 was 
assessed and the two groups compared. Serum and sputum lipidomics were obtained 
in bronchiectasis exacerbations on day 1 and day 14. Serum lipidomics was obtained 




(I) Neutrophil sub type study (Studied on healthy volunteers/ mild/ severe 
bronchiectasis) 
Peripheral blood neutrophils from bronchiectasis patients showed that there was 
significantly more viable neutrophils in mild and severe bronchiectasis compared to 
healthy volunteers, p=0.002 and p=0.005 respectively. In addition, there was 
significantly less apoptotic neutrophils in mild and severe bronchiectasis compared to 
healthy volunteers, p=0.0003 and p<0.0001 respectively. There was a significantly 
higher level of CD11b in the mild (p=0.01) and severe bronchiectasis (p=0.01) 
compared to healthy volunteers. There was more CD62L shedding (p=0.02) and 
myeloperoxidase release (p=0.04) in bronchiectasis compared to healthy volunteers. 
There was lesser phagocytosis in mild (p=0.04) and severe (p=0.03) bronchiectasis 
compared to healthy volunteers. This led to lesser bacterial killing in mild (p=0.04) 
and severe (p=0.0004) bronchiectasis compared to healthy volunteers. 
 
On comparison of serum to airways neutrophils, peripheral blood neutrophils had 
higher phagocytic capacity (p<0.0001 for both mild and severe) and bacterial killing 
(p=0.02 for both mild and severe) than airways neutrophils. 
During exacerbations, there was significantly higher phagocytosis (p=0.02) and 
killing at the end of exacerbation (p=0.03).  
Similarly, in community-acquired pneumonia, there was significantly higher 
phagocytosis (p=0.03) and killing at the end of exacerbation (p=0.03). When I 
compared bronchiectasis exacerbations with pneumonia, I found although there was 
no difference in phagocytosis, there was significantly higher bacterial killing in 
pneumonia than bronchiectasis, both at the start (p<0.0001) and at the end (p<0.0001) 
of infection.  
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(II) Longitudinal cohort study in bronchiectasis 
In patients sufficient in serum LXA4 (>135 pg/ml) they had lesser antibiotic courses 
for an exacerbation (p=0.02), lesser levels of LTB4 (p<0.0001) and myeloperoxidase 
(p<0.0001), over the course of a year compared to lipoxin deficient patients.  
 
(III) Bronchoscopy study (Studied on healthy volunteers/ mild/ severe bronchiectasis) 
In serum, there was significantly higher levels of Lipoxin A4 detected in healthy 
volunteers compared to bronchiectasis patients, p=0.04. 
In peripheral blood neutrophils, there was a statistically significant improvement in 
phagocytosis by LXA4 in mild, moderate and severe bronchiectasis groups, p=0.01, 
p<0.0001 and p=0.01 respectively. Additionally, there was a statistically significant 
improvement in bacterial killing by LXA4 in mild, moderate and severe 
bronchiectasis groups, p=0.04, p=0.03 and p=0.01 respectively, in a dose dependent 
manner. 
In airways neutrophils, in the unaffected segments, there was no significant 
improvement in phagocytosis with LXA4 100nM in any of the groups. In the affected 
segments, there was a statistically significant improvement in phagocytosis by LXA4 
100nM in the mild, moderate and severe bronchiectasis groups by LXA4 100nM, 
p=0.01, p=0.02 and p=0.04 respectively.  
In the unaffected segments, there was a statistically significant improvement in 
bacterial killing with LXA4 100nM in the severe group of patients only; p=0.02. In 
the affected segments, there was a statistically significant improvement in killing by 
LXA4 in the mild, moderate and severe bronchiectasis groups by LXA4 100nM, 
p=0.02, p=0.0005 and p=0.04 respectively.  
There were significantly higher levels of myeloperoxidase (p=0.002) and neutrophil 
elastase (p=0.005) detected in bronchoalveolar lavage fluid from severe patients.  
Serum lipidomics showed that there were significantly higher levels of PGE2, 15 
HETE and LTB4 in patients with moderate-severe disease compared to healthy 
controls, p=0.03, p=0.03 and p=0.02 respectively. BALF lipidomics showed that there 
were significantly higher levels of PGE2, 5HETE and 15 HETE in patients with 
moderate-severe disease compared to patients with mild disease and healthy 
volunteers, p<0.0001, p=0.004 and p=0.005 respectively. There were significantly 
higher levels of 9HODE and LTB4 in moderate-severe patients compared to mild 
patients and healthy volunteers, p=0.04 and p<0.0001 respectively.   
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(IV) Gene expression (Studied on mild and moderate- severe bronchiectasis) 
The delta Ct values for 5-LOX (p=0.01) and 15-LO-B (p=0.01) were both 
significantly increased in subjects with moderate-severe bronchiectasis compared 
with subjects with mild bronchiectasis. Delta Ct value of LTA4 hydrolase was 
significantly decreased in moderate-severe bronchiectasis compared to mild 
bronchiectasis (p=0.007), indicating increased expression of in moderate-severe 
bronchiectasis. LTA4 hydrolase was the most abundant RNA (lowest DCt) in 
bronchial brushings. 
 
(V) In vitro studies of lipoxin on neutrophil function (Studied on healthy volunteers/ 
mild/ severe bronchiectasis) 
Lipoxin was unable to modulate spontaneous apoptosis in any of the three groups; 
p=0.4, p=0.5 and p=0.4 in healthy, mild and severe bronchiectasis, respectively. There 
was a significant reduction in upregulation of CD11b by LXA4 in a dose dependent 
manner in healthy volunteers, mild bronchiectasis and severe bronchiectasis patients; 
p= 0.005, p=0.008 and p=0.01 respectively. There was a significant improvement in 
shedding of CD62L by LXA4 in a dose dependent manner in healthy volunteers, mild 
bronchiectasis and severe bronchiectasis patients; p=0.01, p=0.03 and p=0.04 
respectively. There was a significant reduction in myeloperoxidase release by LXA4 
in healthy volunteers, mild bronchiectasis and severe bronchiectasis patients; p= 0.02, 
p=0.04 and p=0.02 respectively. There was significant reduction of superoxide release 
by LXA4 in healthy volunteers (p=0.004) and severe bronchiectasis (p=0.03) but not 
on mild bronchiectasis (p=0.1). Lastly, on assessing bacterial phagocytosis and 
killing, there was a significant increase in phagocytosis pre treatment with LXA4, led 
to a dose dependent increase in phagocytosis in healthy volunteers (p=0.0001), mild 
bronchiectasis (p<0.0001) and severe bronchiectasis (p=0.03). Similarly, Lipoxin A4 
led to a dose dependent increase in killing of GFP PAO1 in healthy volunteers 





In peripheral blood neutrophils, LXA4 was able to significantly improve bacterial 
phagocytosis (start p=0.03, end p=0.004) and killing (start p=0.01, end p=0.007) 
(blood neutrophils) both at the start and end of pneumonia exacerbations. 
In airways neutrophils, LXA4 was did not improve phagocytosis but improved 
bacterial killing at the start (p=0.02) and end (p=0.01) of exacerbation in 
bronchiectasis.  
In community acquired pneumonia, LXA4 was able to significantly improve bacterial 
phagocytosis (start p=0.01, end p=0.03) and killing (start p=0.04, end p=0.01) both at 





(i) Peripheral blood neutrophils are reprogrammed and persist longer in 
bronchiectasis. These reprogrammed neutrophils are the key contributors to the 
ongoing persistence of inflammation in bronchiectasis.  
(ii) There is a dysregulation of lipid mediators in the serum as well as in the airways 
of bronchiectasis patients. Lipoxin is able to override the pro survival signals in these 
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“This affection of the bronchia is always produced by chronic catarrh, or by some 
other disease attended by long, violent, and often repeated fits of coughing.”  
R.T.H. Laennec, 1819.  
 
1.1.1. DEFINITION AND EPIDEMIOLOGY 
 
Bronchiectasis is a common chronic debilitating respiratory condition. First described 
by Laennec in 1819, then by Osler in the late 1800s, and then further detailed by Reid 
in 1950s, bronchiectasis has since undergone significant changes in prevalence, 
etiology, diagnosis and management (Reid 1950). Patients suffer daily cough, excess 
sputum production and recurrent chest infections because of inflamed and 
permanently damaged airways (Bilton 2008). Pulmonary pathology shows excess 
neutrophilic airways inflammation, but despite this over two thirds of patients are 
chronically infected with potential pathogenic microorganisms (Angrill 2002).   
 
Reid defined bronchiectasis as permanent dilatation of the airways, a term that has 
stayed with the disease for more than 60 years. Bronchiectasis can be characterised by 
the pathologic or radiographic appearances. Cylindrical or tubular bronchiectasis is 
characterised by dilated airways; varicose bronchiectasis (so named because its 
appearance is similar to that of varicose veins) is characterized by focal constrictive 
areas along the dilated airways that result from defects in the bronchial wall; and 
saccular or cystic bronchiectasis is characterized by progressive dilatation of the 
airways, which leads to formation of large cysts or saccules and is always indicative 
of the most severe form of bronchiectasis (figure 1) (Reid 1950). 
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Figure 1. Bronchial dilatation in bronchiectasis as defined by Reid et al. 
 
Quint and colleagues, used the Clinical Practice Research Datalink for participants 
registered between January 2004 and December 2013, to determine incidence, 
prevalence and mortality associated with bronchiectasis in the UK and investigate 
changes over time. The incidence and point prevalence of bronchiectasis increased 
yearly during the study period. Across all age groups, they found that the incidence in 
women increased from 21.2 per 100000 person-years in 2004 to 35.2 per 100000 
person-years in 2013 and in men from 18.2 per 100000 person-years in 2004 to 26.9 
per 100000 person-years in 2013. The point prevalence in women increased from 
350.5 per 100 000 in 2004 to 566.1 per 100000 in 2013 and the numbers in men from 
301.2 per 100 000 in 2004 to 485.5 per 100000 in 2013. Comparing mortality rates in 
women and men with bronchiectasis in England and Wales (n=11 862) with mortality 
rates in the general population, data showed that in women the age-adjusted mortality 
rate for the bronchiectasis population was 1437.7 per 100000 and for the general 
population 635.9 per 100000. In men, the age-adjusted mortality rate for the 
bronchiectasis population was 1914.6 per 100 000 and for the general population 
895.2 per 100000. Bronchiectasis is surprisingly common and is increasing in 
incidence and prevalence in the UK, particularly in older age groups. Bronchiectasis 
is associated with a markedly increased mortality (Navaratnam et al 2016). 
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1.1.2. PATHOPHYSIOLOGY 
The pathogenesis of bronchiectasis is poorly understood. Pulmonary pathology shows 
excess neutrophilic airways inflammation (Angrill 2001), but despite this over two 
thirds of patients are chronically infected with potential pathogenic organisms 
(Angrill 2002). The affected areas may show a variety of changes, including 
transmural airways inflammation, oedema, scarring, and ulceration. Patients suffer 
daily cough, daily sputum production and recurrent chest infections, leading to an 
inflammatory disease condition. The acute inflammatory response is a protective 
mechanism that is evolved to eliminate invading organisms and should ideally be self-
limiting and lead to complete resolution (Serhan 2007, Mantovani et al 2011, 
Medzhitov 2010). However there is failure of resolution of inflammation in 
bronchiectasis, leading to irreversible damage and dilatation of the bronchial airways 
with loss of mucociliary function (Cole 1984). It is assumed there are intrinsic 
abnormalities of the innate and adaptive immune systems that predispose to impaired 
clearance of respiratory pathogens and exaggerated inflammatory responses 
secondary to abnormal immune regulation. Perhaps, repeated micro-aspiration of 
upper airway organisms during recurrent respiratory infections when mucociliary 
clearance is temporarily compromised may help establish lower airway infection. The 
driver for persistent neutrophilic airway inflammation in bronchiectasis is unknown, 
but infection is considered to play a major role (Angrill 2001). This is easy to 
understand as part of a ‘vicious circle’ which was first described by Cole and 
colleagues and all of our current management strategies are directed towards breaking 
this circle (Cole 1984).   
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1.1.3. VICIOUS CIRCLE 
 
Described by PJ Cole in 1984 (Cole 1984), there is a ‘vicious circle’ (figure 2) of 
airways inflammation and bacterial infection in bronchiectasis. The lung is 
continuously exposed to inhaled pathogen and it is the primary and secondary defense 
of the lung that maintains sterility of the lung. The excessive neutrophilic airways 
inflammation leads to damage of the bronchial wall and paradoxically promotes more 
airways inflammation and bacterial infection creating a vicious cycle (Barker 2002, 
Cole 1984). During natural resolution, polymorphonuclear neutrophils are required for 
antimicrobial defense (Medzhitov 2010), but these cells must then apoptose and are 
removed from the inflammatory site by macrophages (Henneke and Golenbock 2004, 
Rossi et 2006, Dinarello 2012). Is this natural resolution impaired in bronchiectasis? 
There are no studies exploring the resolution mechanism in bronchiectasis or perhaps 










Although there are many different disease processes, bronchiectasis is the final 
pathological end point. All the different etiologies ultimately lead to destruction of the 
airway epithelium, damage of the mucociliary clearance thereby leading to persistent 
infection and inflammation. Part of the assessment of patients with bronchiectasis 
involves identifying where possible the primary insult and allowing specific 
management. Identifying an underlying cause may direct appropriate management. 
Examples include the commencement of immunoglobulin replacement therapy in 
patients with common variable immune deficiency and considering oral corticosteroid 
treatment in those with allergic bronchopulmonary aspergillosis. A significant 
proportion of adults have bronchiectasis secondary to previous pneumonia or other 
lower respiratory tract infections but often no cause is identified (Pasteur MC et al 
BTS bronchiectasis guidelines 2010). All other causes are much less frequent.  Causes 
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Table 1. Etiology, clinical findings and relevant investigations in bronchiectasis. 
HRCT= high resolution computed tomography; CFTR= cystic fibrosis 




1.1.4.1 Post infectious 
 
Lower respiratory tract infections are associated with the etiology of bronchiectasis 
and most common is bacterial pneumonia. Pertussis, pulmonary tuberculosis, 
mycoplasma and viral pneumonia (particularly adenoviruses and measles but also 
influenza and respiratory syncytial viruses) have, in addition, all been linked directly 
to permanent lung damage and bronchiectasis (Pasteur et al 2000). Post-tuberculous 
bronchiectasis is often segmental or lobar in the area primarily affected (Scala et al 
2000). In studies investigating the aetiology of bronchiectasis in those over the age of 





1.1.4.2. Mycobacterium tuberculosis and non-tuberculous mycobacteria 
 
Bronchiectasis may result from pulmonary Mycobacterium tuberculosis infection, 
with the incidence reflecting the prevalence of tuberculosis in the population. It is also 
increasingly recognised that environmental mycobacteria are associated with localised 
or widespread bronchiectasis. Environmental mycobacteria have been isolated in 2% 
and 10% of random sputum specimens from patients with bronchiectasis, but the 
clinical significance is unclear (Fowler et al 2006). Patients with Mycobacterium 
avium complex (MAC) infection may develop bronchiectasis over years. Middle-aged 
or elderly women are particularly prone to MAC infection and this is known as Lady 
Windermere disease which particularly affects the middle lobe or the lingula (Reich 
and Johnson 1992). However, isolation of an environmental mycobacterial species 
should not necessarily be interpreted as pathogenic. Persistent isolation (colonisation) 
may occur without any change in clinical status. Careful follow-up is mandatory 
because colonisation can change to infection. Patients should be reassessed if there is 
a change in clinical features, change in sputum conventional microbial culture, there 
is a rapid decline in spirometry, or if there are characteristic HRCT changes 
(exudative ‘tree-in-bud’ bronchiolitis, mucus plugging, cavitating nodules, rapid 
progression of bronchiectasis or indeed cavitatory disease; (figure 3)). The species 
isolated will also influence the likelihood of infection (M avium complex, M kansasii, 
M malmoense), for example mycobacteria such as M gordonae maybe just a 
contaminant (Pasteur MC et al BTS bronchiectasis guidelines 2010). 
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Figure 3a. HRCT showing tuberculous granuloma in bronchiectasis (as indicated by 







Definition of an exacerbation in bronchiectasis  
 
The British Thoracic Society guideline (figure 4) recommends antibiotics for 
exacerbations that present with an acute deterioration (usually over several days) with 
worsening local symptoms (cough, increased sputum volume or change of viscosity, 
increased sputum purulence with or without increasing wheeze, breathlessness, 













1.3. SPUTUM MICROBIOLOGY AND COLONIZATION 
 
In bronchiectasis, the normally sterile airways are chronically colonised with 
pathogenic organisms in about 70% of patients (Angrill 2002). In adults, definitions 
of colonization have included at least three isolates of an organism over a period of at 
least 3 months; and at least two isolates 3 months apart over 1 year (Pasteur MC et al 
BTS bronchiectasis guidelines 2010). 
 
Common gram-positive organisms colonising the airways include Streptococcus 
pneumoniae and Staphylococcus aureus (both methicillin-sensitive and methicillin-
resistant). Gram-negative pathogens include non-capsulated nontypable Haemophilus 
influenzae, Moraxella catarrhalis, Klebsiella, Enterobacter and non-mucoid and 
mucoid Pseudomonas aeruginosa (Angrill et al 2002). The type of bacterial infection 
is important in the determination of the patient’s prognosis. Studies have shown that 
patients colonised with Pseudomonas aeruginosa usually have worse symptoms, 
worse health-related quality of life and accelerated decline in forced expiratory 
volume over one second (FEV1) (Martinez-Garcia et al 2007).  
 
Recently, Finch and colleagues collected data from 21 observational studies that 
included a total of 3683 patients, comparing patient with P. aeruginosa to those 
without it. They concluded that P. aeruginosa was associated with a three fold 
increased risk of death and an increase in hospital admissions and exacerbations in 












The frequency of occurrence of the microorganisms is shown in figure 5 (Chalmers et 
al 2012). 
 






















1.3.1. Haemophilus influenzae 
 
In bronchiectasis, 39% of the patients are colonized with Haemophilus influenzae 
(Chalmers et al 2012). It is a small (1 µm X 0.3 µm), non-motile, pleomorphic, gram-
negative coccobacillus. There are both capsulated and non-capsulated (also known as 
nontypable) strains. It has now been recognized that NTHi (nontypable Haemophilus 
influenzae) is a major cause of respiratory infection, which tends to be chronic and 
recurrent and includes sinusitis, otitis media, tonsillitis, pneumonia and chronic 
bronchitis and systemic infection (Murphy 2001). In the context of infection, it has 
the capacity to live intracellularly especially in macrophages (Craig et al 2002). In a 
study done by King et al, they confirmed that NTHi was the most commonly isolated 
H influenzae in bronchiectasis (King et al 2003). 
 
There is no widely used effective vaccine for NTHi. There have been problems of 
antigenic variability and finding a suitable animal model. Most work has focused 
generally upon enhancing humoral immunity. Developing a vaccine to enhance T 
lymphocyte responses to NTHi may be important (Williams et al 1988).  
 
H influenzae is the most common pathogen isolated from sputum of bronchiectasis 
patients. Most bronchiectasis patients with chronic NTHi infection are able to 
mount a highly effective humoral immune response that prevents systemic 
infection. H influenzae die within 3 hours hence to maximize the chances of 
isolating H influenzae, sputum specimens should reach the microbiology laboratory 
within 3h. This should be done routinely prior to starting antibiotic therapy for 
exacerbations. The choice of antibiotic and the duration of antibiotic therapy for 
treating exacerbations with H influenzae infection are summarized in table 2 and 





1.3.2. Pseudomonas aeruginosa 
P. aeruginosa is a gram-negative bacillus (non capsulate and non sporing) that affects 
particularly the lower respiratory tract (Banerjee and Stableforth 2000). Without any 
treatment, P. aeruginosa infection persists in spite of the recruitment of the host’s 
defence mechanisms and leads to decreased respiratory function (Dudley et al 2008).  
 
In bronchiectasis, chronic infection with P. aeruginosa is observed in 24-33%  
(Pasteur et al 2000) patients. Early aggressive antibiotic treatment is recommended 
and an attempt should be made to eradicate it (Pasteur MC et al BTS bronchiectasis 
guidelines 2010). The BTS guidelines recommends that an attempt to eradicate P. 
aeruginosa should be made with high dose oral ciprofloxacin 750mg BD, for 2weeks 
(Pasteur MC et al BTS bronchiectasis guidelines 2010). Failing this, it is 
recommended to administer intravenous or nebulised anti pseudomonal antibiotic for 
2-4weeks (Pasteur MC et al BTS bronchiectasis guidelines 2010). However, careful 
monitoring of renal function and side effects of high doses of antibiotics should be 
considered and treatment should be based on a balance of benefits outweighing risks. 
In a recent single blind randomised trial by Orriols and colleagues, they showed that 3 
months of nebulised tobramycin following a short course of intravenous antibiotics 
may prevent bronchial infection with P. aeruginosa and has a favourable clinical 
impact on bronchiectasis. At the end of the study 54.5% of the patients were free of P. 
aeruginosa in the tobramycin group and 29.4% in the placebo group. The numbers of 
exacerbations, hospital admissions and days of hospitalisation were lower in the 
tobramycin than in the placebo group (Orriols et al 2015).  
 
Chronic P. aeruginosa infection is associated with poorer lung function, decreased 
quality of life and frequent hospital admissions (Evans et al 1996, Wilson et al 1997). 
Martinez and colleagues (Martinez-Garcia et al 2007) conducted a study in 67 
patients with stable bronchiectasis and followed them up for 2 years, conducting 
spirometry, microbiological analysis of sputum and recorded number of exacerbations 
over the study period. They detected chronic colonization with P. aeruginosa was an 
independent predictor of forced expiratory volume in 1-second (FEV1) decline [odds 




1.3.3. Other potential pathogenic microorganisms (PPM) 
The other PPMs of significance in bronchiectasis are S. pneumoniae, M. catarrhalis, 
enteric gram-negative organisms like E Coli and Klebsiella and S. aureus (both 
methicillin sensitive and methicillin resistant).  
 
1.3.3.1. Streptococcus pneumoniae  
In bronchiectasis, S. pneumoniae is detected in about 1-22% of patients (Angrill et 
al 2002). It is grown on blood agar. S. pneumoniae are lancet-shaped, gram-
positive, facultative anaerobic bacteria with over 90 known serotypes, of which 23 
are included in the pneumococcal vaccine Pneumovax ®. Most S. pneumoniae 
serotypes have been shown to cause disease, but only a minority of serotypes 
produces the majority of pneumococcal infections. Pneumococci are common 
inhabitants of the respiratory tract and may be isolated from the nasopharynx of 5-
70% of adults, depending on the population and setting. S. pneumoniae is the most 
common cause of community acquired pneumonia and bacterial meningitis. In 
bronchiectasis, S. pneumoniae is frequently isolated in sputum cultures, varying 
between 1-22%.  
 
S. pneumoniae infections are estimated to cause 500,000 cases of pneumonia, 55,000 
cases of bacteraemia, and 6,000 cases of meningitis annually in the United States 
(Williams et al 1988). The clinical course of S. pneumoniae infections is affected by a 
number of factors including the site and severity of infection, the underlying health of 
the patient, and the adequacy of antimicrobial therapy. Therefore, it is not surprising 
that estimates of mortality are reported to range from <1% to >50% (Williams et al 
1988). The choice of antibiotic and the duration of antibiotic therapy for treating 
exacerbations with S. pneumoniae infection in bronchiectasis are summarized in table 




1.3.3.2. Moraxella catarrhalis  
It is a gram-negative, aerobic, oxidase-positive diplococcus. Studies have 
demonstrated that M. catarrhalis is isolated in 1-20% of patients with 
bronchiectasis. Its persistence within the respiratory tract is most likely aided by its 
capacity to invade respiratory epithelial cells, inactivate complement and form 
biofilms (Murphy et al 2009). M. catarrhalis is acquired early in life and is a 
prominent colonizer of the upper respiratory tract in infants and children, before 
decreasing substantially during the adult years. Antibiotic recommended for acute 
exacerbations is summarized in Table 2 and long-term antibiotic treatment for M. 
catarrhalis is summarized in Table 3.  
 
1.3.3.3. Staphylococcus aureus  
It is a facultative anaerobic gram-positive coccus. Staphylococci are nonmotile, 
non–spore-forming, and catalase-positive bacteria. The cell wall contains 
peptidoglycan and teichoic acid. Most strains of S. aureus are sensitive to the more 
commonly used antibiotics. Those that are sensitive to methicillin are termed 
methicillin-sensitive S. aureus (MSSA). Methicillin-resistant S. aureus (MRSA) 
and MSSA only differ in their degree of antibiotic resistance. Over the last 20 years, 
community and hospital infections with S. aureus have risen-in particular with 
MRSA and more recently vancomycin resistant S. aureus. Antibiotic recommended 
for acute exacerbations is summarized in Table 2 and long-term antibiotic treatment 
in Table 3. 
 
1.3.3.4. Inflammatory response due to other bacteria (Klebsiella, 
Enterobacteriaceae) 
Angrill and colleagues showed that bronchial colonization by PPMs is common in 
patients with bronchiectasis in a stable clinical situation and in more than 60% of 
these patients the distal airways were colonized. They also concluded that sputum 
culture is an adequate tool for the evaluation of bronchial colonization in 
bronchiectasis and that early diagnosis of bronchiectasis (before the age of 14), 
evidence of varicose-cystic bronchiectasis and a FEV1 of  <80% predicted are risk 
factors for the presence of PPMs in the airways (Angrill et al 2001). Additionally, 
in a further study done by the same group, they performed bronchoalveolar lavage 
(BAL) in 49 patients with bronchiectasis and 9 controls and found that in patients 
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with clinically stable bronchiectasis: (1) there is an active neutrophilic 
inflammatory response in the airways that is present in patients with sterile bronchi 
but is exaggerated in patients with PPMs colonizing the airways; (2) colonizing 
bacteria act as an inflammatory stimulus with greater bacterial load producing 
greater inflammatory response; (3) the bronchial inflammatory response was 
compartmentalized and could not be accurately evaluated in blood samples (Angrill 
et al 2002). Chalmers et al, investigated this further in interventional and 
observational studies in bronchiectasis. They studied the relationship between 
bacterial load and airway and systemic inflammation was investigated in 385 stable 
patients, 15 stable patients treated with intravenous antibiotics, and 34 patients with 
an exacerbation of bronchiectasis treated with intravenous antibiotics. Long-term 
antibiotic therapy was investigated using samples from a 12-month controlled trial 
of nebulized gentamicin. They found that in stable patients, there was a direct 
relationship between airway bacterial load and markers of airway inflammation (P 
< 0.0001 for all analyses). High bacterial loads were associated with higher serum 
intercellular adhesion molecule-1 (ICAM-1), E-selectin, and vascular cell adhesion 
molecule-1 (VCAM-1) (P < 0.05 above bacterial load ≥1×107 cfu/ml). In stable 
patients, there was a direct relationship between bacterial load and the risk of 
subsequent exacerbations (P < 0.0001) and severe exacerbations (P = 0.02). They 
concluded that short- and long-term antibiotic treatments were associated with 
reductions in bacterial load, airways, and systemic inflammation (Chalmers et al 
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Meropenem 2G tds* 
Or 
Aztreonam 2G tds* 
 
Combination therapy: 
The above can be combined 
with gentamicin* (refer to 
BNF) or colistin 1-2 MU 
tds* (under 60 kg, 50 000-
75 000 units/kg daily 
separated into 3 divided 
doses) OR oral ciprofloxacin 
500mg BD*. 
 
Table 2. Choice of antibiotic and duration of treatment. BTS bronchiectasis guidelines 
2010. *dose needs adjusted in renal impairment 
 
1.4. DO LONG-TERM ORAL ANTIBIOTICS INFLUENCE OUTCOME? 
 
The BTS bronchiectasis guidelines 2010 recommend long-term antibiotics in:  
1. Patients having ≥ 3 exacerbations per year requiring antibiotic therapy or 
patients with fewer exacerbations causing significant morbidity should be 
considered for long-term antibiotics.  
2. In the first instance, high doses should not be used, to minimize side effects.  
3. The antibiotic regimen should be determined by sputum microbiology when 
clinically stable  
4. Long-term quinolones should not be used until further studies are available. 
5. Macrolides may have disease-modifying activity and preliminary data suggest 
the need for a large randomised controlled trial. There have been subsequently 
3 RCTs that have been conducted with macrolides in bronchiectasis and all 
three have shown that long-term macrolide treatment leads to decrease in 
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exacerbation frequency (Wong et al 2012, Serisier et al 2013, Altenburg et al 
2013). These trials are discussed in details in section 1.14.1. 
 
Organism Recommended first 
line treatment 
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1.5.1.1.  Chest X ray 
The chest X-ray is usually normal unless patients have severe bronchiectasis. 
However, a normal chest x ray does not rule out bronchiectasis. Digital acquisition 
devices are capable of producing x-rays with improved visualisation of, for example, 
bronchiectatic airways behind the heart, with the added potential of radiation dose 
reduction (Young et al 1991). However, unless disease is severe, the radiographic 
signs of bronchiectasis are usually inconspicuous. Characteristic chest X-ray 
appearances include crowding of bronchi, parallel line opacities (tram lines) caused 
by thickened dilated bronchi, ring opacities or cystic spaces as large as 2 cm in 
diameter resulting from cystic bronchiectasis, sometimes with air-fluid levels, and 
oligaemia as a result of a reduction in pulmonary artery perfusion (figure 6). In terms 
of specificity, the chest x-ray of a patient with COPD showing bronchial wall 
thickening (tramline and ring shadows) and large volume lungs may be erroneously 
interpreted as indicating bronchiectasis. In summary, although a baseline chest x ray 
is recommended in all patients with bronchiectasis, they are not routinely indicated 
for follow up of patients with no change in symptoms (Pasteur MC et al BTS 
bronchiectasis guidelines 2010). Additionally, there is very little correlation during an 





Figure 6. Cystic bronchiectasis- as indicated by arrows.  
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1.5.1.2. High Resolution CT Scan 
 
The current gold standard for diagnosing bronchiectasis is high resolution CT 
(HRCT) of the chest. The appropriate high resolution CT study is a non contrast study 
with the use of 1.0-1.5mm window every 1cm with acquisition times of one second, 
reconstructed with the use of a high spatial frequency algorithm during full inspiration 
(Munro et al 1990). Bronchiectasis is diagnosed when there is bronchial wall 
dilatation, defined as the internal lumen of the bronchus being greater than that of the 
accompanying pulmonary artery, described as the ‘signet’ ring sign (figure 7). 
Characteristic features include, lack of tapering toward the periphery producing 
cylindrical bronchiectasis (figure 8), varicose constrictions along the airway (figure 9) 
and ballooned cysts at the end of a bronchus (figure 10). Cylindrical bronchiectasis is 
by far the most common bronchiectasis identified on CT. The usefulness of 
categorising bronchiectasis into cylindrical, varicose or cystic subtypes is limited, but 
cystic bronchiectasis usually denotes longstanding and more severe disease.  
 
Bronchial wall thickening is a usual but inconsistent feature of bronchiectasis. 
Problems with this variable feature have been widely debated and the definition of 
what constitutes abnormal bronchial wall thickening remains unresolved (Pasteur MC 







Figure 7. Signet ring (as indicated by arrows). 
 
Non-specific findings include consolidation or infiltration of a lobe with dilatation of 
the airways, thickening of bronchial walls, mucus plugs and enlarged lymph nodes 
(Thomas and Blaquiere 1993). Mucus secretions within bronchiectatic airways are 
generally easily recognisable as such. The larger plugged bronchi are visible as 
lobulated or branching opacities. Such airways are usually seen in the presence of 
non-fluid filled obviously bronchiectatic airways. Mucus plugging of the smaller 
peripheral and centrilobular airways produces V- and Y-shaped opacities, the so-
called ‘tree-in-bud’ pattern (Gruden and Webb 1995).  
 
In patients with ABPA there is fleeting infiltrates and ultimately patients can develop 
proximal bronchiectasis. The characteristic distribution with M. avium complex 
infection often involves the middle lobe or lingula (Cartier et al 1999) and typically 
shows bronchiectasis, nodes and ‘tree in bud’ appearances. Airway dilatation can be 
associated with asthma, chronic bronchitis, and pulmonary fibrosis (so-called traction 
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bronchiectasis), however this thesis deals with clinically significant bronchiectasis, 
which is radiological diagnosis and clinical features in keeping with bronchiectasis. 
 
In summary, HRCT is the radiological investigation of choice in bronchiectasis, with 















Figure 10. Cystic bronchiectasis (as indicated by arrows). 
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1.5.2 CLINICAL FEATURES OF BRONCHIECTASIS 
 
1.5.2.1. Cough and sputum 
Cough is the commonest symptom of bronchiectasis and occurs in >90% patients 
(Pasteur MC et al BTS bronchiectasis guidelines 2010). The cough is productive of 
sputum daily in 75-100%, intermittent in 12-20% and non-productive in 5-8% 
(Stockley et al 2001). In bronchiectasis, cough occurs due to overproduction of 
secretions and impaired mucociliary clearance of secretions. Mucus hyper-secretory 
state in bronchiectasis results from hyper secretion of stored mucin or hypertrophy of 
goblet cells. 
 24-hour sputum volume measurement is perhaps a more accurate assessment of 
volume produced, but is entirely dependent on patient compliance. Sputum purulence 
is dependent on the release of myeloperoxidase and is classified as mucoid (clear or 
grey), mucopurulent (pale yellow) and purulent (dark yellow or green) (Stockley et al 
2001). Sputum purulence is related to radiological appearances on CT scan and 
purulent sputum is associated with cystic bronchiectasis on HRCT (O’Brien et al 
2000) and correlates well with the presence of potential pathogenic microorganisms 
(Murray et al 2009).  
 
1.5.2.2. Dyspnoea, hemoptysis, pain and fever 
Dyspnoea is present in about 70% of patients and correlates inversely to FEV1 
(Martinez- Garcia et al 2007). Hemoptysis can occur with exacerbations but major 
hemoptysis can infrequently occur and usually arises from an aberrant blood vessel 
from the bronchial arteries and can sometimes require interventions such as bronchial 
embolization or lobar resection. Patients can present with pleuritic chest pain and 
fever with exacerbations. 
 
1.5.2.3. Infective exacerbations 
As previously mentioned, the BTS bronchiectasis guidelines recommended antibiotics 
for exacerbations that present with an acute deterioration (usually over several days) 
with worsening local symptoms (cough, increased sputum volume or change of 
viscosity, increased sputum purulence with or without increasing wheeze, 
breathlessness, haemoptysis) and/or systemic upset (Pasteur MC et al 2010). Number 
of exacerbations can vary but from the national BTS bronchiectasis audit, the number 
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of exacerbations in a secondary care cohort is 2/year (Hill et al 2012). Studies have 
shown that recurrent exacerbations lead to poor quality of life (Wilson et al 1998).  
 
1.5.2.4. Clinical signs on bronchiectasis 
The most characteristic physical finding of bronchiectasis is coarse crackles on 
auscultation of the lung bases, and is found in about 70% of patients (Pasteur MC et al 
BTS bronchiectasis guidelines 2010). Some patients may have normal lung function, 
airflow obstruction or restrictive pattern and/or clubbing.  
 
1.5.2.5. Impact on quality of life 
The St George’s Respiratory Questionnaire has been validated for use in 
bronchiectasis (Wilson et al 1997). Higher scores on the St. Georges Respiratory 
Questionnaire are associated with worse quality of life. In addition, the Leicester 
Cough questionnaire has also been validated for use in bronchiectasis and a lower 
score indicates worse cough severity and poorer quality of life (Murray et a 2009). 
 
1.5.2.6. Assessment of disease severity 
In the recently published Bronchiectasis Severity Index or BSI (Chalmers et al 2014) 
and FACED (Martinez- Garcia 2014) scores, bronchiectasis patients can be 
categorized into disease severity based on a number of clinical and radiological 
parameters. Parameters included in the BSI score are age; body mass index (BMI), 
percent predicted FEV1, previous hospital admission, hospital admissions per year, 
MRC dyspnea score (Medical Research Council), pseudomonas colonization, 
colonization with other organisms and radiological severity. A score of 0-4 indicates 
mild bronchiectasis, 5-8 moderate and >9 severe bronchiectasis. The one-year 
mortality rates for mild, moderate and severe bronchiectasis are 2.4%, 4.8% and 7.6% 
respectively. BSI scores can be calculated by the available online tool 
http://www.bronchiectasisseverity.com. McDonnell and colleagues recently studied 
the predictive utility of the BSI and FACED across seven European cohorts. They 
concluded that the BSI accurately predicts mortality, hospital admissions, 
exacerbations, quality of life, respiratory symptoms, 6 minute walk test, and lung 
function decline in bronchiectasis, providing a clinically relevant evaluation of 
disease severity (McDonnell et al 2016). The BSI has been used to assess disease 
severity for the purpose of this thesis. 
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1.6. IMMUNE SYSTEM OF THE LUNG AND BRONCHIECTASIS 
 
The innate immune system is the immediate, non-specific and first line of defense 
against invading organisms. Key cells of the innate immune response include 
neutrophils, macrophages, eosinophils, basophils, dendritic cells and γδ T cells. 
Particles >2–3 µm impact on the mucus covering epithelial cells in the upper airways 
and bronchi and are removed by a combination of normal mucociliary clearance and 
cough (Loebinger et al 2009). Airway secretions contain several anti-infective 
proteins and polypeptides, including the bacteriostatic proteins lysozyme and 
lactoferrin. Secretory leucoprotease inhibitor (SLPI), produced by the mucous glands, 
macrophages and epithelial cells, has antifungal, antiviral and antibacterial properties 
(Rogan et al 2006). Secretary IgA is the main antibody isotype in mucosal secretions 
in the respiratory tract that contributes to the initial defense mechanisms, while IgG 
predominates in the plasma (Hill et al 2000). If a high bacterial load overwhelms 
these primary clearance mechanisms, a secondary defense system is activated. Animal 
experiments demonstrate this relationship between bacterial load and activation of the 
secondary host response in that a low bacterial load leads to bacterial clearance, but 
when the bacterial load is greater than 106 colony-forming units/ml (cfu/ml) there is a 
neutrophilic host inflammatory response (Hiemstra 2007). In bronchiectasis, 
Chalmers et al showed that this response occurs at ≥105 cfu/ml (Chalmers et al 2012). 
 
Failure of the local host defenses results in microbial colonization, establishing the 
‘vicious circle’ described by Cole and colleagues. Airway epithelium responds by 
releasing antimicrobial peptides and inflammatory cytokines into the airways. In 
human airway epithelial cells the antimicrobial peptides produced are the β-defensins 
and the cathelicidins (LL-37 in humans). Chemokines and cytokines such as 
interleukin (CXCL)-8 are released into the sub mucosa (Bals and Hiemstra 2004) and 
initiate the inflammatory reaction, leading to recruitment of phagocytes (neutrophils, 
monocytes and macrophages), dendritic cells and lymphocytes (which contribute to 
the adaptive response) (Weng et al 2010). The airways become inflamed leading to 
leakage of serum proteins including circulating antibodies and complement, therefore 
increasing local antibacterial potential.  
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1.7. KEY INFLAMMATORY CELLS IN BRONCHIECTASIS 
 
1.7.1. NEUTROPHILS 
Excessive neutrophilic airways inflammation is the central feature of bronchiectasis. 
This paradoxically both promotes bacterial colonization and perpetuates damage to 
the airways creating a vicious cycle of bacterial colonization and inflammation (Cole 
1984). The lung is a unique vascular and externally exposed organ that is subject both 
to PMN-mediated inflammation and PMN-opposed infection.  
Granule proteins from activated neutrophils, such as azurocidin and α-defensins, 
directly alter permeability (Serhan 2007). Moreover, proteases of neutrophilic origin 
such as neutrophil elastase have been regarded to be important in degradation of 
surfactant proteins, epithelial cell apoptosis, and coagulation. In addition, neutrophils 
produce vast quantities of reactive oxygen (ROS) and nitrogen (RNS) species like O2− 
and NO through their oxidant-generating systems such as the phagocyte NADPH 
oxidase and nitric oxide synthase (NOS), respectively. Besides their important 
antimicrobial effector function, neutrophil-derived oxidants promote deleterious pro-
inflammatory effects thus being a major cause of neutrophil-dependent tissue injury 
(Morel et al 1991).  
 
1.7.1.1. Key functions of neutrophils relevant to bronchiectasis 
 
1.7.1.1.1. Recruitment and migration 
Recruitment is driven by chemo attractants, with interleukin (IL)8 now referred to as 
CXCL8, leukotriene (LT) B4, interleukin-1 beta, C5a and tumour necrosis factor 
(TNF) alpha believed to be of significance in bronchiectasis (Mikami et al 1998). 
Elevated levels of these pro-inflammatory cytokines have been demonstrated in 
bronchiectasis airway secretions (Stockley and Bayley 2000). Neutrophil detection of 
chemotactic stimuli leads to a co-ordinated process of cell signalling, cytoskeletal 
rearrangement and changes in surface receptor expression to facilitate migration. Key 
to the process of transendothelial migration is the expression of the integrins 
CD11/CD18 on neutrophils and the expression of adhesion molecules on endothelial 
cells, principally intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1) and the selectins (Cowburn et al 2008).  
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Neutrophil migration occurs predominantly at the border of endothelial cells where 
modifications of cell junctions allow this. The cell adhesion molecules, platelet 
endothelial cell adhesion molecule 1 (PECAM-1 or CD31) and junction adhesion 
molecule (Martin-Padura et al 1998, Muller et al 1993) are involved in neutrophil 
transmigration. Migration occurs via PECAM-1/PECAM-1 interaction while 
maintaining the permeability barrier of the endothelial cell monolayer (Muller et al 
1993) The endothelial surface density of ICAM-1 is important in regulating this 
migration (Yang et al 2005). 
Neutrophil adhesion to pulmonary endothelial cells and migration into the lung may 
occur by CD11/CD18 dependent or CD11/CD18 independent mechanisms 
(Doerschuk et al 2000). Different stimuli within the lung can determine whether 
CD18 is required for neutrophil migration into the lung. It is felt that stimuli from 
gram-negative bacteria require CD18, as 75–80% of neutrophil migration is inhibited 
by CD18 antibodies (Doerschuk et al 2000).  
 
Once neutrophils migrate to the site of infection, neutrophils perform three key 
actions: phagocytosis of the bacteria, release of products of pre formed granules and 
release of reactive oxygen species-all three actions are directed towards killing of 
bacteria. 
 
1.7.1.1.2. Reverse transmigration of neutrophils  
In a successful response to an acute injury, it is critical to prevent tissue damage by 
promoting the local resolution of inflammation through the removal of neutrophils 
from the site of injury (Soehnlein & Lindbom 2010). This clearance of neutrophils 
can occur through either apoptosis or necrosis and subsequent phagocytosis by 
macrophages (Buckley et al 2013). However, there is evidence to suggest that 
neutrophils at inflamed sites do not necessarily undergo apoptosis. Hughes et al used 
a rat model of glomerular capillary injury to track the fate of radiolabelled neutrophils 
and found that ≥70% of neutrophils that entered inflamed glomerular capillaries were 
able to return to the main circulation and did not undergo apoptosis at the site of 
inflammation (Hughes et al 1997). Recent studies have shown that neutrophils can 
leave sites of tissue damage in a process termed neutrophil reverse migration, which 
describes the interstitial migration of neutrophils away from inflamed sites. 
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Neutrophils have also been described to re-enter the vasculature in a distinct process 
referred to as neutrophil reverse transendothelial migration (rTEM). 
Neutrophil reverse migration within tissues away from the site of injury was first 
directly visualized in vivo in zebrafish larvae, in which the authors showed that not all 
recruited neutrophils die at the site of injury, and most leave the site (Mathias et al 
2006). Subsequent studies using zebrafish, showed that neutrophils that leave a 
wound can undergo rTEM and traffic to distal sites post injury (Yoo and Huttenlocher 
et al 1011; Hall et al 2009). Buckley and colleagues (Buckley et al 2006) described 
the ability of human neutrophils to reverse transmigrate through an endothelial 
monolayer in vitro, identifying markers that are characteristic of these reverse-
transmigrated neutrophils (intercellular adhesion molecule 1 (ICAM1)hiCXCR1low), 
and found this neutrophil phenotype in the peripheral blood of patients with systemic 
inflammation. CXC chemokine receptors are membrane proteins that specifically bind 
and respond to cytokines of the CXC chemokine family, for example CXCL8 binds to 
both CXCR1 and CXCR2. Neutrophil reverse migration and/or rTEM have now been 
visualized in multiple models including zebrafish (Ellett et al 2015; Robertson et al 
2014; Tauzin et al 2014) mice (Duffy et al 2012; Woodfin et al 2011) and in vitro 
using human neutrophils (Hamza et al 2015; Hamza et al 2014). In vitro studies using 
microfluidics showed that greater than 90% of human neutrophils can reverse their 
direction away from a chemoattractant and migrate away continually for distances 
greater than 1,000 µm. Collectively these studies have suggested that reverse 
migration is a possible mechanism to locally resolve inflammation and is a potential 
novel target for drug therapy in diseases characterized by excessive neutrophil 
infiltration. However, a caveat is that neutrophil reverse migration may lead to 
activated neutrophils being redistributed to other locations in the body, contributing to 
inflammation elsewhere. It is also important to note that several aspects of neutrophil 
reverse migration remain controversial including the exact mechanism(s), the fate of 







1.7.1.1.3. Neutrophil phagocytosis 
The internalization of bacteria by neutrophil and formation of a phagosome is 
facilitated by opsonization. Opsonization is a process where the Fab portion of the 
IgG antibody binds to the bacteria and the Fc (receptors are FcγRIIa and FcγRIIIB) 
portion then binds to the phagocyte by specific receptors. Fcγ receptor ligation leads 
to extension of the pseudopod around the bacteria, which finally engulfs it 
completely. Both intracellular and extracellular environment is important to regulate 
neutrophil function (Whitters and Stockley 2012). What is known in bronchiectasis, is 
that peripheral blood neutrophils function normally in bronchiectasis (Watt et al 
2004). Our group demonstrated (unpublished data) that the airway neutrophils do not 
function normally in bronchiectasis- however I do not know the mechanism for this 
but hypothesize that the complex airway environment with the overwhelming 
bacterial load, inflammatory cytokines and chemokines could all in part contribute to 
the impaired neutrophil function. This will be explored further in this thesis.  
 
1.7.1.1.4. Release of products of degranulation 
Granule proteins formed during neutrophil development and released upon activation 
is one of the key functions of neutrophils. Changes in the cytosolic calcium are 
required for granule secretion (Lew et al 1986) and for fusion of the granule to the 
neutrophilic phagosome (Jaconi et al 1990). The granules contain enzymes, host 
defense proteins with receptors, signaling proteins and adhesion molecules that are 
expressed on the cell surface upon activation. Azurophilic granules or primary 
granules release MPO, defensins, neutrophil elastase, proteinase 3 and cathepsin G, 
among others. Secondary granules release lactoferrin, cathelicidin and tertiary 
granules release gelatinase acetyltransferase and lysozyme. Excessive degranulation 
and release of MPO and neutrophil elastase leads to host tissue damage  including 








1.7.1.1.5. Release of superoxide anion 
During phagocytosis, neutrophils increase the oxygen consumption by using up 
NADPH oxidase and releasing superoxide anion (O2-). The O2- then dismutates to 
form H2O2, releasing MPO from primary neutrophilic granules (Morel et al 1991). 
This oxidative burst is critical for bacterial killing but simultaneously 
myeloperoxidase (MPO) causes oxidative damage to the epithelial cells mainly 
through formation of the cytotoxic oxidant HOCl (Worlitzesh et al 1998). Elevated 
MPO levels have been found to correlate to disease severity in bronchiectasis (Hill et 
al 2000). The respiratory burst results in the release of ROS to facilitate bacterial 
killing. The release of uncontrolled ROS by neutrophils may however also lead to 
damage to surrounding tissues, amplifying the lung disease process (Tung et al 2009). 
It had previously been thought that ROS exert a direct toxic effect on ingested 
pathogens. However Reeves et al (Reeves et al 2002) suggested that the respiratory 
burst sets in motion events, which result in creating a favorable environment for 
proteases such as elastase to digest the contents within the phagocytic vacuole. By 
optimizing conditions via ion flux and pH change, the enzymes released from the 
cytoplasmic granules become more active, facilitating the destruction of ingested 
pathogens.  
As NADPH oxidase is key for respiratory burst, patients with chronic granulomatous 
disease (defect in one of the subunits of NADPH oxidase genes) are unable to 
produce ROS and thereby lead to life threatening bacterial infections (Deffert et al 
2014). In 2006, King et al demonstrated that in bronchiectasis, neutrophils have 
normal phagocytic capacity but impaired oxidative burst as compared to controls 
(King et al 2006). However, in contrast, Pasteur et al failed to detect any difference in 
oxidative burst between bronchiectatic patients and controls (Pasteur et al 2000). It 













It has been well established that there is a key role for apoptosis, or programmed cell 
death, in the regulation of inflammation and the host immune response. The process 
of apoptosis, which is distinct from necrosis (toxic cell death), involves a series of 
coordinated morphologic changes in the affected cell, causing its demise and 
subsequent recognition and removal by scavenger phagocytes (Wyllie et al 1980). 
Characteristically, apoptosis initially induces cytoplasmic shrinkage associated with 
membrane blebbing (zeiosis), followed by chromatin condensation and DNA 
fragmentation. Although cells usually manifest these changes sequentially when 
undergoing apoptosis, it is now clear that these events may occur independently under 
the control of separate and distinct metabolic pathways (Duffin et al 2010).  
 
Among the leukocytes, mature human neutrophils have the shortest life span and die 
rapidly via apoptosis in vivo and in vitro, resulting in the demise of the entire 
population within 72h. As neutrophils proceed through apoptosis, functional activity 
declines. Apoptotic neutrophils lose CD16 (FcyRIII) expression and demonstrate a 
reduced ability to degranulate, generate a respiratory burst, or undergo shape changes 
in response to external stimuli such as the chemotactic bacterial peptide formyl-
methyl-leucyl-phenylalanin (fMLF) (Sasmono 2007). Although neutrophils appear to 
be committed to death via apoptosis, it is now clear that the life span and functional 
activity of mature neutrophils can be extended significantly by pro inflammatory 
cytokines, including granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), IFN-γ, TNF-α and IL-2 (Burdon 
2008). 
 
Although elevation of cytosolic-free Ca2+ has been associated with apoptosis in a 
variety of cell types (Whyte et al 1993), transient elevations of cytosolic free Ca2+ 
induced by low doses of calcium ionophores have been reported to inhibit apoptosis 
in neutrophils in vitro (Whyte et al 1993). Other experiments employing inhibitors of 
tyrosine kinases and phosphatases suggest a possible role for tyrosine phosphorylation 
events in the signal transduction pathway mediating neutrophil apoptosis (Erttmann et 
al 2014). Furthermore, it has been shown that intracellular acidification precedes, and 
may be causally related to, the development of morphologic features characteristic of 
apoptosis in neutrophils maintained in short term culture (Erttmann et al 2014).  
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It is also known that the Fas (APO-I; CD95)/ Fas-ligand (FasL) system represents an 
important cellular pathway responsible for the induction of apoptosis in diverse 
tissues. Fas is a widely expressed 45-kDa type I membrane protein member of the 
TNF/nerve growth factor family, which mediates apoptosis following interaction with 
agonistic anti-Fas IgM Ab or FasL (Wajant et al 2002). FasL is a 40-kDa type II 
protein member of the TNF family, which includes TNF-α, TNF-β (lymphotoxin), 
CD40 ligand, and CD30 ligand (Wajant et al 2002). In contrast to Fas, the expression 
of FasL is relatively restricted in its tissue distribution (Wajant et al 2002) but can be 
induced in mature T cells following stimulation with phorbol 12-myristate 13-acetate 
or PMA, ionomycin, anti-CD3, or bacterial antigen (Wajant et al 2005). Furthermore, 
it has been shown that activated T cells can secrete a functionally active soluble form 
of FasL that is capable of inducing apoptosis in other cells susceptible to Fas-induced 
apoptosis (Wajant et al 2005).  The relative contributions of the proapoptotic and pro 
inflammatory functions of Fas/FasL sytem to the pathogenesis of lung disease and the 
effects of inhibiting this pathway, remains poorly understood.  
 
Binding of Fas to its natural ligand FasL, can trigger apoptosis via activation of 
caspase 8. FasL exists in a membrane bound form and a soluble form, both of which 
can activate Fas. In addition to triggering apoptotic pathways, the activation of Fas 
can also lead to NF-κB translocation and cytokine production (Kreuz et al 2004).   
 
FasL expression is detected on the surface of mature human neutrophils, but not on 
monocytes or eosinophils suggesting that neutrophils are susceptible to Fas induced 
cell death.  
 
There is limited data available from two studies in the literature on apoptosis of 
airway neutrophils in bronchiectasis. Vandivier et al (Vandivier et al 2002) concluded 
that sputum of bronchiectatic patients have more apoptotic neutrophils in comparison 
to sputum obtained from patients with chronic bronchitis. However, Watt et al 
demonstrated that there were low levels of apoptotic neutrophils in induced sputum as 
compared to the findings by Vandivier and colleagues (Watt et al 2004). They found 
no significant differences in the levels of apoptotic neutrophils at the beginning and 
end of an exacerbation treated with antibiotics. There was however a reduction in the 
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total number of sputum neutrophils and serum levels of CXCL8, TNF-α, neutrophil 
elastase (NE) and CRP, at the end of exacerbation. In summary, few studies have 
investigated neutrophil apoptosis in bronchiectasis and of the two key studies 
described to date, the opinion remains divided. 
	
	 58	
1.7.1.1.7. Neutrophil extracellular traps (NETs) 
Neutrophil extracellular traps (NETs) are extracellular strands of decondensed DNA 
with histones and neutrophil granular proteins. NETs were discovered more than a 
decade ago (Birkmann et al 2004).  The authors demonstrated that NETs are 
generated in vitro after stimulation of isolated neutrophils with three different agents: 
(i) CXCL8, a major neutrophil chemoattractant; (ii) LPS, a component of Gram-
negative bacteria; and (iii) PMA, a potent activator of protein kinase C (PKC). 
Additionally, these in vitro generated NETs had antibacterial activity, which was 
attributed to the associated histones (Hirsch 1958), proteolytic enzymes from granules 
that could degrade bacterial virulence factors, and enzymatically active 
myeloperoxidase (MPO). Notably, the antibacterial activity of NETs is abrogated by 
DNase (Brinkmann et al 2004). Induction of NETs by CXCL8 and LPS indicates that 
NETs are formed during inflammation and infection. Brinkmann and colleagues were 
able to demonstrate that neutrophils may undergo an alternative death pathway, 
termed NETosis, thereby allowing them to serve in innate immune defense even after 
their death. However, I need to be cautious, as NETosis as a neutrophil death 
mechanism, may largely be an in vitro phenomenon, and NETs seem to be generated 
in vivo by mechanisms different from those described in vitro.  
 
1.7.1.1.7.1. NET morphology 
 
The ultrastructure of NETs is unusual. NETs consist of smooth filaments with a 
diameter of ~17 nm (Brinkmann et al 2004), composed of stacked and modified 
nucleosomes (Urban et al 2009). This backbone is studded with globular domains that 
have a diameter of ∼50 nm made of granular proteins (Brinkmann et al 2004). This 
distinct morphology in high-resolution scanning electron microscopy can easily 
differentiate NETs from other fibrous structures such as fibrin. Interestingly, unfixed, 
fully hydrated NETs have a cloud-like appearance and occupy a space that is 10–15-










1.7.1.1.7.2. The mechanism of NET formation 
 
NETs are the results of a unique form of cell death that is morphologically 
characterized by the loss of intracellular membranes before the integrity of the plasma 
membrane is compromised or lost. Steinberg and Grinstein coined the term 
“NETosis” for neutrophil cell death that leads to formation of NETs. To release 
NETs, activated neutrophils undergo exceptional morphological changes (figure 
11A). Minutes after activation, neutrophils flatten and firmly attach to the substratum 
(figure 11B). Over the next hour, the nucleus loses its multi lobulated structure, the 
chromatin decondenses, and the inner and outer nuclear membranes then 
progressively detach from each other. Simultaneously, the granules disintegrate. After 
an hour, the nuclear envelope then disaggregates into vesicles and the nucleoplasm 
and cytoplasm form a homogenous mass (figure 11C). Lastly, the cells round up and 
seem to contract until the cell membrane ruptures and the interior of the cell is ejected 
into the extracellular space, forming NETs (figure 11D; Fuchs et al 2007).  NETosis 




Molecularly, the few events that have been shown to be required, sequentially, are the 
production of superoxide anion, the migration of the protease neutrophil elastase (NE) 
and myeloperoxidase (MPO) from granules to the nucleus, the processing of histones, 
and finally the rupture of the cell (Brinkmann and Zychlinsky 2012). 
 
NETs are removed during the resolution of inflammation. NETs are susceptible to 
DNase1 (von Köckritz-Blickwede et al 2009; Hakkim et al 2010), an enzyme 
produced by the pancreas. It is not known what happens to the debris left by DNase1 
but perhaps phagocytes, macrophages, and neutrophils newly recruited to the 






Figure 11. Schematic representation of the NETosis pathway. After stimulation of 
receptors (A), neutrophils adhere to the substrate (B) and mobilize granule 
components NE and MPO (C). Granules are depicted as green circles. Histones in the 
nucleus get processed, and the intracellular membranes degenerate. Finally, the cell 
membrane ruptures, and the contents of the cytoplasm and nucleoplasm gets expelled 
to form NETs (D).  
 
Adapted from Brinkmann et al, 2012, J. Cell Biol. 
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1.7.2. MACROPHAGES IN BRONCHIECTASIS 
Little is known about the role of macrophages in bronchiectasis. One of the key 
functions of macrophages is efferocytosis or “burying’’ the dead (apoptotic) 
neutrophils (Serhan 2005). It is well recognized that activated neutrophils must firstly 
‘switch off’ by undergoing apoptosis to limit the inflammatory process and then be 
cleared by macrophages to prevent secondary necrosis and release of granular 
products, and thereby promote resolution of inflammation (Koedel et al 2009).  
In bronchiectatic patients, Vandivier et al demonstrated that neutrophil elastase 
cleaves phosphatidylserine on the surface of apoptotic cells, preventing efferocytosis 




A vital event in the resolution of inflammatory responses is the clearance of recruited 
inflammatory granulocytes, particularly via the co-ordinated induction of 
programmed cell death (apoptosis) and thereafter the clearance of apoptotic cells by 
tissue phagocytes (Walker et al 2005). This mechanism has been confirmed in 
experimental models of inflammation, where accelerating neutrophil apoptosis 
promotes early resolution and reduction in tissue injury (Rossi et al 2006). Neutrophil 
apoptosis leads to loss of expression and function of adhesion molecules (Dransfield 
et al 2005) and greatly reduced responsiveness to external stimuli (Whyte et al 1993) 
which leads to functional isolation from micro-environmental stimuli. In addition, 
apoptotic neutrophils are quickly recognised and ingested by neighbouring 
phagocytes, thereby limiting release of histotoxic intracellular contents (Savill et al 
2002). Apoptotic cells once engulfed are contained within a large fluid-filled vesicle 
called an efferosome that fuses with lysosomes to form the efferolysosome, which 
then eventually digests the redundant cell. Various cell surface signals help 
phagocytes distinguish viable cells from apoptotic cells. The primary signal exposed 
on the surface of apoptotic cells is the membrane phospholipid phospatidylserine (PS) 
(Fadok et al 1992). In viable cells, PS remains confined to the inner membrane via the 
transmembrane lipid transporter protein flippase. However, at early-stage apoptosis, 
PS is translocated from the inner to the outer membrane leaflet via the activity of 
phospholipid scramblase. PS exposed on the surface of apoptotic cells can be detected 
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by phagocytes via several recognition mechanisms involving membrane receptors. 
Although several molecular mechanisms may be involved in the clearance of 
apoptotic cells by phagocytes (Elliott et al 2010), uptake of apoptotic cells suppresses 
toll-like receptor-driven production of pro-inflammatory mediators by macrophages 
and can induce release of IL-10 and transforming growth factor (TGF)-β which have 
the potential to exert anti-inflammatory effects (Rothlin and Lemke 2010), (Fadok et 
al 1998). 
 
Phagocytic functions can be enhanced by exposure or treatment with glucocorticoids 
Glucocorticoids can also stimulate macrophages to switch to an anti-inflammatory 
phenotype (M2) where they shut down release of pro-inflammatory cytokines and 
simultaneously release anti-inflammatory cytokines (IL-10, TGFβ, IL-1ra), thereby 
helping to promote resolution of inflammation and tissue repair (Robb et al 2016). In 
addition, M2 macrophages have enhanced phagocytic capabilities, with their most 
important function being the efficient clearance of apoptotic cells (Savill 1997), 
which contributes significantly to the successful resolution of inflammation. During 
lung infection and injury, migration and retention of monocyte and macrophage 
populations are indicated in triggering and sustaining pulmonary inflammation (Kaur 
et al 2015). Dexamethasone-treated macrophages also display structural 
reorganisation of the cytoskeleton and an increase in cell motility, both essential for 
efficient phagocytosis (Giles et al 2001). Furthermore, dexamethasone augmented the 
expression of active RAC in macrophages, a key signalling protein involved in a 
variety of cellular functions, including phagocytosis as well as cell motility, mitosis 
and wound healing (Giles et al 2001). 
 
Professional phagocytes include alveolar macrophages, interstitial lung macrophages 
and lung ‘immature’ dendritic cells, whereas non-professional phagocytes include 
lung epithelial cells - alveolar and bronchial epithelial cells. Defective efferocytosis 
which thereby results in an increased number of apoptotic cells is implicated in a 
number of lung diseases including asthma, acute lung injury, cystic fibrosis and 
COPD (Yun et al 2008; Grabiec and Hussell et al 2016). Efferocytosis has not been 
studied in bronchiectasis. Furthermore, highly specialised bioactive lipids play key 
roles during the resolution phase of inflammation. 
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1.7.3. EPITHELIAL CELLS 
 
1.7.3.1. Airway host defence and damage 
The airway mucociliary clearance system is a key component of primary host defence 
in the lungs, responsible for maintaining airway sterility and health. The system has a 
mucus gel layer that lines the airway lumen trapping pathogens, inhaled toxins and 
cellular debris as it is swept by beating cilia from the distal airways to the proximal 
airways for expectoration and clearance.  
 
In health, the respiratory tract is lined by equal numbers of ciliated columnar 
epithelial cells and secretory cells. The epithelial cells each have 200 cilia, 
approximately 7µm length that rest in a thin layer of periciliary fluid. The cilia beat in 
a 2 stage process, an effective beat where their tips engage with the airway mucus 
sweeping it through the airways and a recovery beat in the opposite direction where 
their tips disengage and recover (Rubbo and Lucas 2017). Alveoli produce surfactant 
to maintain bronchial patency. Bronchioles are lined with ciliated epithelium and 
secretory cells that produce a thin mucus layer for the airway lumen. The airway 
mucus is composed predominantly of water (97%) and mucins (3%) and accumulates 
as it is transported through the larger airways, trachea and pharynx for expectoration. 
 
Dilated, damaged bronchial wall function impairs clearance of mucus and excessive 
mucus accumulation causes the airways to be persistently exposed to toxic insults and 
pathogens. In bronchiectasis, the airways are permanently damaged and the normal 
mucociliary mechanism is believed to be impaired.  
 
1.7.3.2. Abnormal ciliary function  
In order to ensure effective mucus transport, the cilia must beat at a normal rate, in a 
consistent direction and in a coordinated fashion (Eliezer et al 1970). Studies have  
used ciliated nasal epithelium as a non-invasive means of assessing ciliary function in 
the respiratory tract. Ciliary beat frequency is significantly slower in bronchiectasis 
(Rutland and Cole 1981). This finding has been confirmed in a more recent study of 
152 patients with idiopathic bronchiectasis, which found ciliary beat frequency to be 
significantly slower than healthy controls (Tsang et al 2005b). The purulent sputum in 
bronchiectasis contains excessive quantities of elastase due to the persistent 
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neutrophilic airways inflammation. Such purulent sputum from patients with 
bronchiectasis has been shown to slow ciliary beat frequency on normal ciliated nasal 
epithelium in healthy controls (Smallman et al 1984). The addition to the sputum of 
an elastase inhibitor (α1- antitrypsin) resulted in no significant change in ciliary beat 
frequency over the same time period, suggesting that elastase activity had no effect on 
ciliary function (Smallman et al 1984). The effect of elastase on ciliary function and 
ciliated epithelium has been shown in vitro to increase with a dose dependent effect 
with progressive disruption of the epithelium and slowing of ciliary beat frequency at 
higher levels (Amitani et al 1991). The effect of bacterial products on ciliary function 
has been investigated in vitro. Exposure of ciliated nasal epithelium to the 
supernatants of Pseudomonas aeruginosa and Haemophilus influenzae over a 4 hour 
period was associated with significant slowing of ciliary beat frequency and a 
disorganised beating pattern. A dose related effect was also observed and it may be 
that the release of a factor or factors by these organisms complements the effect of 
human neutrophil elastase on ciliary inhibition (Wilson et al 1985).  
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1.8. INFLAMMATION AND THE ROLE OF LIPID MEDIATORS 
 
Acute inflammation is commonly characterized by the rapid influx of blood 
granulocytes, typically neutrophils, followed swiftly by monocytes that mature into 
inflammatory macrophages that subsequently proliferate and thereby affect the 
functions of resident tissue macrophages. The acute inflammatory response is a 
protective mechanism that is evolved to eliminate invading organisms and should 
ideally be self-limiting and lead to complete resolution (Serhan 2007, Mantovani et al 
2011, Medzhitov 2010). Chemical mediators biosynthesized locally during acute 
inflammation give rise to the events characterized by Celsus in the 1st century, 
namely, rubor (redness), tumor (swelling), calor (heat) and dolor (pain) (Kumar et al 
2005). Despite the fact that these cardinal signs of inflammation were evident over 
2000 years ago, the cellular and molecular events that regulate the inflammatory 
response and its timely resolution are only recently beginning to be recognized and 
understood. Tissue edema is one of the earliest events of the acute inflammatory 
response and is consequent from increased permeability of microvasculature. 
Polymorphonuclear neutrophils (PMN) are the first line of defense against microbial 
invasion, which restrict potentially harmful stimuli via phagocytosis. PMN traverse 
post-capillary venules at sites of inflammation, degrade pathogens within 
phagolysosomes, and undergo apoptosis. Next, mononuclear cells infiltrate, 
differentiate into macrophages, and clear apoptotic PMN by phagocytosis in a non-
phlogistic manner termed efferocytosis (Rossi et al 2008). Finally, clearance of 
microbes and efflux of phagocytes allows for the tissue to return to it normal state 
(Serhan 2007). Disruption of any of these specific events could potentially give rise to 
chronic inflammation, which is characterized primarily by excessive leukocyte 
infiltration and activation, delayed clearance, thereby resulting in tissue damage, and 
loss of function. Lipid mediators (LM) biosynthesized from essential fatty acids play 
key roles in the defined phases of the inflammatory response (Serhan 2007), with 
prostaglandin E2 (PGE2) and cysteinyl leukotrienes (cysLTs) enhancing early vascular 
permeability and leukotriene B4 (LTB4) stimulating leukocyte chemotaxis 
(Samuelsson et al 1987). Prostaglandins play additional roles during the acute 
inflammatory response, which includes the regulation of local changes in blood flow 
and pain sensitization (Flower 2006). During evolution of an inflammatory exudate, 
the profile of lipid mediators changes to biosynthesis of counter-regulatory mediators 
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that would limit further PMN congregation and promote resolution (Levy et al 2001, 
Serhan et al 2000, Lawrence et al 2010). While the mechanisms that mediate 
progression from acute to chronic inflammation are not completely understood, it is 
hypothesized that chronic inflammation is due to excess of pro-inflammatory 
mediators (Nathan et al 2005). Emerging evidence suggests that it is also plausible 
that disruptions in endogenous pro-resolving circuits could underlie some of the 
aberrant mechanisms that lead to chronic inflammation (Nathan et al 2006, Serhan 
2007).   Complete resolution of an acute inflammatory response is the ideal outcome 
after an insult (Kumar et al 2005).  
 
Systematic studies of lipid mediators in the course of acute inflammatory responses 
have demonstrated that prostaglandins such as prostaglandin E2 (Levy et al 2001) are 
generated during the initial phase of resolution of inflammation. These pro 
inflammatory prostaglandins are needed for the control of blood flow and vessel 
dilation essential for leukocytes to undergo firm adhesion and diapedesis (Williams et 
al 1977). It is known that essential trafficking of lymphocytes from the post-capillary 
lumen to the interstitial space is a process that is mediated in part by leukotriene B4 
(Pouliot et al 2002). Also ‘programmed’ in this initial phase is the activation of 
signaling pathways for the normal self-limiting inflammation (Levy et al 2001,Serhan 
et al 2000, Serhan et al 2002). Signaling pathways (Gilroy et al 1999) leading to 
prostaglandins E2 and D2 in turn actively switch on the transcription of enzymes 
required for the generation of other classes of eicosanoids also generated from 
arachidonic acid, such as lipoxins (Levy et al 2001), as well as newly identified 
families of lipid mediators generated from omega-3 polyunsaturated fatty acid called 
resolvins (resolution-phase interaction products) and protectins (Serhan et al 2000, 
Serhan et al 2002, Marcheselli et al 2003) which normally can  dominate the 











1.9. THE CELLULAR PROGRAM IN RESOLUTION 
 
It has been argued that events occurring early in acute inflammation engage an active 
and coordinated ‘resolution program’ involving a switch to local production of 
specialized intercellular messengers, programmed leukocyte death by apoptosis and 
there after clearance of dying cells by phagocytes that eventually leave the inflamed 
site through lymphatics (Nathan 2002, Lawrence et al 2002 and Savill 1997).  
 
In order for resolution to follow, further leukocyte recruitment should be halted and 
accompanied by clearance of leukocytes from inflammatory sites. Resolution of 
inflammation will occur if granulocytes are eliminated and the tissue mononuclear 
cell population (macrophages and lymphocytes) returns to normal pre inflammation 
numbers and phenotypes (Serhan 2007). It is apoptosis of neutrophils, that causes 
specific recognition and clearance by inflammatory macrophages, an important step in 
inflammation reduction that is found at several inflammatory sites (Savill 1997, Savill 
2001). In addition to clearing dead neutrophils, the process of phagocytosis could 
serve a dual purpose by initiating a key signal to the inflammatory macrophage (and 
perhaps the closely related phagocytic dendritic cell) to begin the process of egress 
from the inflamed local tissue site to the nearest draining lymphatics (Savill 2001), 
which is the usual fate of inflammatory macrophages (Bellingan et al 1996). This 
multicellular ‘waste elimination program’ offers key therapeutic targets. For example, 
constitutive neutrophil apoptosis, which is normally relatively rapid, can be 
manipulated to be slowed by a wide range of inflammatory mediators (Lee et al 
1993), which in turn may engage activation of NF-κB and other ‘prosurvival’ 
transcription factors such as Foxo3a (Johnson et al 2005). These prosurvival and 
activation factors cannot be left unregulated. Hence, mechanisms must exist that can 
override such survival signals. One possible mediator of such signals could be the 
macrophage, whose arrival on the inflammatory scene can cause the release of ‘death 
cytokines’ such as Fas ligand, which can then in turn trigger apoptosis in neighboring 
neutrophils (Brown et al 1999). Alternatively, uptake of apoptotic cells may also 
initiate macrophages to release mediators that suppress the inflammatory response 
(Voll et al 1997, Fadok et al 1998). In particular, strong in vitro and in vivo evidence 
(Huynh et al 1998, Lucas et al 2003) suggests that macrophage secretion of the anti-
inflammatory cytokine transforming growth factor-β1 (TGF-β1) can suppress 
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proinflammatory signaling from Toll-like receptors.  
 
The reparative properties of TGF-β1 indicate a link between mechanisms governing 
resolution of inflammation and the ‘end game’: repair of damaged tissue (Serhan et al 
2005). It has been demonstrated that the lipid mediator Lipoxin A4 increases the 
appearance of TGF-β1 in resolving exudates (Banneberg et al 2005). Lipoxin A4 is 
produced during the resolution phase and hence it serves as a mediator of ‘pro-
resolution’ responses (Serhan et al 2005). By its ability to enhance TGF-β, it is also 
involved in governing resolution and/or its turn to tissue fibrosis. Phagocytosis of 
apoptotic cells inhibits activated macrophage killing of resident tissue cells (Duffield 
et al 2001) and also triggers secretion of vascular endothelial growth factor, which is 
important for repair of endothelial and epithelial injury (Golpon et al 2004). 
Macrophage clearance of apoptotic leukocytes, can be enhanced by several early 
inflammatory mediators (Ren et al 2008), which thereafter can be amplified by early 
interactions with apoptotic cells (Lucas et al 2003). It has been demonstrated that 
early macrophage exposure to cytokines increases the capacity of macrophages to 
ingest apoptotic cells (Erwig et al 1998, Erwig et al 2000). It has thereby been 
proposed that once apoptosis in leukocytes and resident cells is engaged (an early 
event), subsequent uptake of apoptotic cells causes a switch in macrophage phenotype 




The driver for persistent neutrophilic airway inflammation in bronchiectasis is 
unknown, but infection is considered to play a major role. I hypothesize that there is 
failure of resolution in bronchiectasis, which leads to persistent inflammation. 
Hence, elucidating the biochemical pathways leading to resolution of the neutrophilic 
airways inflammation and thereby targeting the host resolution program will help in 
understanding the resolution process or thereby the lack of it in bronchiectasis, which 






1.10. PRO RESOLVING LIPID MEDIATORS (Figure 12)  
 
Excessive inflammation is widely accepted to be a unifying component in many 
chronic diseases, including bronchiectasis, vascular diseases, metabolic syndrome and 
neurological diseases, and thus is a public health concern. Understanding endogenous 
control points within the inflammatory response could potentially provide us with 
new perspectives on disease pathogenesis and treatment approaches. Break in the 
barrier, trauma and microbial invasion encourages the host to neutralize invaders, 
clear the site, and remodel and regenerate tissue. The acute inflammatory response is 
protective. Lipid mediators - such as eicosanoids (prostaglandins and leukotrienes) 
(Flower 2006, Samuelsson 2012) produced from the essential fatty acid arachidonic 
acid, as well as many cytokines and chemokines (Dinarello et al 2012, Serhan and 
Savill 2005) have crucial roles in the initial response. Interactions among 
prostaglandins, leukotrienes and pro-inflammatory cytokines amplify inflammation, 
the signs and effects of which can be reduced by pharmacological inhibition and 
receptor antagonists (Flower 2006, Samuelsson 2012, Dinarello et al 2012). However, 
given that excessive inflammation contributes to several widely occurring diseases, 
improvements are required in treatment and in our understanding of the mechanisms 
involved. Phospholipids metabolize to produce omega 6 and omega 3 derivatives. The 
omega 6 derivative arachidonic acid metabolizes to produce prostaglandins (pro 
inflammatory), lipoxins (anti inflammatory; pro resolving) and leukotrienes (pro 
inflammatory).  Omega 3 derivatives are eicosapentanoic acid (EPA) and 
docosahexanoic acid (DHA) (figure 12).  The omega-3 fatty acids EPA and DHA, 
which are found in marine oils, have long been thought to have anti-inflammatory 
properties and they compete with arachidonic acid, reducing pro-inflammatory 
eicosanoids (Lands 2009). EPA metabolites are the e-series resolvins and DHA 
metabolites are d-series resolvins, maresins and protectins. The molecular mechanism 
by which this occurs is unclear, and the evidence is inconclusive as to whether 





Figure 12. Synthesis of lipoxin. There are three major lipoxygenases (LO): 5-LO, 15-
LO, and 12-LO that are involved in lipoxin synthesis from arachidonic acid. In the 
first pathway of lipoxin synthesis, LTA4 is acted upon by 12-LO, and is converted to 
lipoxin A4 and B4. The second pathway involves the action of a series of lipoxygenase 
(5-LO in neutrophils and 15-LO in erythrocytes) activities on arachidonic acid which 
then gets converted to 15-HEPTE. Lipoxins are formed from 15-HEPTE by the action 
of either 5-LO or 12-LO. The third pathway is the formation of epi-lipoxin A4 or 
aspirin-triggered lipoxin (ATL) and epi-lipoxin B4 whose generation is aspirin 
dependent.  
Green filled represent metabolites or end products whereas the blue filled represent 
the enzymes.  
15-HPETE: 15-hydroxyperoxyeicosatetraenoic acid; COX-2: cyclooxygenase-2; 







 Lipoxins were first isolated from human leukocytes by Serhan et al and were first 
described as a novel series of compounds with four conjugated double bonds (Sehran 
et al 1984).  
 
1.11.1. Synthesis (Figure 12) 
Lipoxins are a metabolite of the arachidonic acid pathway, which was well studied by 
Hamberg and Samuelsson (Hamberg et al 1974). Arachidonic acid pathways play an 
important role in inflammation, producing several anti-inflammatory molecules 
(Malhotra et al 2012). Lipoxins can be synthesized by two major routes from 
arachidonic acid. Additionally, lipoxin epimers can be formed under the influence of 
aspirin treatment as described by Serhan and colleagues (Serhan et al 1984) (figure 
13). There are three major lipoxygenases (LO) that are involved in lipoxin synthesis 
from arachidonic acid namely 5-LO, 15-LO, and 12-LO. The first pathway of lipoxin 
synthesis occurs in platelets where leukotriene A4 is metabolized by 12-LO, and is 
converted to lipoxins (Serhan et al 1990). The second pathway of synthesis involves 
the action of a series of LO (5-LO in neutrophils and 15-LO in erythrocytes and 
reticulocytes) activities on arachidonic acid. Arachidonic acid then gets converted to 
15-hydroxyperoxyeicosatetraenoic acid, which is subsequently converted to lipoxin A 
and lipoxin B (Serhan et al 1984). These pathways occur in neutrophils, eosinophils 
(Serhan et al 1987) and alveolar macrophages (Levy et al 1993), or during cell/cell 
(tissue) interactions (Serhan et al 1987). This route may perhaps be prevalent in the 
airways. A reduction in LXA4 formation and expression of 5-LO and 15-LO isoforms 
was detected in bronchoalveolar lavage cells and endobronchial biopsies from 






1.11.2. Aspirin triggered lipoxins (ATL) 
A series of LX epimers with alcohol at C15 in the R configuration was discovered by 
Claria and Serhan (1995). This is the third pathway for lipoxin generation, which is 
aspirin dependent, and leads to the generation of 15 epi-lipoxin A4, also known as 
aspirin-triggered lipoxin (ATL) and 15 epi-lipoxin B4 (Claria et al 1995). Aspirin 
acetylates cyclooxygenase-2 (COX-2) to form 15R-hydroxy eicosatetraenoic acid (15 
HETE). 15R-HETE is converted thereafter by 5-LO to an epoxide intermediate, 
enzymatically transformed into 15-epi-LXA4 and 15-epi-LXB4 (figure 13). Cellular 
models of several methods of ATL generation include co-incubations of PMN with 
aspirin-treated human umbilical endothelial cells (Claria and Serhan 1995), 
transcellular metabolic exchanges between PMN and A459 lung adenocarcinoma 
cells (Claria et al 1996) or between hepatocytes and liver cells (Titos et al 1999).  In 
addition, ATL production is induced by aspirin when administered to healthy 






Figure 13. Aspirin and statins promote the formation of 15- epi lipoxin A4. Aspirin 
acetylates the active site of COX2 (Asp-COX2) that now is able to metabolize 
arachidonic acid to 15(R)-hydroxyeicosatetranoic (15R-HETE), which when released 
from endothelial and epithelial cells is converted by leucocyte 5-LOX to the aspirin-
triggered LXs (ATLs), 15-epi-LXA4. 







1.11.3. Biological actions of lipoxins and aspirin triggered lipoxins 
There is enough evidence now to suggest that neutrophils change their phenotype to 
produce different profiles of lipid mediators depending on the cells and substrates 
present in their local environment (Levy et al 2001, Serhan et al 2000). Neutrophils in 
resolving inflammatory exudates switch from the production of leukotrienes to that of 
lipoxins and resolvins, whereas neutrophils in the peripheral blood, on activation, 
generate and release leukotriene B4 as one of their main bioactive products (Levy et al 
2001). In the same context, local prostaglandin E2 and prostaglandin D2 stimulate the 
processing of 15-lipoxygenase mRNA in leukocytes to then produce a functional 
enzyme for lipoxin production (Levy et al 2001). Other cell types can acquire the 
ability to generate lipoxins when exposed to certain specific cytokines or growth 
factors (Fiore and Serhan 1990), or in macrophages, for example, when they engulf 
apoptotic leukocytes (Friere-de-Lima 2006). These findings are of significance to pro-
resolution mechanisms because lipoxin A4 generated by macrophages probably 
contributes to the stimulation of their phagocytic activity (Cambell et al 2007) without 
elaborating pro-inflammatory mediators- namely, the non-phlogistic process. 
Pathogens can also contribute to the provision of the necessary components for 
lipoxin biosynthesis. It has been demonstrated that Pseudomonas aeruginosa encodes 
the first identified secretory lipoxygenase that converts host arachidonic acid to 15-
HETE for local lipoxin production (Vance et al 2004). 
 
Lipoxin A4 and lipoxin B4 inhibit neutrophil entry into inflamed sites and counter-
regulate some of the main aspects of inflammation (Serhan et al 2008) (figure 14). 
They act on several cell types including blood cells, neural cells and stromal cells 
(Takano et al 1998, Chiang et al 2006, Maddox and Serhan 1996). Lipoxin A4 
regulates leukocyte responses in vitro and trafficking in vivo by activating its specific 
receptor, known as lipoxin A4 receptor (ALX/FPR2). ALX/FPR2 is a G protein-
coupled receptor (GPCR) that is expressed by leukocytes and has cell-type-specific 
signaling pathways (Chiang et al 2006). This is explained by the fact that in 
neutrophils, lipoxin A4–ALX interactions stop neutrophil migration, whereas in 
monocytes lipoxin A4–ALX interactions stimulate monocyte chemotaxis and non-
phlogistic responses (Maddox et al 1997). Unlike the classic GPCRs for chemo-
attractants that mobilize intracellular Ca2+ to evoke chemotaxis, lipoxins instead 
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induce changes in the phosphorylation of proteins of the cytoskeleton, resulting in cell 
arrest (Gronert et al 1998 and Patcha et al 2004). In addition to these effects on the 
resolution of inflammation, lipoxin A4 reduces organ fibrosis, acts directly on 
vascular and smooth muscle and has direct action in reducing pain (Svensson et al 
2007). 
 
Aspirin impinges on the endogenous lipoxingenerating system during cell–cell 
interactions. Inhibition of prostaglandin biosynthesis by aspirin is a well known 
mechanism in its anti-thrombotic and anti-inflammatory effect (Vane et al 1982). 
Aspirin triggers the endogenous formation of carbon-15 epimeric lipoxins, namely 
aspirin-triggered lipoxins (ATLs). Cells that express cyclooxygenase2 (COX2), 
namely vascular endothelial cells, epithelial cells, macrophages and neutrophils, are 
involved in ATL production. Acetylation of COX2 by aspirin blocks its ability to 
biosynthesize prostaglandins (Serhan et al 2008).  
 
 
LX and ATL exert potent anti-inflammatory pro-resolution actions both in vitro and 
in vivo. Leukocytes, which express high levels of ALX/FPR2, are elective targets of 
these eicosanoids. For instance, LXA4, 15-epi-LXA4 and or stable analogs inhibit 
PMN and eosinophil chemotaxis (Bandeira-Melo et al 2000 and Soyombo et al 1994), 
PMN vascular adhesion, transendothelial and transepithelial migration, superoxide 
anion generation (Carlo et al 2013 and Serhan et al 1984), azurophilic degranulation 
(Gewirtz et al 1999), peroxynitrite formation and nuclear factor (NF)-κB activation 
(Jozsef et al 2002). On the other hand, they stimulate monocyte chemotaxis, 
macrophage efferocytosis and bacterial phagocytosis, reducing the release of 
inflammatory cytokines (Godson et al 2000 and Romano et al 1996). LXA4 also down 












Figure 14: Dual anti inflammatory and pro resolution actions of lipoxins. The key 
histological feature in the resolution of inflammation is the loss of neutrophils from 
the local inflamed sites. This is a programmed process that is actively regulated at 
different levels: by reducing neutrophil infiltration into the exudate, increasing 
monocyte recruitment to the exudate, stimulating macrophage uptake of apoptotic 
neutrophils, and enhancing phagocyte exit from the exudate via the lymphatics. 
 























Neutrophils are first responders in an organism’s rapid assault on infectious 
pathogens. Through genetically conserved receptors, neutrophils recognize 
chemoattractants, lipid products, and the molecular patterns present on the surface of 
bacteria, viruses, and fungi (Medzhitov and Janeway 2000). fMLF is recognized by 
neutrophils and is a potent neutrophil chemoattractant. fMLF, upon binding to its 
heterotrimeric G protein-coupled receptor, initiates signaling cascades that activate 
multiple pathways (Haribabu et al 2000). These pathways include the mitogen-
activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI-3K) cascades, 
which are important for the development of the functional responses of neutrophils in 
inflammation (e.g., the respiratory burst, transmigration, and phagocytosis) (Mocsai et 
al 2000, Rane et al 1997). 
1.12.2. Formyl peptide receptor (FPR) 1  
 
The FPR receptor family was extensively characterised throughout the 1980s as seven 
membrane spanning, G-protein coupled receptors (GPCR) via pertussis toxin 
sensitivity; specifically attributed to G-protein coupling (Lavigne et al 2002). The 
human family was cloned in 1990 (Boulay et al 1990) with three genes encoding 
FPR1, ALX/FPR2 and FPR3 clustered on chromosome 19q13.3.  
 
FPR1, the first chemotactic receptor to have its primary structure delineated by 
molecular cloning (Boulay et al 1990), has been extensively studied for its high 
affinity binding to fMLF. Following agonist ligation, FPR1 undergoes rapid 
phosphorylation in a concentration and time dependent manner (Ali et al, 1993) 
leading to conformation changes. Downstream of G-protein interaction there are a 
number of signalling pathways including calcium (Ca
2+
) flux, phospholipase (PL) A, 




PLC is an essential upstream mediator of both PI3K and mitogen- activated protein 
kinase pathways via protein kinase C (PKC). PLA is well characterised for mediating 
PLC activation central to the biosynthesis of eicosanoids. In neutrophils, activation of 
PI3K following fMLF has been shown to selectively regulate oxidative burst and 
actin relocalisation, essential for cell polarisation. The MAP kinase pathway, in 
particular ERK-1/2, selectively regulates chemokinesis as well as signal transducers 
and activators of transcription proteins and adaptor proteins (Wenzel-Seifert et al 
1998).  
 
Signalling via FPR1 is regulated by two processes, receptor desensitisation and 
agonist-induced internalisation (figure 15). Desensitisation is the result of uncoupling 
of G-protein from the receptor, and can occur either by direct ligation or following 
activation of similar GPCRs. It has been shown that receptor desensitisation and 
internalisation is reliant on PKC following both homologous activation of FPR1 or 
heterologous activation of other GPCRs (Le et al 2001b). After initial activation of 
FPR1 with fMLF, the receptor rapidly reduces its responses to secondary stimulation 
with the same agonist; this is termed homologous desensitisation. FPR1 is also 
susceptible to heterologous desensitisation via ligation of a GPCR receptor, C5aR 
(complement receptor) or CXCR2 (interleukin-8 receptor), in a concentration-
dependent manner (Ali et al 1999). These processes complement the classical idea of 
concentration-gradient dependent migration by peripheral cells to a site of 
inflammation. 
 
Apart from the ability of FPR1 to mediate chemotaxis it was also noted that fMLF 
induced a rapid Ca
2+ mobilisation (Andersson et al 1986). Although Ca
2+ has been a 
robust functional response to fMLF, its biological relevance is still unclear. Ca
2+ is 
required for cytoskeleton reorganisation, but phagocytosis and chemotaxis can occur 
in Ca
2+ depleted cells (Fu et al 2006).  
 
Functionally, FPR1 is mostly associated with host defence; fMLF has been associated 
with eliciting shape change, adhesion, phagocytosis, cytokine production, superoxide 






Figure 15. Simplified representation of leukocyte migration cascade via the FPR 
family (Adapted from Dufton and Peretti 2010). Increasing gradient of formyl peptide 
leads to a well-characterised sequential response activating circulating and resident 
leukocytes. FPR1 is activated at low concentration of formyl peptide. FPR activation 
of leukocytes, results in integrin expression and activation inducing firm adhesion to 
the endothelial cells. High concentration or repeated stimulation by formyl peptide 
can lead to receptor desensitisation, which may be a prominent regulatory mechanism. 
FPRs play a role in macrophage phagocytosis and as yet uncharacterised roles in 
innate-adaptive cell interactions. 
FPR1= Formyl peptide receptor 1; ICAM= intercellular adhesion molecule; PSGL-1= 
P-selectin glycoprotein 1; VCAM= vascular cellular adhesion molecule. 
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1.12.3. ALX/FPR2 receptor 
 
Lipoxin A4 binds to the FPR2 receptor and hence it is known as ALX/FPR2 receptor. 
Originally characterised as the low-affinity fMLF receptor (efficacy ∼1000 fold lower 
than FPR1; (Gao & Murphy, 1993)), ALX/FPR2 has a short but fairly complicated 
history. The human receptor was initially reclassified as the receptor for the 
arachidonic acid-derived Lipoxin A4, termed ALX (Fiore et al 1994). However it soon 
became evident that Lipoxin A4 was not the only competitive agonist capable of 
binding this receptor, with reports describing HIV peptides and serum amyloid A 
(SAA; (Su et al 1999)), Annexin A1 (AnxA1; (Perretti et al 2002)), as well as 
synthetic peptide (W-peptide; (Le et al 2001)) and chemical compounds (C43; (Burli 
et al 2006)). There are currently ∼30 ligands that have been shown to bind the FPR 
family and there is considerable promiscuity across the FPR receptors, with ligands 
capable of transducing either pro- or anti-inflammatory actions in vitro and, in some 
cases, in vivo (Dufton and Perretti 2010). 
 
The signal transduction of ALX/FPR2 is a difficult topic, however it is fair to assume 
it shares part of the intracellular machinery of FPR1 as they have close homology in 
their intracellular domains (Gao & Murphy 1993). A comprehensive study of the 
FPR1 and ALX/FPR2 signaling, conducted by creating chimaeric receptors with 
segments of ALX/FPR2 replaced by FPR1, revealed numerous specific binding sites. 
Of importance is the fact that fMLF recognised the same extracellular loops on both 
FPR1 and ALX/FPR2 but with different affinity. This analysis also revealed that N-
glycosylation is required for peptide binding (although not necessarily at the same 
domain) to ALX/FPR2, but not for the lipid agonist LXA4 (Le et al 2005). Similar to 
FPR1, ALX/FPR2 is strongly associated with host defense, but its novel ability to 
convey both pro- and anti-inflammatory (likewise, activating and inhibitory) signaling 
makes it an intriguing and unusual GPCR. 
 
Interaction of ALX/FPR2 with fMLF and the acute phase protein serum amyloid 
protein A (SAA) leads to NF-κB activation and secretion of CXCL8 by human 
neutrophils (He et al 2003). The reduced affinity for formylated-peptides, such as 
fMLF, was initially thought to reflect receptor redundancy, where by the 
desensitisation of one receptor, FPR1, may result in the prevalence of a second lower 
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affinity counterpart ALX/FPR2 (Hartt et al 1999). Although this hypothesis may be 
true in vitro it is perhaps slightly simplistic when considering the role of heterologous 
desensitisation in vivo.  
ALX/FPR2 has been more comprehensively assessed for its anti-inflammatory 
pharmacology such as ability to provoke deactivation and detachment of leukocytes, 
leukocyte apoptosis, increment phagocytosis of apoptotic cells by phagocytes and 
regulation of COX-2 (El Kebir et al 2007 and Lee et al 2006). Indeed, the most 
striking attribute of ALX/FPR2 pharmacology is related to its putative endogenous 
ligands, which includes the glucocorticoid-modulated protein AnxA1 and LXA4 
among others. SAA (mentioned above) a peptide-derivative of beta-amyloid-A 
(termed βA42) and LL-37 are other potent ligands (figure 16).  
These dual roles of ALX/FPR2 make association with disease pathogenesis difficult 
to define. 
ALX/FPR2 expression is induced by both pro-inflammatory stimuli, e.g. TNF-α (Cui 
et al 2002 and Cui et al 2002) and pattern recognition receptors (Chen et al 2009) as 
well as anti-inflammatory signalling, such as through the glucocorticoid receptor 
(Sawmynaden and Perretti 2006). The strongest mechanistic links are with 






Figure 16. The ALX/FPR2 complex is expressed on leukocytes and the respiratory 
mucosa. The expression of two known ligands for ALX/FPR2, Serum Amyloid A 
(SAA) and LL-37 been shown to initiate a pro-inflammatory response. In contrast, 
alternate ligands Lipoxin A4, Resolvin D1 and Annexin A1 can bind to a different 
receptor region and promote distinct receptor conformations that translate to an 



















Systemic name: 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9- 
isopropylpurine 
Molar mass: 354.45 g/mol 
 
 
Figure 17. Roscovitine 
 
 
Neutrophils are key to the immune system and are recruited rapidly to the site of 
inflammation. Neutrophils then release products of degranulation and activation to 
defend and destroy invading microorganisms but these byproducts are detrimental to 
the surrounding tissues (Nathan 2002). Activated neutrophils need to ‘switch off’ and 
undergo apoptosis for the resolution of inflammation. Once apoptosis has been 
engaged, the neutrophil secretory activity is shutdown; the cells remain intact and are 
phagocytosed by macrophages using recognition mechanisms (efferocytosis) that fail 
to elicit a pro-inflammatory response (Savill et al 1989, Whyte et al 1993). 
Impairment of either apoptosis or efferocytosis will lead to persistence of 
inflammation.  
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Neutrophil apoptosis is controlled by a complex network of signalling pathways that 
regulate both the turnover of key molecules, including the anti-apoptotic 
proteinmyeloid cell leukemia 1 (Mcl-1) and the pro-apoptotic Bcl-2 family member 
Bax, and activation of the caspase family of proteases. (Riley et al 2006).  
 
Cell division of eukaryotic cells occurs in four phases (G1, S, G2, M) and in some 
circumstances, where the cell is terminally differentiated, the cell will rest in G0 
phase. Neutrophils are terminally differentiated cells. The cyclin dependent kinases 
(CDK) are key regulators of the cell cycle, whereby different CDKs become activated 
during cell-cycle progression when complexed with their associated cyclin partners 
(Vermeulen et al 2003).   
 
Rossi et al have been investigating the role of CDK inhibitors in neutrophil apoptosis, 
both in vitro and in vivo (Rossi et al 2006). They have shown that human neutrophils 
express functional CDKs and that different CDK inhibitors directly induce caspase-
dependent neutrophil apoptosis and inhibit cell survival induced by several 
biologically important powerful anti- apoptotic agents. In addition, the CDK inhibitor 
R-roscovitine down-regulates Mcl-1 expression induced by survival factors in 
neutrophils. Further studies have demonstrated in vivo that roscovitine markedly 
enhances resolution of inflammation in mouse models of carrageenan-induced acute 
pleurisy, bleomycin-induced lung inflammation and passively induced arthritis. The 
roscovitine-enhanced resolution of established pleurisy is driven by a caspase- 
mediated pro-apoptotic effect (Rossi et al 2006).  
 
Perhaps unsurprisingly, given the terminally differentiated state of these cells, the 
most significantly expressed CDKs (McGrath et al 2011, Leuenroth et al 2000) have 
no direct role in the cell cycle but are essential for transcription of a key subset of 
genes. Mcl-1 (pro survival protein) is down regulated to the level of genes and this is 
essential for the initiation of apoptosis. It has been further demonstrated that 
roscovitine manipulates the transcriptional machinery of the neutrophils to thereby 
promote apoptosis (Leitch et al 2012). 
These findings suggest that CDK inhibitors may provide a therapeutic strategy to 
promote resolution of inflammatory diseases, through specific induction of 
inflammatory cell apoptosis.  
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1.13.2. Cytochalasin B 
 
Cytochalasin b is a cell permeable mycotoxin, which can strongly inhibit network 
formation by actin filaments. It inhibits cytoplasmic division by blocking the 
formation of contractile microfilaments. In addition, it inhibits cell movement and 
induces nuclear extrusion. Cytochalasin B shortens and inhibits actin filaments by 
blocking monomer addition at the fast-growing end of F actin filaments 
(Theodoropoulos et al 1994). This inhibition can affect all three major steps of actin 
polymerization. Of interest to us for the purpose of this thesis, is the property of 
cytochalasin in inhibiting nuclear extrusion. Nuclear extrusion induced by 
cytochalasin B begins with the movement of the nucleus to the plasma membrane, 
followed by bulge formation in the membrane. The nucleus then moves to the outside 
of the membrane, but stays connected to the cell by a thread-like cytoplasmic bridge. 
If the cells are kept in cytochalasin B containing medium for several hours, the 
process becomes irreversible. Extrusion is assisted by cytochalasin b induced 
weakening of the plasma membrane.  
 
1.13.3. Phorbol 12-myristate 13-acetate  
Phorbol 12-myristate 13-acetate (PMA), is a diester of phorbol and a potent tumor 
promoter used in research to activate the signal transduction enzyme protein kinase C 
(PKC) (Castagna 1982) The effects of PMA on PKC result from its similarity to one 
of the natural activators of classic PKC isoforms, diacylglycerol. In reactive oxygen 
species biology, superoxide was identified as the major reactive oxygen species 
induced by PMA (Swindle 2002). Hence PMA has been routinely used as an inducer 
for endogenous superoxide production (Huang 2014). PMA is used specifically in 
cancer diagnostics as a B-cell specific mitogen in cytogenetic testing. PMA is also 
commonly used together with ionomycin to stimulate T-cell activation, proliferation, 












In mild bronchiectasis, the mainstay of treatment is regular chest clearance with 
physiotherapy, annual influenza and prompt treatment of exacerbations. In more 
advanced bronchiectasis, in addition, there should be consideration of long-term 
antibiotic therapy and or anti-inflammatory therapy.   
 
1.14.1 Macrolides in bronchiectasis 
 
In bronchiectasis, several studies have been conducted with macrolides, but only three 
RCTs (randomized control trials) have been conducted to date in adults, assessing the 
role of macrolide as an anti-inflammatory agent with immunomodulatory properties 
in bronchiectasis. Key studies are summarized below.  
 
Wong (Wong et al 2012) confirmed these findings in the Effectiveness of Macrolides 
in patients with Bronchiectasis using Azithromycin to control Exacerbations 
(EMBRACE) trial. This was a randomised double-blind placebo controlled trial of 
141 patients randomised to either taking azithromycin 500mg three times a week or 
placebo for 6 months. They showed a significant reduction in the rate of event-based 
exacerbation from 1.57 in the placebo group to 0.59 with the azithromycin group.  
There was no statistically significant difference in lung function or quality of life.  
 
More recently the Bronchiectasis and long term Azithromycin Treatment (BAT) study 
in 83 bronchiectasis patients with 3 or more exacerbations in the past year were 
randomised to either 250mg azithromycin once daily or placebo for 1 year (Altenburg 
et al 2013). Results showed a significant decrease in exacerbation frequency in the 
azithromycin group with a longer time to first exacerbation during treatment. FEV1 
and FVC improved with azithromycin as did quality of life as assessed by SGRQ. 
Sputum microbiology was similar at baseline and at 1 year but significant macrolide 
resistance was recorded in 88% compared with 26% in the placebo group.  
Haemophilus influenzae, Staphylococcus aureus and Moraxella catarrhalis were 
resistant to macrolides at the end of treatment. Adverse reactions were reported, 
mainly gastrointestinal symptoms, but not severe enough to discontinue treatment. 
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The Bronchiectasis and Low dose Erythromycin Study (BLESS) investigated the 
effect on exacerbations rates and resistance rates post 1-year therapy with low dose 
erythromycin (Serisier et al 2013). Patients were randomised to low dose 
erythromycin or placebo for 48 weeks. Results showed a significant reduction in 
exacerbation frequency, reduced FEV1 decline but an increase in macrolide 
resistance. Erythromycin was well tolerated without any evidence of significant 
adverse effects. However, there was a significant rise in the proportion of 
erythromycin resistant oropharyngeal Streptococci.  












Reduced Reduced Reduced 
Macrolide 
resistance at the 
end of treatment 
Not recorded 





88% (35% at 
baseline) in 
azithromycin group 
compared to 26% 
(28% at baseline) 
in placebo. 
Mean change 
increased to 27% in 
the erythromycin 
group compared to 
0.04% in placebo. 
Gastrointestinal 
side effects 
13% in placebo 
compared to 27% 
in azithromycin 
group. 
21% in placebo 
compared to 54% 
in azithromycin 
group. 
26% in placebo 
compared to 29% 
in erythromycin 
group. 
QTc Not recorded. Not recorded No change in either 
group. 




1.14.1.2 Limitations of long term macrolide use in bronchiectasis 
It is indeed very encouraging to see the results from the above three trials using 
macrolides as an anti inflammatory agent in bronchiectasis in reducing exacerbations. 
However, the inherent limitation with the use of long-term use of antibiotics 
(including macrolides), in respiratory diseases is the emergence of new pathogens and 
increased antimicrobial resistance against the airway microbiota, which limits the 
enthusiasm for widespread use of antibiotics such as macrolides in bronchiectasis. 
About 2-10% of patients with bronchiectasis develop non-tuberculous mycobacteria 
(NTM) disease. The 1st line of treatment for NTM is macrolides and hence there is a 
concern of macrolide resistance in this group of patients. It seems pragmatic that 
macrolide maintenance therapy should be considered in patients that have been 
carefully selected, experience at least 3 exacerbations annually and have had 
mycobacterial disease excluded.  
There remains a drive for novel non-antibiotic therapy in bronchiectasis  
 
1.14.2. Long term antibiotics 
Two major RCTs have been doing assessing the role of long term inhaled antibiotics 
in stable bronchiectasis. Murray et al assessed the role of nebulized gentamicin in 
stable bronchiectasis patients. Time to next exacerbation was increased with the use 
of inhaled gentamicin (80mg bd) compared to saline control in a 65 patient RCT with 
patients who had a potentially pathogenic microbe, who were treated for 1 year with a 
3 month follow up (61.5 vs 120 days p=0.02) and the exacerbation number was also 
reduced in the active group (0 (0-1) vs 1.5 (1-2) p<0.0001) (Murray et al 2011). 
Quality of life measures improved, sputum was less purulent and exercise capacity 
increased. Emergence of resistance did not occur, however benefits were lost quickly 
on stopping treatment during the 3 month follow up. In this study patients were not 
masked to intervention.  Although 7/32 patients in the gentamicin arm reported 
bronchoconstriction, this only led to withdrawal in 2 patients (the same as the saline 
arm). Further analysis of this study also documented reductions in sputum 
inflammatory markers (including MPO activity, neutrophil elastase, CXCL8 and TNF 
alpha).  
Haworth et al studied 144 bronchiectasis patients with chronic pseudomonas infection 
treated with Promixin (colistin) or 0.45% saline who were followed up until the first 
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exacerbation or 6 month (Haworth et al 2014).  Although the study did not reach 
significance in its primary endpoint of time to next exacerbation (165 days vs 111days 
p=0.11), this was significant in a predetermined “compliant” population (those that 
took the medication for >= 80% of the time (168 vs 103 days p=0.028)).  This could 
be accurately defined because of an electronic chip on the inhaler device.  In the 
whole group analysis they also demonstrated a significant reduction in PA CFU count 
at 12 weeks and a significant improvement in the SGRQ total score at 26 
weeks.  There was no difference in FEV1, sputum weight or adverse events.  The 
incidence of adverse effects leading to discontinuation was low and similar in both 
groups. 
 
1.14.3. Anti-inflammatory agents in bronchiectasis- statins 
I did an RCT in bronchiectasis patients, where 30 patients were randomly allocated to 
receive either high dose atorvastatin (80 mg) and 30 patients received a placebo, 
given orally once a day for 6 months, in a double blind RCT. The primary endpoint 
was reduction in cough from baseline to 6 months, measured by the Leicester Cough 
Questionnaire (LCQ) score. The change from baseline to 6 months in LCQ score 
differed between groups, with a mean change of 1.5 units in patients allocated 
atorvastatin versus –0.7 units in those assigned placebo (mean difference 2.2, 95% CI 
0.5–3.9; p=0.01). 12 (40%) of 30 patients in the atorvastatin group improved by 1.3 
units or more on the LCQ compared with five (17%) of 30 in the placebo group 
(difference 23%, 95% CI 1–45; p=0.04). Ten (33%) patients assigned atorvastatin had 
an adverse event versus three (10%) allocated placebo (difference 23%, 95% CI 3–43; 
p=0.02). No serious adverse events were recorded. I were able to conclude that 6 
months of atorvastatin improved cough on a quality-of-life scale in patients with 
bronchiectasis. Multicenter studies are now needed to assess whether long-term statin 
treatment can reduce exacerbations (Mandal et al 2014). 
 










Peripheral blood neutrophils are reprogrammed in bronchiectasis and this alters their 




There is a dysregulation of lipid mediators in bronchiectasis leading to under 
expression of the pro resolution and anti-inflammatory mediator Lipoxin A4 and 
thereby altered balance with the pro inflammatory mediator leukotriene B4. This 
imbalance of lipid mediators contributes to persistent neutrophilic airways 
inflammation in bronchiectasis 
 
 
1.16. SPECIFIC AIMS 
1. Characterize neutrophils in peripheral blood and airways in bronchiectasis in the 
stable state and during exacerbations.  
 
2. Cohort study in bronchiectasis to establish if LXA4 deficiency correlates with 
disease severity.  
 
3. Characterize lipids in bronchiectasis airways and peripheral blood to establish the 
correlation of LXA4  to disease severity. 
 
4. To investigate a potential mechanism for low levels of LXA4 in bronchiectasis, 
lipoxin biosynthetic genes expression will be measured.  
 
5. Assess the anti-inflammatory and pro resolution effect of LXA4 on neutrophils and 
monocyte-derived macrophages from healthy volunteers. 
 
6. Assess the anti-inflammatory and pro resolution effect of LXA4 on neutrophils 





2.1. STUDY METHODS 
2.1.1. NEUTROPHIL ISOLATION 




• Sodium citrate 3.8 % (3.8 g Sodium citrate tribasic dihydrate (SIGMA 25116) 
in 100 ml bottled water (BAXTER UKF7114)) (solution is sterile filtered 
using a 0.22 µm filter unit)  
• 6% Dextran [6.0g Dextran 500 (GE Healthcare 17-0320-02*) in 100ml 0.9% 
NaCl (BAXTER UKF7124)]. Dissolve in 0.9% NaCl Saline warmed to 37°C 
(solution is sterile filtered using a 0.22 µm filter unit)  
• Percoll (GE healthcare 17-0891-02)  
• PBS (phosphate buffered saline) – without Ca
2+
/Mg
2+ (PAA H15-002)  
• PBS (x10) - without Ca
2+ /Mg
2+  (Sigma D1408)  




All procedures carried out at room temperature unless otherwise stated.  
 
Freshly drawn blood was collected from healthy volunteers, into sodium citrate; (4ml 
of citrate per 40 ml of blood in a 50 ml falcon tube) and mixed by gentle inversion of 
tube, parafilm cap before centrifugation. This was centrifuged at 350g for 20 minutes 
(Acc1/ Brake 0 Hettich centrifuge, Acc0/Brake 0 Mistral centrifuge).  
Platelet-rich plasma (PRP) was aspirated without disturbing the pelleted cells. 
Autologous recalcified plasma (serum) was prepared by adding 220 µl of 1M CaCl 
/10 ml plasma in glass tubes at 37°C for 1 hour. “Serum” was separated from platelet 
plug and transferred to a Falcon tube for later use/storage (4°C for short term or 
frozen for longer term storage). Leukocytes were separated from erythrocytes by 
dextran sedimentation: 6 ml of dextran (see above) was added to each tube (adjust 
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volume of dextran added if necessary – 2.5ml / 10ml cell pellet) and then made to 
50ml with saline pre-warmed to 37°C. This was then mixed carefully to ensure cells 
were fully resuspended then allowed to sediment for between 20 and 30 minutes (not 
more than 30 minutes) at room temperature.  
Percoll gradients were prepared at this point-at room temp. Stock Percoll solution was 





81% Percoll made in PBS WITHOUT Ca
2+
/Mg
2+ (8.1ml Percoll “stock” +1.9 ml 




(7ml Percoll “stock” + 3 ml 




(5.5ml Percoll “stock” + 
4.5ml PBS).  
 
Following dextran sedimentation, each leukocyte-rich upper layer was removed and 
transferred to a fresh 50 ml tube and topped up to 50ml with saline and then 
centrifuged at 350g for 6 min (Acc5/ Brake 5 for both Hettich and Mistral 
centrifuges).  
The pellets from 2 tubes of cells were resuspended in 3ml of the 55% Percoll (upper 
layer). 3ml of 81% Percoll (bottom layer) was carefully placed in the bottom of a 
15ml Falcon tube. 3ml of 70% Percoll (middle layer) was carefully over layered onto 
the bottom layer (slowly to avoid mixing of the gradients). 3ml of cells re suspended 
in the 55% Percoll layer was carefully over-layered onto the middle layer (figure 18). 
Gradients were centrifuged at 720g for 20 min, (Acc1/ Brake 0 Hettich centrifuge, 
Acc0/Brake 0 Mistral centrifuge). Granulocytes were harvested (70/81 interface) and 
residual erythrocytes pelleted at the bottom of the tube.  
Leukocytes were then washed twice in PBS without Ca
2+
/Mg
2+ centrifuged at 230g 
for 6 min, (Acc5/ Brake5 Hettich and Mistral centrifuges). Cells were resuspended at 
desired concentrations in media and counted using a haemocytometer. 10µl of the 
granulocyte suspension was placed on the haemocytometer slide and visualised under 
a light microscope, the number of neutrophils present in 25 squares were counted. The 
number obtained was equal to the number of neutrophils per 0.1µl of suspension, to 












Figure 19. Isolation of neutrophils by Percoll gradient. 
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2.1.2. APOPTOSIS ASSAY 
 
Reagents 
• Lipoxin A4 (5 (S), 6 (R)- Lipoxin A4; Cayman Chemicals) 
• Roscovitine (Calbiochem) 
[Roscovitine is a cyclin dependant kinase inhibitor and has been shown to induce 
caspase dependent neutrophil apoptosis] 
• Annexin V (Roche) 
• Propidium iodide (Sigma Aldrich) 
• Iscove's Modified Dulbecco's Medium (IMDM; Gibco) 
• HBSS (Hanks Balanced Salt Solution; + CaCl2, +MgCl2; Gibco) 
 
Method 
Freshly isolated peripheral blood neutrophils (at least 97% purity – performed 
cytocentrifuge preparation as described above) were suspended at 10x106 cells/ml in 
IMDM supplemented with 10% autologous serum and penicillin/streptomycin (1x). 
Then 75 µl of neutrophil suspension was added to wells of a 96 well flat-bottom plate. 
A row of wells was left clear from the periphery of the plate- to allow for addition of 
reaction media to minimise evaporation. To each well 15µl of treatment (10 times 
concentration) or 20µM of roscovitine or buffer control was added. Following this, 
60µl IMDM with 10% serum was added to each well. If two agents were used in 
combination only 45µl of IMDM was required. Each treatment was done in duplicate 
or triplicate. Plates were then covered with a lid, and incubated at 37oC in a 5% CO2 
incubator for the desired length of time (8 or 20 hours). 
 
Dose and time response experiments were done. Following incubation for the desired 
length of time, the plates were taken out of the incubator.  Each well was then 
vigorously pipetted to dislodge adherent cells and transfer 20µl of cells into a flow 
tube containing 200µl of Annexin V buffer [Annexin buffer= annexin V+ HBBS with 
Ca and Mg in the ratio of 1:500]. The flow tubes were then incubated for 5 min on 
ice. Immediately prior to running each sample on a flow cytometer propidium iodide  
(PI; 1µl of 1mg/ml stock solution) was added. Samples were analysed by flow 
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cytometry (BD FACSCalibur™) using FL-1/FL-2 channel analysis following 
appropriate compensation. Cytospins were done for each of the different treatments.  
 
Dextran sedimentation and discontinuous Percoll gradient, as a means to isolate 
neutrophils from peripheral venous blood, result in cell purity of ≥95%, with between 
1% and 5% eosinophils and 1–2% contaminating mononuclear cells. In individuals 
with atopic conditions, such as hay fever and asthma, eosinophils can represent >5–
10% of the granulocyte population. 
 
Treatment conditions and interpretation 
Once isolated by Percoll Gradient, human peripheral neutrophils were exposed to the 
following conditions: Lipoxin A4 (Sigma Aldrich) at final concentrations of 1nM, 
10nM and 100nM, as LXA4 concentrations <1nM had no effect and LXA4 
concentrations greater than 100nM is not physiological.  





Annexin V negative and PI negative Live cells 
Annexin V positive and PI negative 
 
Apoptotic cells 
Annexin V and PI positive 
 
Necrotic cells 
Table 5. Interpretation of Annexin V and propidium iodide staining 
 
Apoptosis was assessed by blinded morphological assessment of May–Gründwald–
Giemsa stained cytospins, confirmed by quantification of annexin-V–fluorescein 
isothiocyanate binding and propidium iodide staining.  
 
Cell counts 
At 8 (early apoptosis is assessed at 8 hours) and 20hours (late apoptosis is assessed at 
20h), cytocentrifuge preparations from treated and control neutrophil suspensions 
were fixed and stained. Cells were examined under oil immersion light microscopy 
(x1000 magnification) and apoptotic cells were defined as cells containing darkly 
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stained pyknotic nuclei.34 For each time point at least 400 cells were counted from at 
least 4 different fields.  
 
Crossing serum  
 
• Bronchiectasis patients 
In addition, apoptosis assays were done using neutrophils from bronchiectasis patients 
and instead of using autologous serum, serum from a healthy volunteer was used. 
Apoptosis assays with autologous serum were also done at the same time- as a 
control.  
 
• Healthy volunteers 
In addition, apoptosis assays were done using neutrophils from healthy volunteers and 
instead of using autologous serum; serum from a bronchiectasis patient was used. 





2.1.3. REACTIVE OXYGEN SPECIES  
 
Reagents 
• Lipoxin A4 (5 (S), 6 (R)- Lipoxin A4; Cayman Chemicals) 
• DHR (Dihydrorhodamine: Sigma Aldrich) 
[DHR is an uncharged and non-fluorescent reactive oxygen species (ROS) 
indicator that can passively diffuse across membranes where it is oxidized to 
cationic rhodamine, which localizes in the mitochondria and exhibits green 
fluorescence] 
• fMLF (Formyl-Methionyl-Leucyl-Phenylalanine; Sigma Aldrich) 
• PMA (Phorbol 12-myristate 13-acetate; Sigma Aldrich)  
[PMA activates the signal transduction enzyme protein kinase C] 
• DPI (Diphenyleneiodonium chloride; Sigma Aldrich) 
[DPI inhibits NADPH oxidase] 
• HBSS (Hanks Balanced Salt Solution; + CaCl2, +MgCl2; Gibco) 
 
Method 
Freshly isolated peripheral blood neutrophils (at least 97% purity – performed 
cytocentrifuge preparation as described above) were suspended at 2x106 cells/ml in 
HBSS with Ca2+/Mg2+. Neutrophils were then loaded with dihydrorhodamine at a 
final concentration of 10µM for 5minutes. 240µl of neutrophils loaded with DHR 
were added to a 2ml eppendorf and incubated with 30µl of varying concentrations of 
Lipoxin A4 (final concentration: 1nM, 10nM and 100nM) for 30 minutes at 37°C. 
After 30 minutes, the eppendorfs were put on a shaking heat block (300rpm) for 
30minutes. Eppendorfs were then taken off the heat block and 30µl of fMLF (final 
concentration of 100nM- as this was the dose at which fMLF had maximum response- 
as demonstrated in the results section) or PMA (final concentration of 10nM- as this 
was the dose at which PMA had maximum response- as demonstrated in the results 





Eppendorfs were then taken off and immediately put on ice to stop the reaction. The 
suspension from each eppendorf was transferred to a flow tube and run on flow 
cytometry.  
 
DPI (at a final concentration of 1µM- as this is the dose that has been widely used in 






2.1.4. NEUTROPHIL GFP PAO1 PHAGOCYTOSIS ASSAY 
 
Materials 
• Lipoxin A4 (5 (S), 6 (R)- Lipoxin A4; Cayman Chemicals) 
• Fluorescently labeled Pseudomonas - GFP PAO1 
• Autologous serum 
• HBSS (Hanks Balanced Salt Solution; + CaCl2, +MgCl2; Gibco) 
• Lysogeny (LB) broth 
 
Method 
- Preparation of bacteria 
Frozen GFP PAO1 colonies were resuspended in lysogeny broth and put on an 
incubator (Gallankamp, Panasonic Biomedical Europe) at 200rpm at 37°C overnight, 
with gentamicin (Sigma Aldrich UK, at a concentration of 50mcg/ml) added to the 
media to ensure that the bacteria were gentamicin resistant bacteria. Bacteria were 
then sub cultured the following day and were collected when they were in their log 
phase (after 1-2hrs of re suspension). The optical density of the bacterial suspension 
was measured. Bacteria were then opsonized with 20% autologous serum and 
incubated at 37°C for 1 hour. Cells were then centrifuged at 300rpm (Mistral 3000i, 
UK) for 5minutes and re suspended in HBSS (with Ca/Mg), to give a 10-fold higher 
concentration than the phagocytosis assay. Bacteria were re suspended at a final 
concentration of 108 bacteria/ml.  
 
-Preparation of neutrophils 
Freshly isolated peripheral blood neutrophils (at least 97% purity – performed 
cytocentrifuge preparation as described previously) were suspended at 10x106 
cells/ml in HBSS with Ca2+/Mg2+. 270µl of the cell suspension were put in 2ml 
eppendorf and incubated with 30µl of varying concentrations of Lipoxin A4 (final 







100µl of bacterial suspension was added to a fresh 2ml eppendorf. 100µl of the 
neutrophil suspension was then added to the eppendorf and the mixture was gently 
pipetted up and down to allow the suspensions to mix. They were then incubated for 
15 minutes -as this was the maximum time required for phagocytosis to take place 
(leaving the neutrophils to co incubate with the opsonized bacteria for longer than 15 
minutes led to >96% phagocytosis irrespective of the conditions), at 37°C. Spinning 
the eppendorfs at 300g for 5minutes stopped the reaction. The supernatant was 
aspirated and the contents of the eppendorfs were transferred to a flow tube, put on 
ice and then run on flow cytometry (figure 20a,b&c).  
 
Figure 20a. Flow plot of isolated peripheral blood neutrophils.  
X-axis (forward scatter)- represents neutrophils and Y-axis (side scatter) represents 




Figure 20b. Flow plot of fluorescent labeled Pseudomonas (GFP PAO1).  
X- axis represents forward scatter and Y-axis (side scatter) represents Mean 
Fluorescent Intensity (MFI) of GFP PAO1.  
 
Figure 20c. Flow plot of GFP labeled PAO1 phagocytosed by neutrophils.  
X-axis (forward scatter)- represents GFP PAOI phagocytosed by neutrophils and Y-








2.1.5. NEUTROPHIL GFP PAO1 KILLING ASSAY 
 
Materials 
• Lipoxin A4 (5 (S), 6 (R)- Lipoxin A4; Cayman Chemicals) 
• Fluorescently labeled Pseudomonas - GFP PAO1 
• Autologous serum 
• HBSS (Hanks Balanced Salt Solution; + CaCl2, +MgCl2; Gibco) 
• Lysogeny (LB) broth 
• Saponin (Sigma Aldrich, UK) 
 
Method 
GFP Pseudomonas was opsonised with autologous serum and co incubated with 
neutrophils for 15 minutes [(serum), as >95% phagocytosis obtained after 15 minutes] 
or 1 hour [(airways neutrophils)- minimum time required for phagocytosis by airway 
neutrophils] as previously described. Next, spinning the Eppendorfs at 300g for 
5minutes stopped the reaction. The supernatant was discarded, the pelleted cells were 
lysed with saponin and then serially diluted using sterile 0.85% saline to achieve 
dilutional factors of 10-1 to 10-4. Pseudomonas isolation agar (Difco) plates were 
inoculated with 100 µl of dilution. These were incubated at 37°C for 24 hrs. (figure 
21). Colonies of the pathogens were then counted to determine the sputum bacterial 
density, expressed as log10 colony forming units/ml (cfu.ml-1). 
 
 





• Lipoxin A4 (5 (S), 6 (R)- Lipoxin A4; Cayman Chemicals) 
• Cell Tracker green (Invitrogen)- final concentration 20µM 
• Anti CD44 antibody (Sigma Aldrich) 
[CD44 as a key regulator of macrophage capacity for phagocytosis of apoptotic 
cells]35 
• Freshly isolated neutrophils  
• Monocyte derived macrophages (MDM) 
• Iscove's Modified Dulbecco's Medium (IMDM) 
 
Method 
Freshly isolated peripheral blood monocytes (at least 97% purity – performed 
cytocentrifuge preparation as described above) were grown to monocyte derived 
macrophages in a 24 well plate, over 5-8 days, in IMDM with 20% autologous serum 
and 1% Penicillin/ Streptomycin. Cells were washed once during this period.  Freshly 
isolated peripheral blood neutrophils were re suspended at 10X106/ml in IMDM. 
Neutrophils were then stained with cell tracer green (1 in 1000) and left in the 
incubator at 37°C for 30minutes.  The dye was then washed off and neutrophils were 
re suspended in IMDM. The neutrophils were left in the incubator for 20hours at 
37°C, 5% CO2 to undergo apoptosis. After 20 hours, the neutrophils and MDMs were 
washed. Neutrophils were re-suspended in IMDM at 4 million/ml. MDMs were 
treated with of varying concentrations of Lipoxin A4 (final concentration: 1nM, 
10nM, 100nM and 500nM) for 30 minutes at 37°C. Following incubation with 
Lipoxin A4, neutrophils were added at a ratio of 3:1 to the MDMs and left in the 
incubator for 40min – 1hour. Neutrophils that were not phagocytosed were washed 
off.  Trypsin was added to each well and put back in the incubator for 5-10minutes. 
The plate was immediately put on ice to stop the reaction. The cells were pipetted off 





2.1.7. RNA extraction 
 
Reagents 
• RNeasy® micro kit (Qiagen) 
o Spin column 
o RLT buffer 
o RW1 buffer 
o RDD buffer 
o DNase I stock solution 
 
• β-Mercaptoethanol (Sigma Aldrich) 
 
Homogenizing lung brushings 
Lung brushings in 1ml of RNA later were taken from -80 freezer on dry ice. 350µl of 
RLT plus buffer containing b-mercaptoethanol was added to each of the suspensions. 
These were then transferred to Precellys® homogenizing kit CK14 (with 1.4 mm 
ceramic beads) 2 ml tubes and put on Precellys24 for homogenization at a speed of 
5000rpm for 30seconds (figure 22). The samples were then returned to ice. 
 
Figure 22. Percellys 24- lung tissue homogenizing machine. 
 
	 107	
RNA extraction method 
 
Samples were spun at full speed for 3 minutes.  1 volume of 70% ethanol was added 
to each sample and mixed well by pipetting. 700µl of this suspension was transferred 
to an RNeasy MinElute spin column and centrifuged for 30s at 10000rpm. Any flow 
through was discarded.  Any remaining sample was added to the spin column and the 
process was repeated. 350µl of buffer RW1 was added to the spin column. The lid 
was closed and was centrifuged for 15s at 10000rpm.  Any flow through was 
discarded. Next 10µl of DNase I stock solution was added to 70µl Buffer RDD. 
Inverting the tube mixed this. The DNase I incubation mix (80µl) was added directly 
to the RNase MinElute spin column membrane. This was then placed on the bench 
top for 15minutes. 350µl of buffer RW1 was added to the RNase MinElute spin 
column. The lid was closed and centrifuged at 10000rpm for 15s. Flow through was 
discarded. 500µl of 80% ethanol was added to the RNase MinElute spin column. The 
lid was closed and centrifuged at 10000rpm for 2 minutes. Flow through was 
discarded. The RNase MinElute spin column was placed in a new 2ml collection tube. 
The lid of the spin column was left open and centrifuged at full speed for 5minutes to 
dry the membrane. The flow through and the collection tube were discarded. The 
RNase MinElute spin column was placed in a new 1.5ml collection tube. 14µl of ultra 
pure water was added directly to the center of the spin column membrane. The lid was 
closed gently and centrifuged at full speed for 1minute to elute the RNA.  
 
Nanospec and DNAse treatment 
 
1. Nanospec the samples 
 
o RNA                           3µg 
o 10X buffer                  3µL 
o RQ1 DNase                3µL 
o dH2O to make up to   30µL 
 
2. Then Incubate at 37oC for 30 minutes. 
3. Add 3µL stop solution and incubate 65oC for 15 minutes. 








 cDNA generation- RT reaction (for 1X) 
 
10X Reaction buffer                  4µL 
25mM MgCl2                            8.8µL 
dNTP                                          8µL 
Random Hexamers                     2µL 
RNase Inhibitor                          0.8µL 
Mustiscribe RT enzyme             1µL 
‘clean’ RNA                               15.4µL 
 
Total                                           40µL 
 
1. Use  program “SLFRT” on PTC-100 thermal cycler. 
2. Conditions:  
o 25oC for 10 mins 
o 48oC for 40 mins 
o 95oC for 5 mins 
o 4oC hold 





1. Defrost samples on ice 
2. Make up mix for each gene: 
o Master mix (2X)                                 12.5µL 
o 18s (20X)                                            1.25µL 
o Primer probe for each gene (20X)      1.25µL 
o cDNA                                                  2µL 
o dH2O                                                   8µL 
 
                   
                  Total                                                          25µL 
 
 
3. Put 25µL sample into each well of a 48 well PCR plate (make sure it is a Fast 
plate) 
4. Run samples in triplicates. 










• Lipoxin A4 (5 (S), 6 (R)- Lipoxin A4; Cayman Chemicals) 
• PMA (Phorbol 12-myristate 13-acetate; Sigma Aldrich;  
[PMA activates the signal transduction enzyme protein kinase C] 
• DPI (Diphenyleneiodonium chloride; Sigma Aldrich) 
[DPI inhibits NADPH oxidase] 
• HBSS (Hanks Balanced Salt Solution; + CaCl2, +MgCl2; Gibco) +Hepes 
20mM 
• Sytox® green nucleic acid stain (Thermo fisher 5mM solution in DMSO) 




-Fluorescent microscope method 
Freshly isolated neutrophils were used in the assay (neutrophils isolated by Percoll 
gradient as described previously). Neutrophils were resuspended in HBSS+ hepes 
buffer at a concentration of 125,000 cells/ml. 400µL of this suspension (i.e 
50,000cells) were seeded onto a 24 well plate and put in the incubator at 37°C for 
30minutes. This is to help the neutrophils to adhere to the bottom of the plate. After 
30minutes, the plate is carefully taken out of the incubator so as not to disturb the 
cells and then treated with 50µL of 1nm, 10nm and 100nm of LXA4 or 1µM (standard 
dose used in the literature) of DPI (final concentration). The other wells get 50µL of 
the vehicle. Then the plate is put back in the incubator at 37°C for 30minutes. 
Following this, the plate is gently taken out as before and treated with 50µL of 100nm 
PMA (final concentration). The plate is put back in the incubator for 4hours. After 4 
hours, 100µL of 1µM sytox green is added and put back in the incubator for a further 
20-30minutes. Following this, the plate is viewed in an EVOS microscope. On the 
EVOS, representative images of the different treatments are taken in the phase, 
fluorescent and overlay filters. The images are stored and then counted for NETs at a 
later date. NETs are visualized as ‘diffuse’ or ‘spread’ fluorescent shaped images 





-Plate reader method 
Serum and airways neutrophils from the above cohort of patients were incubated for 
4h in a 96 well plate and then SYTOX green a cell-impermeable nucleic acid stain, 
with an excitation/emission maxima of 504/523 nm to give a green fluorescent light, 
was added and NET formation was observed by measuring mean fluorescence in 96 














Figure 23a,b&c. X20 magnification images of NETs in EVOS. a. phase image; b. 
fluorescent labeled neutrophils and c. overlay images of a&b. 6d. X60 magnification 





2.1.9. CD62L CD11b  
 
Materials 
• Lipoxin A4 (5 (S), 6 (R)- Lipoxin A4; Cayman Chemicals) 
• fMLF (Formyl-Methionyl-Leucyl-Phenylalanine; Sigma Aldrich) 
• CD62L antibody (BD Pharmigen ™ PE mouse anti human antibody) 
• CD11b antibody (Alexa Fluor® 488 anti human antibody) 
• PBS (Phosphate buffered saline)+ CaCl2, +MgCl2; Gibco  
• PBS without CaCl2, or MgCl2; Gibco 
 
Method 
Neutrophils were isolated using Percoll gradients as described previously. Freshly 
isolated neutrophils were re suspended in PBS + CaCl2, +MgCl2, at a concentration of 
10X106/ml. 75µL of this suspension was placed in a 2ml eppendorf and treated with 
15µL of 1nm, 10nm and 100nm of LXA4 (final concentration) or vehicle control. This 
was put in an incubator at 37°C for 30minutes. After 30minutes, the eppendorfs were 
taken out of the incubator and put on a shaking heat block at 37°C for 30mins at 
300rpm. Next, 15µL of fMLF or vehicle control was added and 45µL PBS (with Ca2+ 
and Mg2+) was added on top and further incubated at 37°C for 30 minutes. After 
30minutes, 75µL of cells were transferred to a FACS tube containing 75µL PBS 
(without Ca2+ and Mg2+) containing 2µL of CD11b and 2µL CD62L antibodies. These 
tubes were then placed on ice and kept in the dark for 30minutes. After 30minutes, 
1ml of PBS was added to each flow tube and centrifuged at 350g for 5minutes. 
Supernatants were discarded and the cell pellets were re suspended in 300µL of PBS 
(without Ca2+ and Mg2+) and the samples were analyzed by flow cytometry (BD 







2.1.10. NEUTROPHIL ACTIVATION ASSAY (MPO MEASUREMENT)  
 
Materials 
• Lipoxin A4 (5 (S), 6 (R)- Lipoxin A4; Cayman Chemicals) 
• fMLF (Formyl-Methionyl-Leucyl-Phenylalanine,; Sigma Aldrich) 
• Cytochalasin B (Sigma Aldrich) 




Neutrophils were isolated by Percolls gradients as described previously. Once isolated 
neutrophils were re suspended in PBS without CaCl2, or MgCl2. 75µL of neutrophils 
were put in a 2 ml eppendorf and treated with 15µL of LXA4 (final concentrations of 
1nM, 10nM and 100nM) or vehicle control. 30µL of PBS was added to all conditions 
and then the eppendorfs were incubated at 37°C for 30 minutes. Following this, 15µL 
of cytochalasin B (at a final concentration of 1µg/ml- standard concentration) or 
vehicle control was added to the eppendorfs. The eppendorfs were put back in the 
incubator at 37°C for 10 minutes. After 10 minutes, 15µL of fMLF (at a final 
concentration of 10nM- as detected by dose response assay) or vehicle control was 
added.  The eppendorfs were put back in the incubator at 37°C for 30 minutes. The 
reaction was stopped after 30minutes by centrifuging the samples at 8000g for 5 
minutes. The supernatants were collected and stored at -80°C for doing 











2.1.11. ALX/FPR2 RECEPTOR EXPRESSION 
Materials 
• Lipoxin A4 (5 (S), 6 (R)- Lipoxin A4; Cayman Chemicals) 
• APC conjugated anti FPRL1/ FPR 2 receptor antibody (R&D systems) 
• WRW 4 (Torcis® ) 
• Purified human IgG control antibody (R&D systems) 
• Anti IgG antibody (Abcam ab 83786) 
• PBS without CaCl2, or MgCl2; Gibco 
 
Methods 
Neutrophils were isolated by Percoll gradients as previously described. Neutrophils 
were re suspended in PBS (without Ca and Mg) with 5% serum at a concentration of 
10x106/ ml. 180µL of neutrophils were put in 2ml eppendorf. 20µL of IgG was added 
at a concentration of 1:1000 and put on ice for 15 minutes to prevent non-specific 
binding. After 15 minutes, the neutrophils were incubated with 30 µL of WRW 4 (at a 
final concentration of 100nM) or vehicle control, for 30 minutes at 37°C. Following 
this incubation, samples were treated with 30 µL of Lipoxin A4 at a final 
concentration 100nM or vehicle control, for 30 minutes at 37°C. After 30 minutes, 
fMLF at a final concentration of 100nM was added for 15 minutes at 37°C. After 15 
minutes, the APC conjugated anti ALX/FPR2 antibody was added at a final 
concentration of 1mg/ml (2µL) or IgG (2µL) (as a control antibody). 10 µL of PBS 
was added to all eppendorfs to bring the final volume of the suspensions to 300 µL. 
This was then incubated on ice for 1 hour. Samples were then washed and ALX/FPR2 











2.1.12. LIPID MEDIATOR ANALYSIS METHODS 
 
2.1.12.1. Sample Preparation  
BALF samples were received as 50% BALF, 50% methanol. Samples were defrosted 
on ice and the entire content of a tube was mixed with 500 µL cold methanol 
containing 1 ng of internal standard mix. Samples were centrifuged at 4°C for 10 
minutes at 4000 rpm. The supernatant was diluted with 10 mL HPLC grade water so 
that the methanol content was below 10%. Samples were acidified with 1N HCl to pH 
~3.5.  
Serum samples were defrosted on ice and mixed with 2 mL methanol containing 1 ng 
of internal standard mix. Samples were then stored at -20°C for 1h for protein 
precipitation and again defrosted on ice. Samples were centrifuged at 4000 rpm for 
10 min at 4°C and the supernatant was diluted with 20 mL HPLC grade water. 
Diluted samples were acidified to pH ~ 3.5 with 1N HCl. 
 
2.1.12.2. Solid Phase Extraction (SPE) Chromatography 
ISOLUTE C18 500 mg/6 mL cartridges were conditioned with 3x 6 mL methanol and 
2x 6 mL HPLC grade water. Samples were applied and allowed to run through by 
force of gravity. Afterwards cartridges were first washed with half the sample volume 
of HPLC grade water and then with 2x 6 mL hexane. Compounds were eluted with 
6 mL ethylacetate and dried under vacuum. Samples were re-dissolved in 100 µL 
methanol/water 50/50 and stored at -80°C until analysis. 
 
2.1.12.3. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
Analysis 
Samples were analysed on a Thermo Scientific TSQ Quantum Ultra triple quadrupole 
mass spectrometer system coupled to a Thermo Scientific Accela 1250 pump and 
autosampler. Separation was achieved on a Phenomenex Kinetex XB-C18 LC column 
of 100 x 2.1 mm with 1.7 µm particle size, maintained at 32°C. The injection volume 
was 10 µL. A solvent gradient was run with solvent A consisting of 90% water, 10% 
methanol and 0.1% acetic acid and solvent B consisting of 100% methanol and 0.1% 
acetic acid. The gradient was the following: linear increase from 45 to 60% solvent B 
between 0 and 10 minutes, linear increase to 70% solvent B between 10 and 11 
minutes, linear increase to 100% solvent B between 11 and 18 minutes, holding at 
	 116	
100% solvent B between 18 and 20 minutes, decrease back to 45% solvent B between 
20 and 21 minutes and column equilibration at 45 % solvent B between 21 and 25 
minutes.  
 
Figure: 24. Graph of a representative sample. 
 
The mass spectrometer was coupled to an electrospray ionisation (ESI) source 
operated in negative mode and compounds were detected by multiple reaction 
monitoring (MRM). 56 compounds were monitored, including six deuterium labelled 
internal standards (see table 6 below, internal standards shown in italics). Compounds 
were quantified through comparison to original standards. The LC-MS/MS system 
was controlled and data analysis was performed with Thermo Xcalibur 2.2 software. 
Results were normalised to the sample volume and recovery of the associated internal 
standard. 
Prof Phil Whitfield and his team (University of Islands and Highlands) did 




















6 keto PGF1a 369.2 163.2 9 HETE 319.2 151.3 
20 OH LTB4 351.2 195.2 11,12 dHET 337.2 167.2 
20 COOH LTB4 365.2 195.1 14,15 dHET d11 348.3 207.2 
11 dehydro TxB2 367.2 161.2 15 HEPE 317.2 219.2 
8IsoPGF2a 353.2 193.2 8,9 dHET 337.2 127.2 
TxB2 369.2 169.1 12 HEPE 317.2 179.2 
iPF2a VI 353.2 115.2 5 HEPE 317.2 115.2 
11beta PGF2a 353.2 193.1 5,6 dHET 337.2 145.1 
PGE2 351.2 271.2 13 HODE 295.3 195.2 
dihydro PGE2 351.2 235.0 20 HETE 319.2 245.3 
PGE2 d4 355.2 193.2 7 HDHA 343.2 141.2 
PGD2 351.2 233.1 9 HODE 295.3 171.2 
dihydro PGD2 351.2 175.2 15 OxoETE 317.2 113.3 
PGF2a 353.3 193.2 15 HETE 319.2 219.2 
RvD2 375.2 175.1 8 HETE 319.2 155.2 
LXA4 351.2 115.3 11 HETE 319.2 167.2 
RvD1 375.2 215.2 12 HETE 319.3 179.2 
LTD4 495.3 177.0 15 HETE d8 327.3 226.1 
5,6 EET 319.2 191.3 17 HDHA 343.3 281.3 
Maresin 1 359.2 177.2 14 HDHA 343.3 205.2 
LTB4 335.2 195.2 9,10 EpOME 295.2 171.2 
LTB4 d4 339.2 197.2 5 OxoETE 317.2 203.3 
10,17 diHDHA 359.2 153.2 5 HETE 319.3 115.2 
LTE4 438.2 333.3 14,15 EET d11 330.3 175.2 
LTE4 d5 443.3 338.2 11,12 EET 319.2 167.2 
15deoxy D 12,14 
PGJ2 
315.2 271.2 8,9 EET 319.3 155.2 
14,15 dHET 337.2 207.2 14,15 EET 319.3 175.2 
9,10 diHOME 313.2 201.2    
Table 6: Compounds monitored by liquid chromatography mass spectrometry. 
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2.2. COHORT STUDY 
169 patients who met inclusion and exclusion criteria were recruited from the 
Edinburgh Bronchiectasis clinic in the Royal Infirmary of Edinburgh. 
 
Assessments were done at baseline and after one year as shown in table 7. Serum and 
sputum were collected and stored at -800C.  ELISAs were performed as per 
manufacturers instructions in batches. In serum, I measured total white cell count, c- 
reactive protein and erythrocyte sedimentation rate. Interleukin 8, myeloperoxidase 
and free neutrophil elastase were measured in sputum.  
 
Baseline 
Start of Study 
 
End of study 
At 1 year 
Serum 




LTB4, MPO, Elastase, CXCL8 
Sputum  
LTB4, MPO, Elastase, CXCL8 
FEV1 + FVC 
FEV1/FVC 
FEV1 + FVC 
FEV1/FVC 
Exacerbation frequency Exacerbation frequency 
Quality of life questionnaires 
o LCQ 
o SGRQ 
Quality of life questionnaires 
o LCQ 
o SGRQ 
Table 7. Assessments at each study visit. FEV1= Forced expiratory volume in one 
second; FVC= forced vital capacity; LCQ= Leicester cough questionnaire; 




2.3. BRONCHIECTASIS SEVERITY INDEX 
The BSI is a risk stratification tool for mortality and morbidity in bronchiectasis. The 
minimum score is 0 and the maximum score is 26. A score between 0-4 indicates mild 
disease; 5-8 indicates moderate disease and a score of >9 indicate severe disease.  
The BSI was calculated in all bronchiectasis patients taking part in the study. The BSI 
was calculated online on the website www.bronchiectasisseverity.com. The 
breakdown of the BSI is given in table 8. Furthermore table 9 provides the breakdown 

















































≥ 3 2 




















Radiological severity: ≥ 3 lobes 







Table 8. Break down of the bronchiectasis severity index.  
 
 
MRC Dyspnoea Scale 
 
Grade 1 Not troubled by breathless except on strenuous exercise 
 
Grade 2 Short of breath when hurrying on a level or when walking up a slight hill 
 
Grade 3 Walks slower than most people on the level, stops after a mile or so, or 
stops after 15 minutes walking at own pace 
 
Grade 4 Stops for breath after walking 100 yards, or after a few minutes on level 
ground 
 
Grade 5 Too breathless to leave the house, or breathless when dressing/undressing 
 










2.4. QUALITY OF LIFE QUESTIONNAIRES 
 
The patients all completed Leicester cough questionnaire and St. George respiratory 
questionnaire at each visit. 
 
2.4.1. Leicester Cough Questionnaire (LCQ)  
Cough is assessed using the Leicester Cough Questionnaire (LCQ). It is a 19 item 
self-completed quality of life measure of chronic cough. It has 3 domains: physical (8 
items), psychological (7 items) and social (4 items). The total severity score ranges 
from 3-21, a lower score indicating greater impairment of health status due to cough. 
It assesses the impact of symptoms over the preceding 2 weeks and has been used in 
COPD and asthma. It has been validated for use in bronchiectasis (Murray et al 2009). 
The LCQ offers a pertinent, timely and useful clinical tool for bronchiectasis. It 
focuses purely on the impact of cough severity on HRQoL, unlike other 
questionnaires that encompass multiple respiratory symptoms. Cough is the dominant 
symptom of bronchiectasis, present in up to 98% of patients and measuring its impact 
on HRQoL is critical for both disease assessment and targeted management. 
Additionally, the LCQ is concise, consisting of only 19 items, offering greater patient 
acceptance than lengthier questionnaires. The minimum clinically important 
difference for change (MCID) is 1.3 units (Birring et al 2003). 
 
2.4.2. Health related quality of life- St. George’s Respiratory Questionnaire  
(SGRQ)  
Health related quality of life was measured using the St George’s Respiratory 
Questionnaire (Wilson et al 1997). It is a 50-item self-administered health related 
quality of life questionnaire divided into 3 main domains, symptoms, activities and 
impacts. The total score ranges from 0-100; a higher score indicates a poorer health 










2.5. SPUTUM GRAM STAINING 
 
A 10µl sterile loop was used to transfer sputum to a clean, dry, frosted glass slide. 
10µl of sterile saline was gently pipetted onto the sputum and the sample smeared 
uniformly and thinly across the slide. The sample was air-dried and subsequently heat 
fixed by passing the slide through a low flame several times until all moisture had 
evaporated. The slide was then flooded with the primary staining reagent methyl 
violet for one minute followed by gentle rinsing in deionized water. The mordant 
iodine was then used to flood the slide for one minute followed by further gentle 
rinsing in deionized water. Following draining, acetone was used as a decolourising 
agent, flooding the slide until the fluid appeared colourless (approximately ten 
seconds). The slide was immediately rinsed in deionized water. The counterstain basic 
fuschin was then used to flood the slide for one minute before further rinsing in 
deionized water. The slide was gentle blotted using paper towel and allowed to air 
dry. The results of the staining procedure were observed under oil immersion 
microscopy. At low (x100) magnification, the number of squamous cells and 
polymorphonuclear leukocytes per field were counted. At high (x1000) magnification, 
bacterial cell colour was described as purple (gram positive) or pink (gram negative- 
figure 25) and morphology was noted (rods or cocci).  
All sputum samples were considered to be valid if there were >25 polymorphonuclear 
leukocytes and <10 squamous cells on gram stain per low-power (x100 
magnification) field (Gleckman et al 1988).  
 
Figure 25. Gram negative stain of sputum 
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 2.6. QUANTITATIVE AND QUALITATIVE SPUTUM MICROBIOLOGY 
 
2.6.1. 24 hour sputum volume: Collected the day before each clinic visit.  Patients 
were advised to store sputum samples at 4°C (in the fridge) during collection. 
 
2.6.2. Induced sputum: 
Sputum was induced in all study patients at both study visits. Any upper respiratory 
secretions were cleared before the procedure was commenced. Patient was positioned 
in a chair to achieve maximum deposition. 30mls hypertonic saline (3%) was used to 
induce sputum. Most patients were already practicing active cycle breathing 
techniques (ACBT) or if patients were physiotherapy naïve, the researcher taught 
ACBT, before commencing procedure.  Once commencing the induced sputum 
procedure, the aerosol was run for 5 minutes and then stopped.  At this point the 
patient was asked to perform ACBT and try to provide a sample. If this is 
unsuccessful, the whole procedure was repeated again at 5-minute intervals (up to 20 
minutes).   
Our senior chest physiotherapist advised us that the procedure was to be discontinued 
if patient started to spontaneously cough or if the patient became distressed, was 
coughing excessively or saturations dropped below 90%. Sputum induction was 
successfully carried out in all patients in the study.  
 
Each sample was confirmed to be a valid sample suitable for processing if there are 
>25 polymorphonuclear leukocytes and <10 squamous cells present on Gram stain on 












Sputum colour: Graded as mucoid, mucopurulent or purulent (Murray et al 2009). 
 
 
Figure 26. Sputum colour chart (Murray et al 2009) 
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2.6.3. Sputum processing 
 
Sputum was homogenized and liquefied using an equal volume of dithiothreitol and 
serially diluted using sterile 0.85% saline to achieve dilutional factors of 10-1 to 10-4. 
Pseudomonas isolation agar (Difco), chocolate blood agar containing bacitracin 
(Oxoid) and horse blood agar (Oxoid) plates were inoculated with 100 µl of dilution. 
These were incubated at 37°C for 48 hrs. Colonies of the pathogens were then 
counted to determine the sputum bacterial density, expressed as log10 colony forming 
units/ml (cfu.ml-1).  The rest of the sample was divided equally into portions; the first 
was ultracentrifuged at 30000g for 90 min at 4°C (Hill et al 1999). The sol phase was 
stored at -70°C until needed for analyzing. 
 
2.6.4. Qualitative sputum bacteriology  
 
Bacterial Count was calculated:  Number of bacteria x 2 x 10 x dilution factor to give 
the number of cfu/ml. 
Viable pathogens were identified following incubation based on colonial morphology, 
Gram stain and further, specific standardised identification tests. The identification 




2.7. Haemophilus influenzae  
The primary isolation media used for Haemophilus influenzae was chocolate with 
bacitracin agar incubated at 37°C at 5%CO. Colonies are small, round and convex 
and typically appear after 24hrs incubation. The species appear negative on Gram 
staining as spherical, oval or rod shaped cells of less than 1µm diameter. Colonies 
suspected to be Haemophilus species from morphology and Gram stain appearance 
were further identified based on their requirement for X and V factors (figure 27a&b). 
One or more colonies were selected using a sterile straight wire loop and emulsified 
in distilled water to produce a light suspension. 100µl of suspension was inoculated 
onto nutrient agar and spread evenly using a sterile hockey stick spreader. Three filter 
paper discs incorporating X factor (comprising protoporphyrin IX and haemin), V 
factor (comprising nicotinamide adenine dinucleotide) and XV factors together 
respectively, were positioned on the inoculated agar surface in the configuration of an 
equilateral triangle with a minimum of 3.5cm distance between the discs. Following 
overnight incubation at 37°C, the agar plate was examined for growth around the 
discs. H influenzae was distinguished from H parainfluenzae as detailed in table 10. 
Factor Haemophilus influenzae Haemophilus 
parainfluenzae 
 
X Negative for growth 
around disc 
Negative for growth 
around disc 
V Negative for growth 
around disc 
Positive for growth around 
disc 
X and V Positive for growth around 
disc 
Positive for growth around 
disc 









Figure 27. (a) HI influenzae and (b) XV testing: showing growth around the XV disc 
as indicated by the arrow but no growth around X or V discs. This indicates that the 
organism isolated is Haemophilus influenzae.  
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2.8. Streptococcus pneumoniae  
The primary isolation media used for Streptococcus species was horse blood agar. 
Colonies appear white, 1-2mm in diameter and may have a classic draughtsman 
appearance due to autolysis after incubation. Streptococcus species are positive on 
Gram staining, appear round and are in pairs, chains or clusters. Colonies suspected 
from morphology and Gram stain appearance to be Streptococcus pneumoniae was 
further identified by assessing their sensitivity to ethylhydrocupreine hydrochloride 
(optochin test). Ethylhydrocupreine hydrochloride causes changes in surface tension 
of the cell membrane causing Streptococcus pneumoniae to lyse. Fresh suspicious 
colonies were selected using a sterile straight wire loop and streaked across a horse 
blood agar plate. An optochin disc (filter paper disc impregnated with 5µg of 
ethylhydrocupreine hydrochloride) was placed in the centre of the inoculated agar and 
incubated at 37°C at 5% CO for 24hours. Following incubation, the inoculated agar 
was examined for zones of inhibition. A positive result was defined as a radial zone of 
inhibition measuring 5mm or more from the edge of the disc. A negative result was 
defined as either no zone of inhibition or a zone of inhibition less than 5mm radius 
from the edge of the disc (figure 28a&b).  
 
Figure 28a. S. pneumoniae. b. Optochin disc test confirming S pneumoniae. Solid 
arrow represents area around optochin disc inhibiting growth of S. pneumoniae.  
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2.9. Staphylococcus aureus  
The primary isolation media used for Staphylococcus aureus was horse blood agar. 
Colonies are opaque with either a creamy white colour or a yellow-orange colour. 
Gram staining shows gram-positive cocci occurring either singly, in pairs or in 
irregular clusters. Colonies suspected to be Staphylococcus aureus were confirmed 
using the commercial test kit Dryspot Staphytect Plus, a latex slide agglutination test 
according to the manufacturer’s instructions (Oxoid Limited, Basingstoke, 




Figure 29. Staphylococcus aureus isolated in our laboratory.  
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2.10. Pseudomonas aeruginosa  
Cetrimide (Difco) Pseudomonas isolation agar was used as the primary selective 
media for Pseudomonas aeruginosa. Morphological identification of colonies may 
have included several characteristics. The most common type of colony is a large, low 
oval convex shape with a rough appearance. There may be a characteristic smell of 
aminoacetophenone and colonies may have a blue-green appearance due to the 
production of pyocyanin (blue) and pyoverdin (yellow). The production of this 
pigment is indicative of Pseudomonas aeruginosa, although some strains particularly 
mucoid strains may not produce pyocyanin. Further identification of colonies was 
confirmed using the commercially available API20NE kit (bioMerieux UK Limited, 
Basingstoke, Hampshire) according to the manufacturers’ instructions. Briefly, 
approximately one to four colonies were selected using a sterile straight wire loop and 
emulsified with 2ml of 0.85% sterile saline to produce a suspension approximating a 
0.5McFarland standard. The API20NE test strip consists of twenty microtubes 
containing dehydrated substances. These microtubes were inoculated with the 
bacterial suspension and incubated for 24 or 48 hours at 30°C with the addition of 
reagents and interpretation of reactions done according to the manufacturer’s 
directions. The biochemical reactions were converted accordingly into an octal profile 
number and decoded using the Analytical Profile Index (API Database Vn6.0, 







Figure 30 a. Mucoid P. aeruginosa isolated in our laboratory- green in colour due to 










2.11. Moraxella catarrhalis  
The primary isolation media used for Moraxella species was chocolate brown agar. 
Colonies are white or buff and convex in shape (figure 31). The species appear as 
negative cocci on Gram stain, are approximately 0.6-1.0µm diameter, and occur either 
singly or in pairs. Colonies suspected to be Moraxella species from morphology and 
Gram stain appearance were tested for a positive oxidase reaction. Filter paper was 
soaked in the test reagent N, N, N’, N’-tetra-methyl-p-phenylenediamine 
dihydrochloride. A sterile wooden stick was used to select at least one suspicious 
colony and rub it onto the pre- soaked filter paper. A reaction was looked for within 
ten seconds. A positive result was confirmed with the development of a blue colour, 














2.12. Enterobacteriaceae  
Enterobacteriaceae were selected from horse blood agar. The colonies are 2-3mm in 
diameter, are low, convex, grey and maybe smooth or mucoid (figure 32). The cells 
appear as Gram negative rods. Further identification of suspicious colonies was 
initially with a negative oxidase test as described previously and then the commercial 
kit API20E was used (bioMerieux UK Limited, Basingstoke, Hampshire). The 
principle and preparation of the API20E strip is similar to the API20NE strip 
described above, with incubation for only 24 hours at 30°C.  
 
 
Figure 32. Gram-negative microorganism isolated from sputum of bronchiectasis 









2.13. SPUTUM INFLAMMATION MARKERS 
For measurement of markers of airway inflammation, sputum, not treated with DTT, 
was ultracentrifuged (Sorvall™ Ultracentrifuge, UK) at 23200rpm for 90 minutes at 
4°C. The sol phase was removed, immediately frozen in aliquots at -80°C. I measured 
sputum Myeloperoxidase, free neutrophil elastase and CXCL8. 
 
2.13.1. Myeloperoxidase (MPO): MPO activity was measured by a chromogenic 
substrate assay. 
Myeloperoxidase (Calbiochem ®) and samples were diluted as necessary in 
phosphate buffered solution. All reagents were brought to room temperature first.  
25µL of standard or sample was added to the wells of a 96 well microtitre plate 
(Costar®). 25µL of tetramethylbenzidine (Sigma) was added to each well. The plate 
was then incubated for 5minutes at 25ºC. Reaction was stopped by adding 50uL of 
sulphuric acid solution to each well. Absorbance was measured using a dual 
wavelength of 450 and 560nm and MPO concentration interpolated from the standard 
curve and expressed as µg/ml. The MPO concentration was determined in duplicate 
for each sample or standard and the mean determined for each. 
 
2.13.2. Free Elastase activity (NE):  
NE activity present in the samples was measured spectrophotometrically using the 
synthetic substrate methoxysuccinyl-ala-ala-pro-valparanitroanilide  
[MeOSAAPVpNa 4-(2-hydroxyethyl)- 1-piperazineethanesulfonic acid] (Sigma) as 
described below (Hill et al 1999, Stockley et al 2000). 
Standards (NE from Sigma Aldrich) and samples were diluted as necessary in buffer. 
40µL of standard or sample were added to each well of a 96 well microtitre plate 
(Costar®). 40µl of MeoSAAPvn was added to each well and samples read 
immediately at 37ºC for a minimum of thirty minutes with readings every two 
minutes.  
The rate of change in optical density is converted into elastase activity and expressed 
in units per milligram. The elastase concentration for each sample is determined in 




2.13.3. Measurement of CXCL8:  
CXCL-8 is a key neutrophil chemoatttractant in bronchiectasis (Milkami et al 1998). 
Untreated sputum sol phase was assayed using commercially available specific  
enzyme linked immunosorbant assay (ELISA, R+D systems, Abingdon, UK) using 
kits previously validated for sputum use according to established methodology 













2.13.4. Validation of sputum ELISA’s  
All assays for sputum were validated as described (Stockley and Bayley 2000). 
Standard curves for each assay were obtained using pure mediator provided by the 
manufacturer following the assay protocol. Three pools of sputum solvent were 
prepared from 4 patients each with mucoid (grade 1), muco-purulent (grade 2) and 
purulent sputum (grade 3 or 4) based on a previously published sputum colour chart 
(Murray et al 2009). Three parameters were assessed in validating assays: Reliability, 
recovery of spiked mediators and the effect of sample dilution.  
  
Reliability: The quantity of mediator in each sputum pool was determined by 
interpolation against the standard curve. Individual samples were assayed 5 times on a 
single plate to obtain the intraassay co-efficient of variation. Each sample was also 
assayed 5 times on different plates to obtain the inter-assay co-efficient of variation.  
 
Spike and recovery: a known quantity of each mediator was spiked into the 3 pools of 
sputum. These “spiked” samples were then assayed and compared to the values 
obtained for the original pool. The obtained value was divided by the predicted value 
to calculate the % recovery.  
Dilution effect: The 3 sputum pools were assayed at dilutions ranging from 1 in 1000, 
to 1 in 5.  
 
An assay was deemed to be valid if it had a reliable standard curve, an intra-assay and 
inter- assay coefficient of variation <10%, recovery of spiked samples in the range 
80-120% of predicted and a linear dilution effect (Stockley and Bayley 2000). Table 

































































Forced expiratory volume in 1 second (FEV1) and Forced Vital Capacity (FVC) were 
measured according to standardized guidelines (Miller et al 2005) using a 
MicroMedical Microloop ML3535 (Viasys Healthcare).  
 
FEV1 is the maximal volume of air exhaled in the first second of forced expiration 
following a forced expiration from a position of full inspiration and is expressed in 
litres. FVC is the maximal volume of air exhaled with maximally forced effort from a 
maximal inspiration and is expressed in litres. The highest of three technically 
satisfactory measurements (within 10%) was recorded for each and the ratio was 
calculated. Actual values were recorded and were also expressed as % predicted for 
the patients age, sex, and height.  
 
 
2.15. SYSTEMIC MARKERS OF INFLAMMATION 
30 ml of venous blood was collected for full blood count, erythrocyte sedimentation 
rate and c reactive protein were measured.  
5 ml of blood was centrifuged at 750g for 10 min and the supernatant collected and 
stored at -70C, for measuring pro and anti inflammatory cytokines and 























• 1% Xylocaine throat spray 
• Topical 2% lidocaine spray to be inserted via the bronchoscope- total 14mls 
• Fentanyl 100µg/ml 
• Midazolam- 1mg/ml 
• Olympus bronchoscope 
• Monitor 
• Brush; traps 
• 0.9% saline 
• Lignocaine jelly 
• Emergency drugs for reversal of anesthetics administered 
o Flumazenil (for reversal of midazolam) 
o Naloxone  (for reversal of fentanyl) 
 
Method 
I performed all procedures under supervision of a Consultant Respiratory Physician 
at the Royal Infirmary of Edinburgh (figure 33).  
 
Ensure patient meets inclusion and exclusion criteria. Patient remains fasted from the 
midnight before the procedure. On the day of the procedure, patient is put in a 
monitored bed and his oxygen saturations and heart rate are recorded.  The patient is 
laid flat and just prior to the procedure, 12mls of 1% xylocaine throat spray is sprayed 
to anaesthetize the vocal cords. Following this, a mouth guard is inserted and 
midazolam (maximum 5mg) and fentanyl (maximum 100µg) is administered to 
ensure that the patient is lightly sedated and ready for the procedure. The sterile 
bronchoscope is checked and then after applying xylocaine jelly around the tip of the 
bronchoscope, the scope is carefully inserted into the mouth of the patient and the 
vocal cords are visualized and checked for vocal cord palsy. The scope is then 
advanced into the trachea and the main bronchus and on reaching the main carina, 
both the left and right main bronchus are topically anaesthetized with 2% lidocaine 
spray through the scope. All the while, the anatomy of the bronchi is observed to 
ensure that there is no abnormality. In bronchiectasis patients, the target sites to be 
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washed and brushed are identified before starting the procedure- based on the results 
of an up to date CT scan that the patient had done prior to the procedure. In healthy 
volunteers, generally the right middle lobe was targeted. In general, I washed and 
brushed an area of the lung unaffected with bronchiectasis and an area affected by 
bronchiectasis. Once the target area is reached- 60mls of saline is gently flushed into 
the segment of the lobe and aspirated back into a trap attached to the outside. After 
washing out the segments, the same segments are brushed and samples are collected 
in RNA later. After a quick visualization of the lobes, the scope is withdrawn and the 
patient is made to sit upright. The research nurses then recover the patient for 2 hours 



















2.17. ISOLATION OF AIRWAY NEUTROPHILS 
 
Reagents 
• Brochoalveolar lavage 
• Phosphate buffered saline 
• Sputolysin 
• Tryptan blue 




Bronchoalveolar lavage was washed with 8 times volume of phosphate buffered 
saline (PBS). This was then centrifuged at 2000rpm for 10minutes.  The supernatant 
was discarded and then washed with 4 times volume of PBS at 1500rpm for 10 
minutes. Supernatant was discarded and then 4 times volume of sputolysin was added 
and left on a roller for 10 minutes. Following this, the lavage fluid was filtered 
through sterile gauze filter (40µm) and viability was ascertained by exclusion of 
tryptan blue. Viable cells were counted by a hematocytometer. Final centrifuge was 
done at 2000rpm for 10 minutes at 4˚C. After discarding the supernatant, lavage cells 
were re suspended in PBS at desired concentration. Cytospins were prepared in a 
Shandon cytospin 4 (Shandon, Pittsburgh, PA, USA) and stained with Diff-Quick 
stain (Merz Dade, Switzerland) to check for purity of neutrophils isolated.  
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2.18. STATISTICAL ANALYSIS 
 
Normality of data was checked using Shapiro-Wilk’s test (p>0.05). Overall, 
parametric data is presented as mean ± standard error of mean (SEM) unless 
otherwise specified. 
-For the neutrophil sub type study and the study assessing the effect of lipoxin on 
neutrophil function:  In experiments that mainly involved three groups, data was 
analyzed by one-way ANOVA with a Bonferroni’s multiple comparison post hoc test. 
For comparison of two groups, unpaired t tests were done. Flow cytometry analysis 
was performed using FlowJo v10.0.4 (Tree Star, Ashland, OR, USA). 
-For the longitudinal study: Unpaired t tests were done to compare the lipoxin 
sufficient and deficient groups. Microbiology data is presented as median (inter 
quartile range). 
-For the bronchoscopy study: Continuous data is presented as n (%) and parametric 
data as mean ± standard error of mean (SEM). For all data with more than 2 groups, 
one-way ANOVA was done. To analyze data from affected and unaffected segments, 
paired t tests were done. Unpaired t tests were done to compare two study groups as 
shown in the results section. Microbiology data is presented as median (inter quartile 
range).  
Significance was accepted with P values: *P < 0.05. 









NEUTROPHIL AND LIPOXIN STUDIES 
 
3.1. NEUTROPHIL SUBTYPE STUDIES 
Study Aim: To characterize neutrophils in the blood and airways in bronchiectasis 
patients in the stable state and during exacerbations.  
Blood neutrophil apoptosis, CD11b and CD62L expression, myeloperoxidase release, 
and superoxide generation was assessed. Measuring phagocytosis and killing of GFP 
labeled bacteria (PAO1) assessed neutrophil function. Once neutrophils were 
characterized, the effects of Lipoxin A4 on the function of these neutrophils were 
assessed.  The results will be discussed as blood neutrophils and airways neutrophils 
separately.  
 
For blood neutrophil studies, 8 healthy volunteers, 8 patients with mild 
(Bronchiectasis Severity Index 0-4) and 8 patients with severe bronchiectasis 
(Bronchiectasis Severity Index >9) were recruited. 60mls of blood was taken, as 
described in the methods section. For airways neutrophil studies, only the 
bronchiectasis patients (8 mild and 8 severe) underwent bronchoscopy. 
Bronchoalveolar lavage fluid was obtained and airways neutrophils were isolated, as 
described in materials and methods. No healthy volunteers were bronchoscoped.  
The experiments described below pertain to the samples from these participants.  
 
3.1.1. Blood neutrophil spontaneous apoptosis rate is altered in bronchiectasis 
Blood neutrophils were isolated by percoll gradient as previously described. The 
assays were done on cells incubated in the presence of 10% autologous serum. Late 
apoptosis (20 hours) was measured at 20 hours (Figure 34a, b and c). The same effect 
was observed when analysis of total cell numbers were done as compared to the gold 
standard microscopic counts, demonstrating that these percentages were not skewed 
by an artefact of cell loss. 
 
Analysis by one way ANOVA, comparing healthy volunteers, mild and severe 
bronchiectasis (separate ANOVAs for viable, apoptotic and necrotic cells), showed 
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that in these untreated neutrophils, there was a higher proportion of viable cells in 
the preparations from bronchiectasis patients, with the overall p value being 
p<0.0001, with the healthy volunteers being the control group. Using Bonferroni’s 
multiple comparison post hoc tests, there were statistically significant differences in 
the percentage of viable neutrophils between healthy volunteers and mild 
bronchiectasis patients (p<0.0001), and between healthy volunteers and severe 
bronchiectasis patients (p=0.0003). There was a corresponding statistically 
significant, lower percentage of apoptotic neutrophils in the preparations from 
bronchiectasis patients, with the overall p value being p=0.0003, with the healthy 
volunteers being the control group. Using Bonferroni’s multiple comparison, post hoc 
tests, there were statistically significant differences in the percentage of apoptotic 
neutrophils between healthy volunteers and mild bronchiectasis patients (p=0.003), 
and between healthy volunteers and severe bronchiectasis patients (p=0.0002). There 
was no difference in the necrotic neutrophils, between healthy volunteers, mild and 
severe bronchiectasis, p=0.7.  
Cell counts were also done, for all conditions and this confirmed that there were 
significantly lower apoptotic cells (p<0.0001) and significantly higher viable cells in 





Figure 34a. Blood neutrophils from mild and severe bronchiectasis patients survived 
longer and underwent later apoptosis as compared to healthy volunteers.  
1a. Blood neutrophils from mild and severe bronchiectasis and healthy volunteers 
were cultured for 20 hours and cell viability (Q4: AnnV-ve/ PI-ve), apoptosis (Q3: 
AnnV+ve/PI-ve) and necrosis (Q2: AnnV+ve/PI+ve) was assessed by flow cytometry. 
N=8 in each group; percentage of viable, apoptotic and necrotic neutrophils in each 























Figure 34b. Cumulative data from N=8 donors in each group. There was no difference 
in the proportion of necrotic neutrophils between the groups.  
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Figure 34c. At 20 hours, cytocentrifuge preparations (gold standard for quantifying 
apoptosis) from neutrophil suspensions were also fixed and stained. Cells were 
examined under oil immersion light microscopy and apoptotic cells were defined as 
cells containing darkly stained pyknotic nuclei. Solid arrow represents healthy 
neutrophils with multi lobulated nuclei, more abundant in neutrophils from mild and 
severe bronchiectasis. Dashed arrow represents dark, pyknotic nuclei in apoptotic 


















Viable neutrophils Apoptotic neutrophils  
Figure 34d. Significantly higher viable and lower apoptotic neutrophils in 
bronchiectasis compared to healthy volunteers, at 20 hrs. At 20 hours, at least 400 
cells were counted from at least 4 different fields. Pooled data from n=8, presented as 
mean ± SEM. ****P<0.0001. 
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3.1.1.1. Bronchiectasis neutrophil apoptosis is increased when incubating cells 
with serum from healthy volunteers 
 
Having found that the spontaneous apoptosis rate was altered in blood neutrophils 
from mild bronchiectasis patients, in the presence of autologous serum, the question 
of whether a patient serum factor was responsible was addressed by assessing 
apoptosis in the presence of serum from healthy volunteers and patient’s autologous 
serum. 
 
Spontaneous neutrophil apoptosis was assessed as above in 6 mild bronchiectasis 
patients by comparing rates of apoptosis of their blood neutrophils in the presence of 
10% autologous serum, with that in 10% serum from healthy volunteers (figure 35). 
Using non parametric paired t- tests, after 20 hours, there was a small, but statistically 
significant (from 51% to 43%, p=0.02) reduction in the percentage of viable 
neutrophils when incubated with healthy volunteer serum, compared to autologous 
patient serum, and a corresponding small, significant increase in the percentage of 
apoptotic neutrophils (from 38% to 43%, p=0.02). There was no change in the 
percentage of necrotic neutrophils (p=0.3). 
 
This part of the study indicates that there is perhaps a pro survival factor in serum of 

























Figure 35. A serum or survival factor is missing in mild bronchiectasis serum 
compared to healthy volunteers. This results in reduction in viability and increased 
apoptosis when cells are incubated using serum from healthy volunteers. There is no 
change in necrotic neutrophils. Paired t- tests used for all comparisons. *P<0.05. 
Pooled data from n=6 donors; data presented as mean (+/- SEM). 










3.1.1.2. Blood neutrophil apoptosis is not altered in healthy volunteers when 
incubated with bronchiectasis serum 
 
Having found that viability and apoptosis rates were altered when bronchiectatic 
neutrophils were incubated with serum from healthy volunteers, I wanted to confirm 
that there was a survival factor in bronchiectasis patient serum that was not present in 
serum from healthy volunteers. 
 
Spontaneous neutrophil apoptosis was assessed as above in 6 healthy volunteers by 
comparing rates of apoptosis of their blood neutrophils in the presence of 10% 
autologous serum, with that in 10% serum from mild bronchiectasis patients. 
 
Using non parametric paired t- test- Wilcoxon test, after 20 hours; there was no 
statistically significant (from 43% to 42%, p=0.8) change in the percentage of viable 
neutrophils when incubated with autologous serum, compared to bronchiectasis 
patient serum. There was no significant change in the percentage of apoptotic 
neutrophils (from 42% to 39%, p=0.2) when incubated with autologous serum, 
compared to bronchiectasis patient serum. There was no change in the percentage of 
necrotic neutrophils (p=0.3) (figure 36).  
 
These data raise that possibility that a factor in healthy serum, deficient in serum from 
bronchiectasis patients, can promote neutrophil apoptosis. However, the effect of 
serum was minimal compared to the overall disease-specific differences between the 
rates of spontaneous apoptosis of neutrophils, suggesting some level of 

























Figure 36. Blood neutrophil apoptosis is not altered in healthy volunteers when 
incubated with mild bronchiectasis serum. There was no significant change in viable, 
apoptotic or necrotic neutrophils when healthy volunteers neutrophils were incubated 
with bronchiectatic serum. Paired t tests used for all comparisons. Pooled data from 
n=6 donors; data presented as mean (+/- SEM). 














3.1.2. NEUTROPHIL ACTIVATION 
 
Neutrophil activation leads to upregulation of CD11b and shedding of CD62L. 8 
healthy volunteers, 8 patients with mild (Bronchiectasis Severity Index 0-4) and 8 
patients with severe bronchiectasis (Bronchiectasis Severity Index >9) were recruited 
and 60mls of blood taken as described in the materials and methods section. 
Neutrophils were activated with N-Formylmethionine-leucyl-phenylalanine (fMLF) 
100nM or vehicle control (PBS with calcium and magnesium) for 30mins. fMLF is a 
potent neutrophil chemoattractant that upon binding to its heterotrimeric G protein-
coupled receptor, initiates signaling cascades that activate multiple pathways. fMLF is 
found in both gram positive and gram-negative bacteria and is hence used extensively 
for in vitro experiments in this research (as bronchiectasis patients are infected with 
both positive and gram negative bacteria). Described in this section, is measurement 
of CD11b and CD62L in untreated blood neutrophils only. Activation of neutrophils 
with fMLF and subsequent measurement of CD11b and CD62L is described in 
section 3.9.2. The reason, CD11b and CD62L measurement has been done in 
untreated neutrophils is to assess and compare neutrophil activity at baseline in 




3.1.2.1. CD11b expression is higher in severe bronchiectasis patients compared to 
mild bronchiectasis and healthy volunteers 
 
Analysis by one way ANOVA, comparing healthy volunteers, mild and severe 
bronchiectasis showed that in these vehicle treated (PBS with calcium and 
magnesium) neutrophils, after 30 minutes, there was a higher proportion of CD11b 
expression (via setting a gate against a control) in cells from severe bronchiectasis 
patients, with the overall p value being p=0.01 using Bonferroni’s multiple 
comparison, post hoc test (p=0.02 for comparison between healthy volunteers and 
severe bronchiectasis; p=0.02 for comparison between mild and severe 
bronchiectasis; severe bronchiectasis was the control group against which mild and 














































Figure 37. The baseline level of CD11b was higher in severe bronchiectasis compared 
to healthy volunteers and mild bronchiectasis.  
a. Representative baseline overlay flow plots (from a single experiment) of the three 
groups. X-axis represents the mean fluorescent index (MFI) and y-axis represents the 
total cell counts. 
b. Cumulative data from N=8 donors in each group; results expressed as mean ± 
SEM. In untreated blood neutrophils there was significantly higher levels of CD11b in 
severe bronchiectasis, with the overall p value being p=0.01 using one way ANOVA. 
Using Bonferonni’s post hoc comparison, there was a significant difference in CD11b 
measured between the healthy volunteers and severe group and between mild and 
severe bronchiectasis. *P<0.05. Bx= bronchiectasis.  
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3.1.2.2. CD62L shedding is higher in bronchiectasis patients  
 
 
Analysis by one way ANOVA, comparing healthy volunteers, mild and severe 
bronchiectasis showed that in these vehicle treated (PBS with calcium and 
magnesium) neutrophils, after 30 minutes, there was a higher proportion of CD62L 
shedding (via setting a gate against a control) in cells from mild and severe 
bronchiectasis patients, with the overall p value being p=0.02 using Bonferroni’s 
multiple comparison, post hoc test (p=0.04 for comparison between healthy 
volunteers and mild bronchiectasis; p=0.03 for comparison between healthy 
volunteers and severe bronchiectasis; healthy volunteers was the control group against 













































Figure 38. At baseline, there was higher proportion of CD62L shedding in mild and 
severe bronchiectasis compared to healthy volunteers. X-axis represents the mean 
fluorescent index (MFI) and y-axis represents the total cell counts. 
a. Representative baseline overlay flow plots (from a single experiment) of the three 
groups. 
b. Cumulative data from N=8 donors in each group; results expressed as mean ± 
SEM. In untreated blood neutrophils there was significantly higher levels of CD62L 
shedding in mild and severe bronchiectasis, with the overall p value being p=0.02 
using one way ANOVA. Using Bonferonni’s post hoc comparison, there was a 
significant difference in CD62L levels measured between the healthy volunteers and 




In summary, this section showed that at baseline, there were higher levels of CD11b 
expression and higher proportion of CD62L shedding in severe bronchiectasis 
compared to healthy volunteers and mild bronchiectasis. This indicates that at 
baseline blood neutrophils are both already primed and activated when obtained  (or 
in response to preparation) OR spontaneously start to activate in severe 
bronchiectasis. This will be explored in detail with activation of neutrophils using 
fMLF in section 3.9.2, to distinguish why the neutrophils are more activated in severe 
bronchiectasis.
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3.1.3. NEUTROPHIL DEGRANULATION  
 
MPO release is higher in severe bronchiectasis patients compared to mild 
bronchiectasis and healthy volunteers 
 
Myeloperoxidase is released from the neutrophil primary granules when these cells 
are activated. 8 healthy volunteers, 8 patients with mild (Bronchiectasis Severity 
Index 0-4) and 8 patients with severe bronchiectasis (Bronchiectasis Severity Index 
>9) were recruited and 60mls of blood taken as described in the materials and 
methods section. Neutrophils were treated with cytochalasin B (1µg/ml) for 10 
minutes and fMLF (10nM) for 30 minutes to activate neutrophils and MPO was 
measured from supernatants.  
As in the studies measuring CD11b and CD62L, described in this section, is 
measurement of MPO in untreated blood neutrophils only. Activation of neutrophils 
with fMLF and subsequent measurement of MPO is described in section 3.9.3. The 
reason, MPO measurement has been done in untreated neutrophils is to assess and 
compare neutrophil MPO activity to CD11b and CD62L levels, at baseline in healthy 
volunteers, mild and severe bronchiectasis.  
 
Analysis by one way ANOVA, comparing healthy volunteers, mild and severe 
bronchiectasis showed that in untreated neutrophils, there was a higher proportion of 
MPO release in cells from severe bronchiectasis patients, with the overall p value 
being p=0.02 using Bonferroni’s multiple comparison, post hoc test (p=0.04 for 
comparison between healthy volunteers and severe bronchiectasis; p=0.02 for 
comparison between mild and severe bronchiectasis; severe bronchiectasis was the 































Figure 39. There is more myeloperoxidase release in severe bronchiectasis compared 
to healthy volunteers and mild bronchiectasis. Cumulative data from N=8 donors in 
each group; results expressed as mean ± SEM.   
In untreated blood neutrophils there was significantly higher levels of MPO release in 
severe bronchiectasis, with the overall p value being p=0.01 using one way ANOVA. 
Using Bonferonni’s post hoc comparison, there was a significant difference in MPO 
measured between the healthy volunteer sand severe group and between mild and 
severe bronchiectasis. *P<0.05. Bx= bronchiectasis.  
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3.1.4. PHAGOCYTOSIS  
 
Phagocytosis of GFP PAO1 is decreased in bronchiectasis  
 
8 healthy volunteers, 8 patients with mild (Bronchiectasis Severity Index 0-4) and 8 
patients with severe bronchiectasis (Bronchiectasis Severity Index ≥9) were recruited 
and 60mls of blood taken as described in the materials and methods section. Freshly 
isolated blood neutrophils were co incubated with opsonized GFP labeled 
Pseudomonas aeruginosa PAO1 for 15 minutes (as there was almost 100% 
phagocytosis at time points greater than 15 minutes across all three groups) and 
phagocytosis was measured by flow cytometry. Total phagocytosis was calculated on 
Flow Jo v10.0.4. Once this was done, phagocytosis was divided into high FLI and low 
FLI (50:50; see figure 40a) to distinguish the neutrophils that had high fluorescence 
secondary to phagocytosing more GFP PAO1 compared to the neutrophils with low 
fluorescence. For the purpose of this thesis, all phagocytosis data presented here, 
represents high FLI. Analysis by one way ANOVA, comparing healthy volunteers, 
mild and severe bronchiectasis showed that, there was a lower proportion of 
phagocytosis of GFP PAO1 in cells from bronchiectasis patients, with the overall p 
value being p=0.02, with the healthy volunteers being the control group. Using 
Bonferroni’s multiple comparison, post hoc test, there was significantly higher 
phagocytosis in healthy volunteers compared to mild bronchiectasis, p=0.04; and 
significantly higher phagocytosis in healthy volunteers compared to severe 
bronchiectasis, p=0.02 (figure 40b). True phagocytosis as opposed to adherence of 
PAO1 to the outside of the neutrophils was confirmed by Z stacks done by confocal 







































Figure 40. There is a lesser proportion of phagocytosis of GFP PAO1 in 
bronchiectasis patients compared to healthy volunteers.  
a. FACS plot of a representative experiment showing phagocytosis of GFP PAO1 by 
blood neutrophils. After 15 mins of co incubation of neutrophils with opsonized 
bacteria, there is at least 75-80% phagocytosis both in healthy volunteers and in 
bronchiectasis patients. Hence, FACS plots were divided into high and low 
fluorescence, with the high fluorescence demonstrating neutrophils that have 
phagocytosed more GFP PAO1, hence have high overall fluorescence.  
b. Pooled % neutrophil phagocytosis data, showing means +/- SEM of n=8 per group. 
One-way ANOVA with Bonferroni’s correction for multiple comparisons used; with 
p values representing the comparison of severe and mild bronchiectasis to healthy 
volunteers (used as control). *P<0.05. 
c. Merged confocal images of neutrophil phagocytosis of GFP labeled bacteria- 
PAO1. 
(Neutrophil cell membrane in red; neutrophil nuclear stain in blue; GFP labeled 




3.1.5. BACTERIAL KILLING 
 
Blood neutrophil killing of GFP PAO1 
Blood neutrophils were isolated by percoll gradients as previously described. Blood 
neutrophils were co-incubated with GFP Pseudomonas aeruginosa PAO1 for 15 
mins- as >95% phagocytosis obtained after 15 minutes. Next, spinning the 
Eppendorfs at 300g for 5minutes stopped the process. The supernatant was discarded 
to minimize contamination with bacteria that had not been internalized. The pelleted 
cells were immediately lysed and internalized bacteria were plated out over a dilution 
series on to Pseudomonas isolation agar (Difco) plates to assess bacterial killing, with 
colony forming units counted after 24 hours of incubation. Hence I assessed the total 
of surviving PAO1 that interacted with the neutrophils (figure 41).  
Analysis by one way ANOVA, comparing healthy volunteers, mild and severe 
bronchiectasis showed that there was a reduced proportion of killing of GFP PAO1 
in cells from bronchiectasis patients with the overall p value being p=0.0005, with the 
healthy volunteers being the control group. Using Bonferroni’s multiple comparison, 
post hoc test, p=0.006 for comparison between healthy and mild bronchiectasis; 




















Figure 41. There was significantly lower bacterial killing (PAO1) in severe 
bronchiectasis compared to healthy volunteers and mild bronchiectasis. Pooled 
bacterial killing data (in log scale cfu/ml), showing median with IQR of n=6 per 
group. Significantly higher bacterial killing at the end of exacebation compared to 
beginning, using paired t tests. Paired t tests used to compare exacebation data and 
unpaired t tests used to compared stable state to exacerbations. *P<0.05; ***P<0.001. 
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In summary, this section shows that in bronchiectasis, despite neutrophils being 
activated and primed when obtained, they phagocytose bacteria less well than 
neutrophils from healthy volunteers. In addition, these neutrophils have impaired 
bacterial killing. The ability of neutrophils to kill bacteria is of critical importance in 
bronchiectasis as recurrent infections is one of the key clinical features in this 
condition. Can this be regulated or increased extrinsically? This has been explored 




























3.1.6. REACTIVE OXYGEN SPECIES (ROS) 
 




Freshly isolated peripheral blood neutrophils from healthy volunteers (n=6) were 
loaded with dihydrorhodamine for 5minutes. Loaded neutrophils were put on a heat 
block for 30 minutes and varying doses of fMLF (between 0.1nM and 100nM) were 
subsequently added for 30 minutes to obtain a concentration response curve. Reactive 
oxygen species generation was measured by flow cytometry. A maximum response at 
100nM fMLF and this was taken as standard for the experiments described below. 
Described below is measurement of ROS in untreated neutrophils to compare ROS 
generation in neutrophils in healthy volunteers and mild and severe bronchiectasis 








































Figure 42. Concentration response curve obtained for fMLF. Neutrophils were 
obtained from 6 healthy volunteers and stimulated with fMLF (at varying 
concentrations) for 30 minutes. Reactive oxygen species was measured by flow 
cytometry. A maximum response at 100nM was standardized and is what is widely 
been described in the literature.  
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fMLF= n- formyl- methyl- leucyl- phenylalanine 
 
 
• 3.1.6.2. Difference between groups  
 
Using one way ANOVA for comparison of the three groups for comparison of 
superoxide release in untreated neutrophils, there was no significant difference 
between healthy volunteers, mild bronchiectasis and severe bronchiectasis; p=0.3, 

































Figure 43. No difference at baseline at reactive oxygen species generation, between 
healthy volunteers, mild and severe bronchiectasis in untreated neutrophils. Pooled 
ROS data showing means +/- SEM of n=6 per group. One way ANOVA was done to 
compare the results obtained. 
 
 
This section shows that although neutrophils are primed and pre activated in 
bronchiectasis, there is no difference in the reactive oxygen species generated when 
compared to healthy volunteers.  
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3.1.7. COMPARISON OF BLOOD AND AIRWAYS NEUTROPHILS IN 
BRONCHIECTASIS 
 
6 patients with mild and 6 patients with severe disease participated in this study, all in 
the stable state. 60mls of blood was taken and all participants underwent 
bronchoscopy. I assessed phagocytosis and killing of GFP PAO1 by both blood and 
airways neutrophils, as described before. 
 
 
• 3.1.7.1. Phagocytosis 
Blood neutrophils were isolated by percoll gradients as previously described. Airways 
neutrophils were obtained from mild and severe bronchiectasis patients from 
bronchoalveolar lavage, as described previously. Blood and airways neutrophils were 
co-incubated with GFP labeled bacteria for 15mins (for blood neutrophils) and 60 
minutes (for airways neutrophils). Using paired t-test, comparison of the phagocytosis 
between blood and airways neutrophils showed that there was significantly higher 
phagocytosis by blood neutrophils compared to airways neutrophils, both in patients 
with mild and severe bronchiectasis, p<0.0001 for mild bronchiectasis and p=0.0004 
































Mild Bx Severe Bx
p<0.0001 p=0.0004
 
Figure 44. Significantly higher phagocytosis by blood neutrophils compared to 
airways neutrophils, using paired t tests, p<0.0001 for mild and p=0.0004 for severe 
bronchiectasis. Phagocytosis was measured at 15minutes for blood neutrophils and at 
60 mins for airways neutrophils. Pooled data presented as mean +/- SEM for n=6 per 
group.  
Data is presented here with both mid and severe bronchiectasis on the same graph, to 
allow better understanding and comparison of the data. 
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• 3.1.7.2. Bacterial killing 
 
Blood neutrophils were isolated by percolls gradients as previously described. 
Airways neutrophils were obtained from mild and severe bronchiectasis patients from 
bronchoalveolar lavage, as described previously. Blood and airways neutrophils were 
co-incubated with GFP labeled bacteria for 15mins (for blood neutrophils) and 60 
minutes (for airways neutrophils). Cells were lysed and internalized bacteria were 
plated out and bacterial killing was assessed after 24 hours. Using paired t-tests, 
comparison of the bacterial killing between blood and airways neutrophils showed 
that there was a significantly higher bacterial killing in blood neutrophils compared to 
airways neutrophils, both in patients with mild bronchiectasis, p=0.02 and severe 
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Figure 45. Significantly higher bacterial killing by blood neutrophils compared to 
airways neutrophils, using paired t tests, p=0.02 for mild and p=0.02 for severe 
bronchiectasis. Bacterial killing was measured after co incubation with neutrophils- 
15minutes for blood neutrophils and at 60 mins for airways neutrophils. Plates were 
read after 24 hours. Pooled data presented as median +/- IQR for n=6 per group.  
Data is presented here with both mid and severe bronchiectasis on the same graph, to 




Study aim: To characterize peripheral blood and airways neutrophils in 
bronchiectasis patients during exacerbations. 
 
• 3.2.1. Blood neutrophils   
 
3.2.1.1. Phagocytosis by blood neutrophils during exacerbations and comparison 
to stable state. 
Once I established that blood neutrophils had higher phagocytic and anti bacterial 
capacity compared to airways neutrophils, I wanted to establish if there was a 
difference in these functional abilities in neutrophils during exacerbations, and if so, 
how did it compare to neutrophil function in the stable state. Hence, 6 bronchiectasis 
patients while in the stable state and 6 bronchiectasis patients with exacerbations were 
recruited to assess this. The stable state patients and exacerbation patients were not 
the same patients. Patients with exacerbations received intravenous antibiotics for 14 
days. Baseline demographics of these exacerbation patients are shown in table 12. 
These patients were reviewed on Day 1, before the start of antibiotics and on day 14 
after completing their last dose of antibiotics. Blood was taken on both occasions and 
peripheral blood neutrophils were isolated, as previously described. Neutrophils were 
treated with vehicle control and phagocytosis of opsonized GFP labeled PAO1 was 
recorded, after co incubating neutrophils with GFP PAO1 for 15 minutes. Using 
paired t-tests, there was significantly higher phagocytosis at the end of exacerbation 
compared to beginning of exacerbation, p=0.02. On comparison of stable state to start 
and end of exacerbation using unpaired t-test Mann Whitney-U test, there was 
significantly more phagocytosis in the stable state compared to start of exacerbation, 
p=0.01. There was no difference in phagocytosis between the stable state and the end 
of exacerbation, p=0.9; figure 46. 
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Figure 46. Significantly higher phagocytosis at the end of exacerbation compared to 
start. There was higher phagocytosis in the stable state compared to start but not at the 
end of exacerbation by blood neutrophils, using paired t tests. Phagocytosis was 
measured at 15minutes for blood neutrophils. Pooled data presented as mean +/- SEM 
for n=6 per group.  
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3.2.1.2. Comparison of bacterial killing during bronchiectasis exacerbations to 
stable state bronchiectasis 
On comparison of bacterial killing of GFP PAO1 by blood neutrophils (after co 
incubation for 15 minutes as previously described),  at the beginning of exacerbation 
in bronchiectasis (N=6) to end of exacerbation (N=6) using paired t-tests; there was 
significantly higher in bacterial killing at the end of exacerbation; p=0.03.  
On comparison of bacterial killing at the start of exacerbation in bronchiectasis to 
stable state bronchiectasis using unpaired t-tests; there was a statistically significant 
difference in bacterial killing with higher killing in the stable state; p=0.02.  
However, there was no significant difference in bacterial killing on comparison of 


































Figure 47. Significantly higher bacterial killing at the end of exacebation compared to 
beginning, using paired t tests, in blood neutrophils. 
Unpaired t tests demonstrated that there was higher bacterial killing in the stable state 
compared to start of exacerbation, but not when compared to end of exacerbation. 
Pooled bacterial killing data (in log scale cfu/ml), showing median with IQR of n=6 
per group.  
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3.2.2. Airways neutrophils 
 
3.2.2.1. Phagocytosis by airways neutrophils during exacerbations and 
comparison to stable state. 
 
Sputum from the same 6 bronchiectasis patients while in the stable state and 6 during 
exacerbations was obtained and airways neutrophils isolated as described in the 
methods section. Results at the beginning and end of exacerbation were recorded. 
Phagocytosis of GFP PAO1 was recorded afetr co incubation for 15 minutes as 
previously described using paired t-tests, there was significantly higher phagocytosis 
at the end of exacerbation compared to beginning, p=0.008. On comparison of stable 
state to start and end of exacerbation using unpaired t-test Mann Whitney-U test, there 
was more phagocytosis in the stable state compared to start of exacerbation although 
this failed to reach statistical significance, p=0.08. There was no difference in 

































Figure 48. Significantly higher phagocytosis at the end of exacerbation compared to 
start by airways neurophils (paired t tests). There was higher phagocytosis (although 
not significant) in the stable state compared to start but not at the end of exacerbation 
by airways neutrophils, using unpaired t tests. Phagocytosis was measured at 60 





3.2.2.2. Comparison of bacterial killing during bronchiectasis exacerbations to 
stable state bronchiectasis	
 
On comparison of bacterial killing of GFP PAO1 by airways neutrophils (afetr co 
incubation for 60 minutes as previously described),  at the beginning of exacerbation 
in bronchiectasis (N=6) to end of exacerbation (N=6); there was a statistically 
significant higher in bacterial killing at the end of exacerbation; p=0.02, using paired t 
tests.  
Using paired t-tests for comparison of bacterial killing at the start of exacerbation in 
bronchiectasis to stable state bronchiectasis; there was a statistically significant 
difference in bacterial killing with higher killing in the stable state; p=0.02.  
Using unpaired t-tests, there was trend towards higher killing at the end of 
exacerbation compared to stable state, but this just failed to reach statitical 
































Figure 49. Significantly higher bacterial killing at the end of exacebation compared to 
beginning, using paired t tests, by airway neutrophils. 
Unpaired t tests demonstrated that there was higher bacterial killing in the stable state 
compared to start of exacerbation, but not when compared to end of exacerbation. 
Pooled bacterial killing data (in log scale cfu/ml), showing median with IQR of n=6 
per group.  
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In summary, this section shows that in bronchiectasis, blood neutrophils have higher 
phagocytic and anti bacterial capacity compared to airways neutrophils and this holds 
in both mild and severe bronchiectasis. Neutrophil function (both blood and airways) 
was impaired at the start of an exacerbation and this improved significantly with 
antibiotics. It could be that bronchiectasis neutrophils have impaired phagocytic and 
killing capacity and to compare this to healthy neutrophils, I assessed the functional 
ability of neutrophils during pneumonia, in healthy individuals, which is described in 




























3.3. COMMUNITY ACQUIRED PNEUMONIA 
 
Study Aim: To assess neutrophil function in pneumonia patients (with no 
background lung disease) and compare it to neutrophil function during 
bronchiectasis exacerbations 
3.3.1. Phagocytosis 
6 community acquired pneumonia patients (with no comorbidities) who were 
admitted to hospital, were recruited. All patients received intravenous (co-amoxiclav) 
and oral (clarithromycin) antibiotic therapy. Streptococcus pneumoniae was isolated 
in 4 of the 6 patients and 2 patients did not isolate a bacteria. Results at the beginning 
(day1) and end of infection (day 5) were recorded. Blood neutrophils were co-
incubated with GFP labeled bacteria for 15mins. Phagocytosis was measured by flow 
cytometry immediately. For bacterial killing, cells were lysed (after 15 minutes co-
incubation of neutrophils with GFP PAO1) and internalized bacteria were plated out 
and bacterial killing was assessed after 24 hours  (figure 50a&b). 
Baseline demographics of the 6 patients are summarized in table 13. 
Patient characteristics (N=6) Mean (SEM) 
Age 54 (4.6) 
















• Start of exacerbation 





• Start of exacerbation 




Table 13. Baseline demographics of pneumonia patients recruited in the study.  
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CRP= c- reactive protein; WCC= white cell count. 
Using paired t-tests, there was significantly higher bacterial phagocytosis and killing 
by blood neutrophils, at the end of treatment with antibiotics compared to beginning, 
p=0.03 for both comparisons. However, phagocytic capacity remains low even after 
completion of antibiotic therapy compared to phagocytosis at baseline in healthy 
volunteers (section 3.1.4).  Future studies assessing neutrophil phagocytic capacity in 
these individuals after 4 weeks to determine if phagocytic capacity is improved, 























































Figure 17 a&b. There was a significantly higher phagocytosis and killing after 
antibiotic treatment compared to beginning in pneumonia. Phagocytosis and killing 
was measured at 15minutes (and plates counted at 24 hours for killing). Pooled data 
presented as mean +/- SEM (for phagocytosis) and median +/- IQR (for killing); n=6 
per group.  
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3.4. COMPARISON OF BRONCHIETASIS VERSUS PNEUMONIA 
 
Once phagocytosis and bacterial killing was assessed during bronchiectasis 
exacerbations and pneumonia, I then compared phagocytosis and bacterial killing at 
the start and end in bronchiectasis to pneumonia start and end. This was done to 
assess the difference in neutrophil function during and after exacerbations in patients 
with a chronic lung disease (bronchiectasis) with those of an acute severe lung disease 
that fully recover (pneumonia patients with no prior history of chronic lung disease). 
 
3.4.1. Phagocytosis 
Using unpaired t-test Mann Whitney-U test, for comaprison of phagocytosis of GFP 
PAO1 by blood neutrophils,  during exacerbation in bronchiectasis to pneumonia; 
there was no statistically significant difference in % phagocytosis at the beginning 




































Figure 51. There was no difference in phagocytosis between bronchiectasis and 
pneumonia,  either at the start or at the end of exacerbation. Phagocytosis was 
measured at 15minutes. Pooled data presented as mean +/- SEM (for phagocytosis); 
n=6 per group. Unpaired t tests done for both comparisons.  
Bx= bronchiectasis; CAP= community acquired pneumonia. 
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3.4.2. Bacterial killing 
Using unpaired t-test Mann Whitney-U test, for comaprison of bacterial killing of 
GFP PAO1 by blood neutrophils,  at the beginning of exacerbation in bronchiectasis 
to beginning of pneumonia; there was a statistically significant difference; p=0.0007, 
with lower bacterial killing in bronchiectasis patients.  
On comaprison of bacterial killing at the end of exacerbation in bronchiectasis to end 
of treatment in pneumonia; there was a statistically significant difference; p=0.003, 
































Figure 52. Significantly lesser bacterial killing at the beginning and end of 
exacerbation in bronchiectasis patients compared to pneumonia patients. Bacterial 
killing was measured at 15minutes and plates counted at 24 hours. Pooled data 
presented as median +/- IQR; n=6 per group. Unpaired t tests done for both 
comparisons.  
Bx= bronchiectasis; CAP= community acquired pneumonia. Log scale is in cfu/ml.
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3.5. REVERSE TRANSMIGRATING NEUTROPHILS  
 
Once it was established that there was a distinct sub type of neutrophils in 
bronchiectasis, I wanted to detect if this sub type of neutrophils were reverse 
transmigrating neutrophils. Neutrophils were isolated from both bronchiectasis 
patients and healthy volunteers. Reverse migrating neutrophils are ICAM 1 high. 
However, there was no difference in ICAM 1 staining in bronchiectasis patients as 
compared to healthy volunteers, as shown in figure 53.  
 
Figure 53. Overlay graphs from a representative experiment showing similar ICAM 1 
antibody staining in bronchiectasis patient compared to healthy individuals. 














3.6. NEUTROPHIL EXTRACELLULAR TRAPS (NETs)  
 
3.6.1. NETs by fluorescence 
To investigate the fate of neutrophils at the end of exacerbation, I assessed NET 
formation at the start and end of bronchiectasis exacerbations. Blood samples were 
obtained from 6 bronchiectasis patients at the beginning and end of exacerbation (day 
1 and day 14). Neutrophils were treated with vehicle control or Phorbol 12-myristate 
13-acetate (PMA) and blood NET formation was evaluated after 4hours, by 
fluorescence emitted using a plate reader (figure 54). 
 
3.6.2. NETs production during bronchiectasis exacerbation 
Using paired t-tests, for comaprison there was a significant reduction in NETs 
produced at the end of treatment (with antibiotics) of an exacerbation, both in 













































Figure 54. Reduction in NETs formation at the end of exacerbation both in vehicle 
and PMA treated neutrophils.  NET formation was assessed 4 hours after stimulation 
with PMA or vehicle control, by measuring fluorescence with a plate reader. Pooled 





3.6.3. NETs production during pneumonia 
As a control, blood samples were also obtained from 6 pneumonia patients at the 
beginning and end of pneumonia (day 1 and day 5) and blood NET formation was 
evaluated after 4 hours by fluorescence emitted by a plate reader.  
Using paired t-tests, there was a significant reduction in NETs produced at the end of 
treatment (with antibiotics) of pneumonia, both in untreated neutrophils (p=0.0003) 



































Figure 55. Reduction in NETs formation at the end of pneumonia treatment with 
antibiotics both in vehicle and PMA treated neutrophils.  NET formation was assessed 
4 hours after stimulation with PMA or vehicle control, by measuring fluorescence 
with a plate reader. Pooled data presented as mean +/- SEM; n=6 per group. Paired t 











3.6.4. Comparison of NETs produced in bronchiectasis exacerbations and 
pneumonia  
I now compared the data obtained from bronchiectasis excaerbations and pneumonia, 
to assess the difference in NETs produced.  
 
Using unpaired t-test Mann Whitney-U test for comparison of the start of 
exacerbation in bronchiectasis patients compared to pneumonia patients, there was no 
difference in NETs produced in PMA treated neutrophils, p=0.1. Using unpaired t-
tests for comparison of the end of exacerbation in bronchiectasis patients to 
pneumonia patients, there was significantly lower NETs produced in PMA treated 
neutrophils in bronchiectasis patients, p=0.0004 (figure 56a). 
Using unpaired t-test Mann Whitney-U test for comparison of the start of 
exacerbation in bronchiectasis patients compared to pneumonia patients, there was 
significantly higher NETs produced in vehicle treated neutrophils in bronchiectasis 
patients, p=0.01. Using unpaired t-tests for comparison of the end of exacerbation in 
bronchiectasis patients compared to pneumonia patients, there was significantly lower 















































































Figure 56. Higher NETs produced at the beginning (S) and significantly lower NETs 
produced at the end (E) of exacerbation (in vehicle treated neutrophils), in 
bronchiectasis compared to pneumonia. NET formation was assessed 4 hours after 
stimulation with PMA or vehicle control, by measuring fluorescence with a plate 
reader. Pooled data presented as mean +/- SEM; n=6 per group. Unpaired t tests done 
for both comparisons, *P<0.05, ***P<0.001, ****P<0.0001 
BX= bronchiectasis; CAP= Community acquired pneumonia; E =end; S= start. 
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3.7. EFFECT OF LXA4 ON NEUTROPHIL FUNCTION 
 
My main hypothesis for this thesis is that there is failure of resolution of inflammation 
in bronchiectasis.  
Study aim: Assess the anti-inflammatory and pro resolution effect of LXA4 on blood 
and airways neutrophils in the stable state and during exacerbations in bronchiectasis.  
There is enough evidence in the literature to suggest that Lipoxin A4 plays a major 
anti-inflammatory and pro resolution role. However the effects of Lipoxin A4 have not 
been studied in bronchiectasis. As bronchiectasis is a neutrophilic airway disease, I 
have studied the effects of Lipoxin A4 on neutrophils, as described below.  
 
Blood was obtained from 7 healthy volunteers, 6 patients with mild bronchiectasis 
and 6 patients with severe bronchiectasis (as calculated by the Bronchiectasis Severity 
Index). The following studies were done as outlined below. 
 
 
3.7.1. RESULTS FROM SPONTANEOUS APOPTOSIS ASSAYS 
Blood neutrophils were isolated by percoll gradient as previously described and late 
apoptosis (20hours) assays were done using autologous blood. Roscovitine was used 
as a positive control and has been described in detail in section 3.9.1.2. 
 
• 3.7.1.1. Effect of Lipoxin A4 
 
Spontaneous apoptosis was measured at 20 hours in three groups- healthy volunteers, 
mild bronchiectasis and severe bronchiectasis patients. Analysis by two way 
ANOVA, comparing healthy volunteers, mild and severe bronchiectasis showed that, 
after treatment with vehicle or LXA4 1nM, 10nM, and 100nM, LXA4 was unable to 
modulate spontaneous apoptosis in any of the three groups with Bonferoni’s post hoc 
analysis of multiple comparisons being p=0.4, p=0.5 and p=0.4 in healthy (figure 









































57a. Blood neutrophils from healthy volunteers were cultured for 20 hours and cell 
viability, apoptosis and necrosis were assessed by flow cytometry. There was no 
effect of LXA4 even at a maximum dose of 100nM on spontaneous apoptosis at 20 
hours. Pooled data presented as mean +/- SEM; n=6 per group. Analysis done by two 


































57b. Blood neutrophils from mild bronchiectasis patients were cultured for 20 hours 
and cell viability, apoptosis and necrosis were assessed by flow cytometry. There was 
no effect of LXA4 even at a maximum dose of 100nM on spontaneous apoptosis at 20 





































Figure 57c. Blood neutrophils from severe bronchiectasis patients were cultured for 
20 hours and cell viability, apoptosis and necrosis were assessed by flow cytometry. 
There was no effect of LXA4 even at a maximum dose of 100nM on spontaneous 
apoptosis at 20 hours. Pooled data presented as mean +/- SEM; n=6 per group. 
Analysis done by two way ANOVA. 
LX= Lipoxin A4; NC= negative control; rosco= roscovitine.
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• 3.7.1.2. Effect of Roscovitine (figure 58) 
Two way ANOVA showed, that in the roscovitine 20µM treated neutrophils, there 
was a statistically significant difference in the percentage of apoptotic neutrophils 
between healthy volunteers and severe bronchiectasis, p=0.04 but not between healthy 
and mild bronchiectasis p=0.2. There was a statistically significant difference in in the 
percentage of necrotic neutrophils between healthy volunteers and severe 
bronchiectasis, p=0.02 but not between healthy and mild bronchiectasis p=0.4. There 
was no difference in the viable group, between healthy volunteers and mild 
























Figure 58. Blood neutrophils from healthy, mild and bronchiectasis patients were 
cultured for 20 hours and cell viability, apoptosis and necrosis were assessed by flow 
cytometry. There was a statistically significant difference in the percentage of 
apoptotic (p=0.04) and necrotic (p=0.02) neutrophils between healthy volunteers and 
severe bronchiectasis patients, in roscovitine treated neutrophils. Pooled data 
















3.7.1.3. Cell counts 
 
At 20 hours, cytocentrifuge preparations from treated and control neutrophil 
suspensions were fixed and stained. Cells were examined under oil immersion light 
microscopy and apoptotic cells were defined as cells containing darkly stained 
pyknotic nuclei. For each time point at least 400 cells were counted from at least 4 






Figure 59. At 20 hours, cytocentrifuge preparations (gold standard for quantifying 
apoptosis) from neutrophil suspensions were also fixed and stained. Cells were 
examined under oil immersion light microscopy and apoptotic cells were defined as 
cells containing darkly stained pyknotic nuclei. For each time point at least 400 cells 
were counted from at least 4 different fields. Solid arrow represents healthy 
neutrophils with multi lobulated nuclei, more abundant in neutrophils from mild and 
severe bronchiectasis. Dashed arrow represents dark, pyknotic nuclei in apoptotic 
neutrophils - more abundant in healthy volunteers.  
(i)& (iv): healthy volunteers 
(ii) & (v): mild bronchiectasis 
(iii) & (vi): severe bronchiectasis 
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3.7.2. NEUTROPHIL ACTIVATION 
 
3.7.2.1. CD11b upregulation 
 
Neutrophil activation leads to upregulation of CD11b and shedding of CD62L.  
Once neutrophils were isolated (as described previously), they were pre treated with 
LXA4 1nM, 10nM and 100nM for 30 minutes and thereafter were activated with 
fMLF 100nM or vehicle control (PBS) for 30minutes. CD11b expression was 
measured by flow cytometry. 
 
• 3.7.2.1.1. Activation with fMLF 
 
Analysis by one way ANOVA, comparing healthy volunteers, mild and severe 
bronchiectasis showed that in fMLF alone (control) activated and LXA4 (1nM, 
10nM and 100nM) pretreated, then activated with fMLF neutrophils, after 30 
minutes, there was a change of fMLF induced CD11b upregulation by LXA4 in a dose 
dependent manner (via setting a gate against a control), in healthy (p=0.005), mild 


















































60a. Healthy volunteers: There was a dose dependent reduction of fMLF-induced 
activation (30 minutes) and CD11b expression by LXA4; p=0.005. Pooled data 




























































60b. Mild bronchiectasis: There was a dose dependent reduction of fMLF-induced 
activation (30 minutes) and CD11b expression by LXA4; p=0.008. Pooled data 


























































60c. Severe bronchiectasis: There was a dose dependent reduction of fMLF-induced 
activation (30 minutes) and CD11b expression by LXA4; p=0.01. Pooled data 
presented as mean ± SEM; n=6 per group. Analysis done by one-way ANOVA. 





Neutrophil activation leads to shedding of CD62L. Once neutrophils were isolated (as 
described previously), they were pre treated with LXA4 1nM, 10nM and 100nM for 
30 minutes and thereafter were activated fMLF 100nM or vehicle control (PBS) for 
30minutes.  CD62L expression was measured by flow cytometry. 
 
 
• 3.7.2.2.2. Activation with fMLF 
 
Analysis by one way ANOVA, comparing healthy volunteers, mild and severe 
bronchiectasis showed that in fMLF alone (control) activated and LXA4 (1nM, 
10nM and 100nM) pretreated, then activated with fMLF neutrophils, after 30 
minutes, there was a change of fMLF induced CD62L shedding by LXA4 in a dose 
dependent manner (via setting a gate against a control), in healthy (p=0.01), mild 


















































Figure 61a. Healthy volunteers: There was a dose dependent reduction of fMLF-
induced activation (30 minutes) and CD62L shedding by LXA4; p=0.01. Pooled data 
























































Figure 61b. Mild bronchiectasis: There was a dose dependent reduction of fMLF-
induced activation (30 minutes) and CD62L shedding by LXA4; p=0.03. Pooled data 



















































Figure 61c. Severe bronchiectasis: There was a dose dependent reduction of fMLF-
induced activation and CD62L shedding by LXA4; p=0.04. Pooled data presented as 
mean ± SEM; n=6 per group. Analysis done by one way ANOVA. 
NC= negative control; fMLF= n- formyl- methyl- leucyl- phenylalanine; LX= 
Lipoxin A4. 
 3.7.3. NEUTROPHIL DEGRANULATION  
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3.7.3.1. MPO measurement 
 
Once isolated, neutrophils were treated with cytochalasin B (1µg/ml) for 10 minutes 
and fMLF (10nM) for 30 minutes, to activate neutrophils. Myeloperoxidase (MPO) 
was measured from supernatants by a chromogenic assay to assess neutrophil 
degranulation.  
 
• 3.7.3.1.1. Activation with cytochalasin B and fMLF 
 
I have previously demonstrated in section 3.1.3, that there was a significantly higher 
release of MPO in severe bronchiectasis patients, even at baseline. Here, I was able to 
demonstrate that there was a significant reduction in cytochalasin B and fMLF-
induced activation of neutrophils and release of MPO. A one-way ANOVA showed 
that there was a reduction of MPO release by Lipoxin A4 in a dose dependant manner 
in healthy volunteers (p=0.02), mild bronchiectasis (p=0.02) and even in severe 
bronchiectasis patients (p=0.02), where significantly higher levels of MPO are 










































Figure 62a. Healthy volunteers: There was a dose dependent reduction of fMLF (30 
minutes) and cytochalasin B (10 minutes) induced activation and release of MPO; 












































Figure 62b. Mild bronchiectasis: There was a dose dependent reduction of fMLF (30 
minutes) and cytochalasin B (10 minutes) induced activation and release of MPO; 












































Figure 62c. Severe bronchiectasis: There was a dose dependent reduction of fMLF 
(30 minutes) and cytochalasin B (10 minutes) activation and release of MPO, p=0.02. 
Pooled data presented as mean ± SEM; n=6 per group. Analysis done by one way 
ANOVA.  
Cyt= Cytochalasin B; F=fMLF= n- formyl- methyl- leucyl- phenylalanine; NC= 
negative control; LX= Lipoxin A4. 
*LX100nM on its own seems to increase MPO generation- this is due to the result 




3.7.4.1. Neutrophil phagocytosis of GFP labeled PAO1 
 
Neutrophils pre treated with LXA4, 1nM, 10nM and 100nM for 30 minutes were co 
incubated with opsonized GFP PAO1 for 15 minutes and phagocytosis was assessed 
by flow cytometry. As before, confocal images and z stacking were done (Leica TCS 
SP5 II, Leica Microsystems); to ensure that the GFP PAO1 were internalized by the 
neutrophils and were not simply adhering to the neutrophils.  
 
• 3.7.4.1.1. Effect of Lipoxin A4 on phagocytosis- figure 63 
There was a statistically significant difference in phagocytosis between healthy 
controls and mild and severe bronchiectasis, at baseline as previously demonstrated.  
Pre treatment with LXA4, led to a dose dependent increase in phagocytosis in healthy 
volunteers (p=0.0001), mild bronchiectasis (p<0.0001) and severe bronchiectasis 
(p=0.03); figure 30.  There was no significant difference between phagocytosis in 
healthy volunteers at baseline 38% (±2.2) and severe bronchiectasis treated with 
LX100nM 42% (±2.3); p=0.2. This demonstrates that LXA4 is able to restore 





Figure 63. There was a dose dependent increase in phagocytosis with LXA4, in 
healthy volunteers, mild and severe bronchiectasis. One-way ANOVA with 
Bonferroni’s correction for multiple comparisons used; with p values representing the 
comparison of control to 1nm, 10nM and 100nM of LXA4. Pooled % neutrophil 
phagocytosis data, showing means +/- SEM. *P<0.05; ***P<0.001; ****P<0.0001. 
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3.7.5. BACTERIAL KILLING 
 
3.7.5.1. Neutrophil killing of GFP PAO1 
 
Blood neutrophils were isolated by Percoll gradients as previously described. Blood 
neutrophils were co-incubated with GFP labeled bacteria for 15mins; cells were lysed 
and internalized bacteria were plated out and bacterial killing was assessed after 24 
hours.  
 
• 3.7.5.1.1. Effect of Lipoxin A4 on bacterial killing- figure 64 
There was a statistically significant difference in killing between healthy controls and 
mild and severe bronchiectasis, at baseline as previously demonstrated.  Pre treatment 
with LXA4, led to a dose dependent increase in killing in healthy volunteers 
(p=0.001), mild bronchiectasis (p=0.04) and severe bronchiectasis (p=0.01); figure 
31.  There was no significant difference between killing in healthy volunteers at 
baseline 7.7 log units (±0.08) and severe bronchiectasis treated with LX100nM 7.5 
log units (±0.1); p=0.1. This demonstrates that LXA4 is able to restore functional 
capacity of bronchiectasis neutrophils to that of healthy volunteers.  
 
Figure 64. There was dose dependent increase in killing with LXA4 in healthy 
volunteers, mild and severe bronchiectasis. One-way ANOVA with Bonferroni’s 
correction for multiple comparisons used; with p-values representing the comparison 
of control to 1nm, 10nM and 100nM of LXA4. Pooled % neutrophil killing data, 
showing median +/- IQR. *P<0.05; **P<0.01.
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3.7.6 REACTIVE OXYGEN SPECIES 
 
• 3.7.6.1.With fMLF as stimulant 
 
As previously demonstrated in section 3.1.6.1, a dose response curve was done with 
fMLF and a maximum response was attained at fMLF 100nM and this was taken as 
standard for the superoxide generation experiments performed thereafter. 
 
• 3.7.6.2. Effect of Lipoxin on superoxide anion release 
 
 
Freshly isolated peripheral blood neutrophils from healthy volunteers (n=7), mild 
(n=6) and severe (n=6) were initially pretreated with Lipoxin A4 1nM, 10nM and 
100nM for 30 minutes. Subsequently, they were loaded with dihydrorhodamine for 
5minutes. Loaded neutrophils were put on a heat block for 30 minutes, then 100nM 
fMLF added for 30 minutes and reactive oxygen species generation was measured by 
flow cytometry (figure 65). 
 
Analysis by one way ANOVA showed that there was a dose dependent reduction in 
super oxide release by LXA4 in the healthy volunteers, p=0.004 and in severe 
bronchiectasis, p=0.03. There was however no effect of superoxide release by LXA4 
in the mild bronchiectasis group; p=0.4 (figure 66).   
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Figure 65a. Representative experiment showing overlay flow plots of LXA4 1nM, 
10nM and 100nM on reduction of fMLF induced superoxide release.  
b. Representative experiment showing overlay flow plots of LXA4 100nM only, on 
reduction of fMLF induced superoxide release.  









Figure 66. Individual graphs representative of cumulative data from experiments in 
each group. Pooled ROS data showing means ± SEM of n=7 in healthy, n=6 each in 
mild and severe bronchiectasis. One way ANOVA showed that there was a dose 
dependent reduction by LXA4 of fMLF induced generation of reactive oxygen species 
in healthy (p=0.004) and severe bronchiectasis ((p=0.03) but not in mild 
bronchiectasis (p=0.1). 
a. healthy volunteers; b. mild bronchiectasis and c. severe bronchiectasis. 
fMLF= n- formyl- methyl- leucyl- phenylalanine; LX= Lipoxin A4. 
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In reactive oxygen species biology, superoxide was identified as the major reactive 
oxygen species induced by PMA (Swindle 2002). Hence PMA has been routinely 
used as an inducer for endogenous superoxide production (Huang 2014). Hence after 
assessing reactive oxygen species generation with fMLF, I next assessed this using 
PMA as a stimulant, to see if similar results could be obtained.  
 
Freshly isolated peripheral blood neutrophils from healthy volunteers (n=6) were 
loaded with dihydrorhodamine for 5minutes. Loaded neutrophils were put on a heat 
block for 30 minutes and varying doses of PMA (between 3nM and 300nM) were 
subsequently added for 30 minutes to obtain a concentration response curve (figure 
67a). Reactive oxygen species generation was measured by flow cytometry. A 
response at 10nM PMA was taken as standard, as this has been widely used in the 
literature. In addition, at PMA 10nM, a mean fluorescence of 1000 was attained, and 
this corresponded to the maximum fluorescence attained by fMLF at 100nM 
(demonstrated in section 3.1.6). Hence, this value was taken as standard for the 

















































Figure 67a. Concentration response curve obtained for PMA. Neutrophils were 
obtained from 6 healthy volunteers and stimulated with PMA (at varying 
concentrations) for 30 minutes. Reactive oxygen species was measured by flow 
cytometry. Although a maximum response was obtained at PMA 300nM, I used PMA 
10nM for the experiments below as this is the concentration at which these 
experiments have been done in the literature.  
 
 
Figure 67b. Representative experiment showing overlay flow plots of PMA 3nM, 
10nM, 100nM and 300nM on superoxide release.  
PMA= Phorbol myristate acetate. 
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• 3.7.6.5. Effect of Lipoxin on superoxide anion release 
 
Freshly isolated peripheral blood neutrophils from healthy volunteers (n=6) were 
initially pretreated with Lipoxin A4 1nM, 10nM and 100nM for 30 minutes. 
Subsequently, they were loaded with dihydrorhodamine for 5minutes. Loaded 
neutrophils were put on a heat block for 30 minutes and then 10nM PMA added for 
30 minutes and reactive oxygen species generation was measured by flow cytometry 
(figure 68). 
There was a dose dependent reduction in super oxide release by LXA4 pre treated 
neutrophils n the healthy volunteers. Diphenyleneiodonium chloride (DPI) was used 




























































Figure 68. Graph representative of cumulative data from n=6 healthy volunteers. 
Pooled ROS data showing means ± SEM. One way ANOVA showed that there was a 
reduction by 100nM LXA4 of PMA induced generation of reactive oxygen species; 
p=0.02 and by DPI; p=0.005. DPI was used as a positive control (known NADPH 
oxidase inhibitor).  




3.7.7. ALX/FPR2 EXPRESSION 
 
Neutrophils were isolated from 7 healthy volunteers, 6 mild bronchiectasis and 6 
severe bronchiectasis patients. Neutrophils were treated with FPR1 receptor agonist 
fMLF 100nM (or vehicle), ALX/FPR2 receptor agonist LXA4 100nM (or vehicle) and 
ALX/FPR2 antagonist WRW4 100nM [C61H65N15O6] (or vehicle). ALX/FPR2 
antibodies were added and ALX/FPR2 expression was assessed by flow cytometry. 
Key findings are summarized in figure 69. ALX/FPR2 internalization was not 
measured in these experiments.  
 
One-way ANOVA was done for each of the different conditions (i.e no treatment, 
treatment with LXA4 100nM alone, treatment with WRW4 and finally treatment with 
LXA4 and WRW4 together), separately and has been then put together on a single 
graph.  
 
At baseline, there was higher detection of ALX/FPR2 receptor in healthy volunteers 
compared to mild and severe bronchiectasis, although this failed to reach statistical 
significance; p=0.07. There was statistically significant difference in ALX/FPR2 
expression in healthy volunteers compared to mild bronchiectasis, with more 
expression detected in healthy volunteers; p=0.03, when neutrophils were pre treated 
with LXA4 100nM. 
 
Similarly, when pre treated with WRW4 100nM, there was higher detection of 
ALX/FPR2 receptor in healthy volunteers compared to mild and severe 
bronchiectasis, although this failed to reach statistical significance; p=0.09. 
 
Finally, pre treatment with WRW4 100nM and LXA4 100nM, led to higher detection 
of ALX/FPR2 receptor in healthy volunteers compared to mild and severe 
bronchiectasis, although this too failed to reach statistical significance in all three 

































igure 69. Pooled ALX/FPR2 expression data showing means ± SEM, from healthy 
volunteers (n=7), mild bronchiectasis (n=6) and severe bronchiectasis (n=6), subject 
to 4 different treatment conditions. One way ANOVA showed that there was a trend 
towards increase ALX/FPR2 expression in healthy volunteers, in untreated 
neutrophils, neutrophils treated with WRW4 and neutrophils treated with LX and 
WRW4, compared to mild and severe bronchiectasis; p=0.07, p=0.09 and p=0.08 
respectively. There was significantly higher ALX/FPR2 expression in healthy 
volunteers, in neutrophils pre treated with LX compared to mild bronchiectasis; 
p=0.03.  
WRW4= selective ALX/FPR2 receptor signaling antagonist, LX= Lipoxin A4. 
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3.7.7.1. FUNCTIONAL ASSESSMENT OF ALX/FPR2 EXPRESSION 
 
Next I wanted to establish the functional assessment of ALX/FPR2 expression. For 
this, blood neutrophils once isolated were stimulated with cytochalasin B (1µg/ml) for 
10 minutes and fMLF 10nM for 30 minutes. This would cause neutrophils to activate 
and degranulate, releasing MPO. Neutrophils were first treated with WRW4 100nM 
or vehicle control and then treated with Lipoxin A4. MPO was measured by a 
chromogenic assay and results were analyzed.  
 
There was a statically significant reduction of fMLF induced MPO generation by 
Lipoxin A4 in a dose dependent manner, as previously demonstrated; p=0.02 (by one 
way ANOVA; figure 70). Simultaneously performed experiments with the 
ALX/FPR2 receptor antagonist WRW4 showed that LXA4 induced attenuation of 
MPO production was reversed by WRW4 100nM; p=0.07 (by one way ANOVA). 
This thereby demonstrates that the effect of LXA4 in MPO release is ALX/FPR2 











































Figure 70. Pooled ALX/FPR2 expression data showing means ± SEM, n=6 in each 
group. There was a dose dependent reduction of fMLF (30 mins) induced MPO 
generation by LXA4, p=0.02; and this was partly reversed by pre treating with WRW4 
(for 30 mins); p=0.07. Cyt= Cytochalasin B; F=fMLF= n- formyl- methyl- leucyl- 
phenylalanine; LX= Lipoxin A4; WRW4= selective ALX/FPR2 receptor signaling 
antagonist. 
	 208	




3.8.1.1. Phagocytosis  
6 severe bronchiectasis patients were recruited. All patients received intravenous 
antibiotics for 14 days. Patients were reviewed on Day 1, before the start of 
antibiotics and on day 14 after completing their last dose of antibiotics. Blood was 
taken on both occasions and peripheral blood neutrophils were isolated, as previously 
described. Neutrophils were pre treated with vehicle control or LX 1nM, LX 10nM or 
LX100nM. Phagocytosis of opsonized GFP labeled PAO1 was recorded, after co 
incubating pre treated neutrophils with GFP labeled PAO1 for 15 minutes. The trend 
was an improvement in phagocytosis in all the patients. One way ANOVA showed 
that there was a dose dependent increase in phagocytosis with Lipoxin A4 both at the 
beginning and at the end of the exacerbation; p<0.0001 and p=0.0002 respectively, 
with highest phagocytosis being induced by Lipoxin A4 100nM (figure 71).	 
Figure 71. Significantly higher phagocytosis by LXA4 both at the start and end of 
exacerbation (by one way ANOVA), p<0.0001 and p=0.0002 respectively. 
Neutrophils were pre treated with LXA4 for 30 minutes and phagocytosis was 
measured after 15 minutes of co-incubation with GFP PAO1. Pooled data presented 
as mean ± SEM for n=6 per group.  NC= negative control; LX= Lipoxin A4. 
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3.8.1.2. Bacterial killing  
 
Blood neutrophils (from n=6 bronchiectasis patients) were co-incubated with GFP 
labeled bacteria for 15mins. For bacterial killing, cells were lysed (after 15 minutes 
co-incubation of neutrophils with GFP PAO1) and internalized bacteria were plated 
out and bacterial killing was assessed after 24 hours. Killing of GFP PAO1 was 
recorded. One way ANOVA showed that there was a dose dependent increase in 
blood neutrophil killing of GFP labeled PAO1 with Lipoxin A4 both at the beginning 
and at the end of the exacerbation; p=0.01 and p=0.0007 respectively (figure 72). 




6.6 (0.2) 6.5 (0.2) 6.4 (0.3) 6.0 (0.2) 
End of 
exacerbation 
6.4 (0.2) 6.3 (0.3) 6.2 (0.2) 5.9 (0.2) 
Table 14: Colony counts in log units (standard error of mean), at the start and end of 
exacerbation. 
 
Figure 72. Significantly higher bacterial killing by LXA4 both at the start and end of 
exacerbation (by one way ANOVA), p=0.01 and p=0.0007 respectively. Neutrophils 
were pre treated with LXA4 for 30 minutes and killing was measured after 15 minutes 
of co-incubation with GFP PAO1 and then reading plates after 24 hours. Pooled data 
presented as median (IQR) for n=6 per group.   





3.8.1.3. Blood Lipidomics  
 
To evaluate, if there was a change in the interplay of the pro inflammatory and anti 
inflammatory mediators of arachidonic acid, during exacerbations, I measured certian 
key metabolites in serum.  Pro inflammtory mediators measured were PGE2, 5 HETE, 
15 HETE, 9 HODE and LTB4. Blood was obtained from the 6 patients at the start 
(Day 1) and end of exacerbation (Day 14) after being treated with intravenous 
antibiotics (same patients as in the preceding section). Serum samples were prepared 
with 50% methanol and then subsequently the metabolites were obtained by Liquid 
Chromatography-Mass Spectometry. . Analysis of the mediators showed that there 
was no significant reduction of PGE2, 5 HETE, 15 HETE, 9 HODE or LTB4, after 
end of treatment with antibiotics (figure 73).  Lipoxin was not detected in any of the 
samples. 
 
Figure 73. No significant change in blood lipidomics at the start and end of 
exacerbation, obtained from 6 bronchiectasis patients. Pooled data presented as mean 
± SEM. Paired t tests used for all comparisons. p>0.1 for all comparisons. 
5 HETE (hydroxyeicosapentanoic acid), 15 HETE hydroxyeicosapentanoic acid), 9-





3.8.2.1. Phagocytosis  
 
Once I assessed the role of Lipoxin A4 on blood neutrophils during exacerbations, I 
wanted to assess its role on sputum neutrophils during exacerbations. Sputum from 
the same 6 bronchiectasis patients (patients who took part in the exacerbation study in 
section 3.8.1) was obtained and airways neutrophils isolated as described in the 
methods chapter. Airways neutrophils were pre treated with vehicle control or 
LX100nM. Phagocytosis of opsonized GFP labeled PAO1 was recorded, after co 
incubating pre treated neutrophils with GFP labeled PAO1 for 60 minutes. Results at 
the beginning and end of exacerbation were recorded. Paired t tests showed that there 
was no significant difference in phagocytosis with Lipoxin A4 either at the beginning 
or at the end of the exacerbation; p=0.8 and p=0.9 respectively (figure 74).	
	
 
Figure 74. No increase in airways neutrophil phagocytosis of GFP labeled PAO1 by 
Lipoxin A4 100nM, at the beginning or end of exacerbation, p=0.8 and p=0.9 
respectively (by paired t-tests). Neutrophils were pre treated with LXA4 for 60 
minutes and phagocytosis was measured after 60 minutes of co-incubation with GFP 
PAO1. Pooled data presented as mean ± SEM for n=6 per group. 
LX= Lipoxin A4 
3.8.2.2. Bacterial killing 	
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Airways neutrophils (from n=6 bronchiectasis patients) were co-incubated with GFP 
labeled bacteria for 60mins. For bacterial killing, cells were lysed (after 60 minutes 
co-incubation of neutrophils with GFP PAO1) and internalized bacteria were plated 
out and bacterial killing was assessed after 24 hours. Killing of GFP PAO1 was 
recorded. Paired t-tests showed that there was a significant increase in airways 
neutrophil killing of GFP labeled PAO1 with Lipoxin A4 100nM both at the 
beginning and at the end of the exacerbation; p=0.02 and p=0.01 respectively (figure 
75). Colony counts at the start and end of exacerbation in control and in airways 
neutrophils treated with Lipoxin A4 100nM are shown in table 15. 
 
 Control LX 100nM 
Start of exacerbation 7.1 (0.2) 6.7 (0.3) 
End of exacerbation 6.8 (0.2) 6.6 (0.2) 
Table 15: Colony counts in log units (standard error of mean), at the start and end of 
exacerbation. 
 
Figure 75. Significantly higher bacterial killing of GFP PAO1 by LXA4 100nM both 
at the start and end of exacerbation (by paired t-tests), p=0.02 and p=0.01 
respectively. Airways neutrophils were pre treated with LXA4 for 30 minutes and 
killing was measured after 60 minutes of co-incubation with GFP PAO1 and then 
reading plates after 24 hours. Pooled data presented as median (IQR) for n=6 per 
group.   
3.8.2.3. Sputum lipidomics 
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To evaluate, if there was a change in the interplay of the pro inflammatory and anti 
inflammatory mediators of arachidonic acid, during exacerbations, I measured certain 
key metabolites in sputum, similar to what was done in serum.  Pro inflammatory 
mediators measured were PGE2, 5 HETE, 15 HETE, 9 HODE and LTB4. Sputum was 
obtained from the 6 patients at the start (Day 1) and end of exacerbation (Day 14) 
after being treated with intravenous antibiotics (same patients as in the preceding 
section). Sputum samples were prepared with 50% methanol and then subsequently 
the metabolites were obtained by LC-MS. Sputum lipidomics was done on patient 
samples at the beginning and end of an exacerbation, treated with antibitoics. There 
was a reduction in 15 HETE, p=0.03 and LTB4 although this just failed to reach 
statistical significance, p=0.08. Although there was a trend, there was no significant 
reduction in reduction of PGE2 and 5 HETE p=0.4 and p=0.1 respectively, after end 
of treatment with antibiotics (figure 76).  
 
Figure 76. Significant reduction in 15HETE p=0.03 and reduction (not statistically 
significant) in LTB4 p=0.08 in sputum, at the end of treatment with antibiotics. No 
significant change in PDE2 and 5HETE. Pooled data presented as mean ± SEM, n=6 
per group. Paired t tests used for all comparisons. 5 HETE (hydroxyeicosapentanoic 
acid), 15 HETE hydroxyeicosapentanoic acid), 9-HODE (hydroxyoctadecadienoic 
acid), LT (leukotriene) B4 and PG (Prostaglandin) E2. 
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3.9. COMMUNITY ACQUIRED PNEUMONIA 
 
Study aim: Assess the anti-inflammatory and pro resolution effect of LXA4 on 
neutrophils at onset and post treatment of community acquired pneumonia. 
3.9.1. Phagocytosis 
6 community acquired pneumonia patients (with no comorbidities) who were 
admitted to hospital, were recruited. All patients received intravenous (co-amoxiclav) 
and oral (clarithromycin) antibiotic therapy. Streptococcus pneumoniae was isolated 
in 4 of the 6 patients and no bacteria could be isolated from 2 patients. Results at the 
beginning (day1) and end of infection (day 5) were recorded. Blood neutrophils were 
co-incubated with GFP labeled bacteria for 15mins. Phagocytosis was measured by 
flow cytometry immediately. For bacterial killing, cells were lysed (after 15 minutes 
co-incubation of neutrophils with GFP PAO1) and internalized bacteria were plated 
out and bacterial killing was assessed after 24 hours. These were the same patients 
who took part in previous section on community-acquired pneumonia (section 3.3) 
One way ANOVA showed that there was a dose dependent increase in phagocytosis 
with Lipoxin A4 both at the beginning and at the end of infection; p=0.01 and p=0.03 
respectively (figure 77).  







Figure 77. Significantly higher phagocytosis by LXA4 both at the start and end of 
exacerbation (by one way ANOVA), p=0.01 and p=0.03 respectively. Neutrophils 
were pre treated with LXA4 for 30 minutes and phagocytosis was measured after 15 
minutes of co-incubation with GFP PAO1. Pooled data presented as mean ± SEM for 
n=6 per group.  NC= negative control; LX= Lipoxin A4. 
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3.9.2. Bacterial killing  
 
Blood neutrophils (from n=6 pneumonia patients) were co-incubated with GFP 
labeled bacteria for 15mins. For bacterial killing, cells were lysed (after 15 minutes 
co-incubation of neutrophils with GFP PAO1) and internalized bacteria were plated 
out and bacterial killing was assessed after 24 hours. Killing of GFP PAO1 was 
recorded. One way ANOVA showed that there was a dose dependent increase in 
blood neutrophil killing of GFP labeled PAO1 with Lipoxin A4 both at the beginning 
and at the end of the exacerbation; p=0.04 and p=0.01 respectively (figure 78). 
 




7.1 (0.1) 6.9 (0.1) 6.8 (0.2) 6.6 (0.1) 
End of 
exacerbation 
6.9 (0.1) 6.7 (0.2) 6.5 (0.2) 6.2 (0.2) 
Table 16: Colony counts in log units (standard error of mean), at the start and end of 
exacerbation. 
Figure 78. Significantly higher bacterial killing by LXA4 both at the start and end of 
exacerbation (by one way ANOVA), p=0.04 and p=0.01 respectively. Neutrophils 
were pre treated with LXA4 for 30 minutes and killing was measured after 15 minutes 
of co-incubation with GFP PAO1 and then reading plates after 24 hours. Pooled data 
presented as median (IQR) for n=6 per group.  NC= negative control; LX= Lipoxin 
A4. 
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3.9.3. Blood lipidomics  
 
Next I wanted to assess if there was a change in blood lipidomics at the start and end 
of treatment for pneumonia, as assessed in the previous sections with bronchiectasis 
patients. I measured  PGE2, 5HETE, 15HETE, 9HODE and LTB4, as before. Paired t-
tests showed that although there was a trend towards reduction in blood PGE2, 15 
HETE and 9 HODE, these were not statistically significant, with p values being 0.1, 
0.2 and 0.1 respectively (figure 79). LXA4, LTB4 and 5 HETE levels were not 




Figure 79. No significant change in blood lipodimics on pneumonia blood at the start 
and end of infection, in pneumonia. Pooled data presented as mean ± SEM, n=6 per 
group. Paired t tests used for all comparisons. 
5 HETE hydroxyeicosapentanoic acid), 9-HODE (hydroxyoctadecadienoic acid) and 
PG (Prostaglandin) E2. 
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3.10. NEUTROPHIL EXTRACELLULAR TRAPS (NETs) 	
 
Study aim: To assess alternative ways of cell death during bronchiectasis 
exacerbations and pneumonia. 
 
3.10.1. NETs by fluorescent microscopy 
	
Peripheral blood neutrophils were isolated from 6 healthy volunteers, as previously 
described and were pretreated with Lipoxin A4 doses of 1nM, 10nM and 100nM or 
vehicle control. Neutrophils were then stimulated with PMA 10nM and NETs were 
counted after 4 hours. Cells were visualised by fluorescent microscopy carried out on 
an Evos fl inverted microscope (AMG, Bothwell, WA). 
After 4 hours incubation, there was an 11% (from 27% in PMA treated and 16% in 
LXA4 100nM treated) statistically significant reduction in the percentage of NETs 
formed by PMA, by Lipoxin A4 100nM; p=0.01 (figure 80). DPI is a known NADPH 



















































Figure 80. Reduction of PMA 10nM (after 4 hours) induced NETs by Lipoxin A4 in a 
dose dependent manner. Pooled data presented as mean ± SEM, n=5. One way 
ANOVA used for comparison. *P<0.05. 
DPI= diphosphoinositide; LX= Lipoxin A4; PMA= phorbol myristate acetate.  
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3.10.2. NETs by fluorescence  
Blood samples were obtained from 6 bronchiectasis patients (same patients as in 
section 3.2) at the beginning and end of exacerbation (day 1 and day 14) and blood 
NET formation was evaluated by fluorescence emitted using a plate reader.  
 
As a control, blood samples were also obtained from 6 pneumonia patients (same 
patients as in section 3.3) at the beginning and end of pneumonia (day 1 and day 5) 
and blood NET formation was evaluated by fluorescence emitted by a plate reader.  
 
Briefly blood neutrophils were incubated for 4h in a 96 well plate and then SYTOX 
green a cell-impermeable nucleic acid stain, with an excitation/emission maxima of 
504/523 nm to give a green fluorescent light, was added and NET formation was 
observed by measuring mean fluorescence in 96 well plates.   
 
3.10.3. NETs, LXA4 and bronchiectasis exacerbations 
 
3.10.3.1. Start of exacerbation- figure 81a 
Paired t-tests showed that there was no reduction on PMA stimulated NETs 
production, even by the highest concentration of LXA4 100nM. On the contrary, there 
was an increase in NETs when LXA4 100nM was added to PMA stimulated NET 
formation, p=0.001. However, LXA4 only treated neutrophils were able to reduce 
NETs produced by untreated neutrophils (NC- neutrophils treated with vehicle control 
only); p=0.0005.   
 
3.10.3.2. End of exacerbation- figure 81b  
Similar to findings at the start of exacerbation, there was no reduction by LXA4 on 
PMA stimulated NETs production at the end of exacerbation, but on the contrary 
there was an increase in NETs when LXA4 100nM was added to PMA stimulated 
NET formation, p<0.0001. However, LXA4 only treated neutrophils were able to 
reduce NETs produced by untreated neutrophils (NC- neutrophils treated with vehicle 






































Figure 81a. Representative graph from blood neutrophils of bronchiectasis patient 
producing NETs as measured by fluorescence, at the start of an exacerbation.  LX 




































Figure 81b. Representative graph from blood neutrophils of bronchiectasis patient 
producing NETs as measured by fluorescence, at the end of an exacerbation.   
LX only treated neutrophils were able to significantly reduce NETs produced at 
baseline (NC). 
DPI= diphosphoinositide; LX= Lipoxin A4; PMA= phorbol myristate acetate.  
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Although, lipoxin A4 was not able to reduce PMA induced NET formation, paired t-
tests showed that there was a significant reduction in NETs produced at the beginning 
(p=0.0005) and at the end of treatment with antibiotics (p=0.0003) in bronchiectasis 









































Figure 81c. Reduction in NET formation by LXA4 in untreated neutrophils at the start 
and at the end of exacerbation. Pooled data presented as mean ± SEM, n=6. Paired t-
test used for comparison. ***P<0.001.  
 
 
 3.10.4. NETs, LXA4 and pneumonia 
 
3.10.4.1. Start and end of infection- figure 82a&b 
Paired t-tests showed that there was no reduction on PMA stimulated NETs 
production in blood neutrophils, even by the highest concentration of LXA4 100nM. 
On the contrary, there was an increase in NETs when LXA4 100nM was added to 
PMA stimulated NET formation, p=0.0003. Additionally, LXA4 only treated 
neutrophils were not able to reduce NETs produced by untreated neutrophils (in 
contrast to bronchiectasis patients), and on the contrary increased NETs production; 






Similar to findings at the start of infection, there was no reduction on PMA stimulated 
NETs production, at the end of pneumonia treatment. Additionally LXA4 only treated 
neutrophils were not able to reduce NETs produced by untreated neutrophils (NC- 
neutrophils treated with vehicle control only).  
 






























Figure. 82a. Representative graph from blood neutrophils of pneumonia patient 
producing NETs as measured by fluorescence, at the beginning of an infection. 
LX only treated neutrophils were not able to significantly reduce NETs produced at 
baseline (NC). 
 



























Time in minutes  
Figure 82b. Representative graph from blood neutrophils of pneumonia patient 
producing NETs as measured by fluorescence, at the end of treatment with antibiotics.   
LX only treated neutrophils were not able to significantly reduce NETs produced at 
baseline (NC). 
DPI= diphosphoinositide; LX= Lipoxin A4; PMA= phorbol myristate acetate.  
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Although, Lipoxin A4 was not able to reduce PMA induced NET formation, when 
comparing NETs produced at the start and end of pneumonia, there was a significant 
reduction in NETs produced at the end of treatment (with antibiotics) of pneumonia, 
both in untreated neutrophils (p=0.0003) and PMA treated neutrophils (p=0.004) 




































Figure 82c. Significant reduction in NETs formation at the end of pneumonia 
treatment with antibiotics in untreated and PMA treated neutrophils. Pooled data 







3.10.5. Comparison of NETs in bronchiectasis to pneumonia  
 
In the previous section, I concluded that for both bronchiectasis and pneumonia there 
was no effect of Lipoxin A4 on PMA treated neutrophils. However, LXA4 was able to 
reduce NETs produced in unstimulated neutrophils both at the start and end of 
exacerbations in bronchiectasis only. I now wanted to assess if there was a difference 
in NETs produced in in unstimulated neutrophils during exacerbations. On 
comparison, I found that there was significantly higher NETs produced at the start of 
exacerbations in bronchiectasis (p=0.01) and significantly lower at the end of 
exacerbations (p=0.0003) compared to pneumonia patients (figure 83). This shows 
that NETs are perhaps one of the methods of cell death in bronchiectasis but fewer 
NETs at the end of exacerbations compared to pneumonia suggests that perhaps cells 
are directed towards another pathway for clearance that contributes to ongoing 






































Figure 83. Significant difference in NETs formation at the start and end of 
bronchiectasis exacerbations compared to pneumonia, in untreated neutrophils. 





Study aim: Assess the anti-inflammatory and pro resolution effect of LXA4 on 
monocyte-derived macrophages from healthy volunteers. 
Monocytes were isolated from 6 healthy volunteers and were grown to monocyte-
derived macrophages in 5-7 days. Upon, co incubating MDMs with apoptotic 
neutrophils for 40-60 minutes, there was a dose dependent increase in the 
phagocytosis of apoptotic neutrophils (also known as efferocytosis) by MDMs that 
were pre-treated with Lipoxin A4, however this failed to reach statistical significance; 
p=0.07 (one way ANOVA). 
 
CD44 was added as a positive control. The cell surface receptor CD44 is a known to 
be a key regulator of macrophage capacity for phagocytosis of apoptotic cells. Paired 
t tests of vehicle treated (MDM and neutrophils only) and CD44 treated cells showed 











































Figure 84. Significant increase in MDM phagocytosis of apoptotic neutrophils when 
MDM were pre-treated with CD44. No significant increase in phagocytosis when 
neutrophils were pre treated with LXA4. Pooled data presented as mean ± SEM, n=5. 
One way ANOVA used for comparisons. 
LXA4= Lipoxin A4; MDM= monocyte derived macrophages. 
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3.12. REPROGRAMMING OF BLOOD NEUTROPHILS IN 
BRONCHIECTASIS 
 
3.12.1. Characteristics and functions of blood neutrophils in bronchiectasis 
I studied the behavior of peripheral blood neutrophils in mild (6) and severe 
bronchiectasis (6) and compared it to the activity of peripheral blood neutrophils 
isolated from healthy volunteers (7). Untreated neutrophils from bronchiectasis 
patients (both in mild and severe groups) had increased survival and decreased 
apoptosis when compared to healthy volunteers. Further studies done demonstrated 
that when neutrophils from bronchiectasis patients underwent apoptosis using serum 
from healthy volunteers (and not autologous serum), there was a reduction in viability 
and increased apoptosis in bronchiectasis neutrophils. However, the reverse was not 
true when treating healthy volunteers patients neutrophils with bronchiectasis serum. 
This suggests that there is perhaps a re programming of neutrophils in bronchiectasis 
and the findings are not secondary to blood factors.  
 
Neutrophil activation was measured by assessing expression of CD11b and CD62L. 
Upon activation, neutrophils express more CD11b and shed CD62L. At baseline 
(untreated neutrophils), there was an increase in expression of CD11b in severe 
bronchiectasis compared to healthy volunteer sand mild bronchiectasis patients. There 
was more shedding of CD62L in mild and severe bronchiectasis patients compared to 
healthy volunteers indicating that, even when unstimulated, neutrophils in 
bronchiectasis remain more activated. Having more baseline activation would thereby 
explain why these neutrophils have a longer life span. This could be speculated to be 
secondary to more activating survival factors in a more proinflammatory environment 
in bronchiectasis patients blood and airways.  
 
Measuring myeloperoxidase release assessed neutrophil degranulation. In untreated 
blood neutrophils, there was significantly more myeloperoxidase release in 
bronchiectasis patients compared to healthy volunteers. Reactive oxygen species 
generation by neutrophils upon stimulation with fMLF was measured.  There was no 
difference in superoxide generation by unstimulated neutrophils in the groups.  
 
Assessment of phagocytosis and killing of GFP labeled Pseudomonas aeruginosa by 
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blood neutrophils was done in all three groups. There was a significantly higher 
phagocytosis and killing in healthy volunteers compared to mild and severe 
bronchiectasis. 
 
Table 17 summarizes the overall key blood neutrophil functions that were assessed in 
mild and severe bronchiectasis patients, in comparison to blood neutrophil function 







Apoptosis ↓ ↓ 
Viable neutrophils ↑ ↑ 
CD11b upregulation ↔ ↑↑ 
CD62L shedding ↓ ↓ 
Myeloperoxidase release ↔ ↑ 
Phagocytosis ↓ ↓ 
Bacterial killing ↓ ↓↓ 
Superoxide release ↔ ↔ 
Table 17. Summary of key neutrophil functions evaluated at baseline in mild 
bronchiectasis and severe bronchiectasis; n=8 per group. 
 
3.12.2. Comparison of blood neutrophils to airways neutrophils in bronchiectasis 
Mild and severe bronchiectasis patients were recruited in this study. Blood 
neutrophils were isolated from blood and airways neutrophils were isolated from 
bronchoalveolar lavage fluid obtained during bronchoscopy. Phagocytosis and killing 
of GFP labeled bacteria by both blood and airways neutrophils were assessed. There 
was significantly higher bacterial phagocytosis and killing by blood neutrophils in 
both mild and severe patients compared to airways neutrophils. 
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3.12.3. Neutrophil function during exacerbations in bronchiectasis 
6 patients during stable state and 6 patients with exacerbations were recruited in this 
study. There was a significantly higher bacterial phagocytosis and killing by blood 
neutrophils at the end of exacerbations compared to beginning. This suggests that 
neutrophil function is improved by treatment with antibiotics. In addition, comparison 
of neutrophil function during exacerbations was made to stable state. There was 
significantly higher phagocytosis and bacterial killing in the stable state compared to 
the beginning of exacerbation. However, there was no difference in phagocytosis or 
bacterial killing in the stable state compared to end of exacerbation. This thereby 
suggests that antibiotic treatment is able to restore phagocytic and killing ability of 
neutrophil to the stable state. However, what still remains unexplained is the ongoing 
inflammation in bronchiectasis. Can addition of an anti-inflammatory or pro 
resolution mediator, such as Lipoxin A4 be additive and negate the persisting 
inflammation? 
On assessing airways neutrophil function, obtained from sputum, there was a 
significantly higher bacterial phagocytosis and killing by airways neutrophils at the 
end of exacerbations compared to beginning. In addition, comparison of neutrophil 
function during exacerbations was made to stable state. There was higher 
phagocytosis (although not significant), and significantly higher bacterial killing in 
the stable state compared to the beginning of exacerbation. However, there was no 
difference in phagocytosis or bacterial killing in the stable state compared to end of 
exacerbation, in airways neutrophils. 
 
3.12.4. Blood neutrophil function in community acquired pneumonia 
In this study, 6 patients with community-acquired pneumonia were recruited and 
neutrophils were isolated from blood obtained at the start and end of infection. There 
was significantly higher bacterial phagocytosis and killing at the end of infection 
compared to beginning, in community acquired pneumonia. On comparison of 
neutrophil function in bronchiectasis exacerbation to community-acquired 
pneumonia, there was no difference in bacterial phagocytosis between the two groups, 
either at the beginning or at the end of exacerbation. However, on comparison of 
bacterial killing, there was significantly higher bacterial killing by blood neutrophils 
in community acquired pneumonia compared to bronchiectasis, both at the beginning 
and at the end of infection. This suggests that there is perhaps a defect in the killing 
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and clearance of bacteria in bronchiectasis that antibiotics are unable to do. 
Antibiotics do perhaps not attenuate the survival signals for bacteria and hence the 
roles of anti-inflammatory agents need to be explored. This is discussed in the next 
section.  
 
Neutrophil extracellular trap (NETs) formation was evaluated in both bronchiectasis 
exacerbations and pneumonia. There was a reduction in neutrophil extracellular trap 
formation at the end of treatment of exacerbation both in bronchiectasis and in 
pneumonia, compared to beginning of exacerbation. On comparison of NETs in 
bronchiectasis to pneumonia, I found that there was significantly higher NET 
formation in bronchiectasis than pneumonia at the start of infection. At the end of 
treatment of infection, there was significantly lesser NETs produced in bronchiectasis, 
suggesting perhaps another alternate pathway for cell death in bronchiectasis. 
 
 
3.12.5. Bronchiectasis and Lipoxin A4 
Once I had established neutrophil function in bronchiectasis, I wanted to assess the 
role of Lipoxin A4 on these neutrophil functions. Would LXA4 be able to restore the 
neutrophil function in bronchiectasis patients to healthy volunteers? Lipoxin A4 
improved CD11b upregulation, CD62L shedding, myeloperoxidase and superoxide 
release (except in mild bronchiectasis) release, neutrophil phagocytosis and killing of 
GFP PAO1, in a dose dependent manner. Neutrophil activation was measured by 
assessing expression of CD11b and CD62L. There was no effect of LXA4 on 
apoptosis. This part of the study established that LXA4 stabilizes neutrophils, which 
improves phagocytosis and killing of GFP PAO1, which is key in bronchiectasis 






3.12.6. NETs and Lipoxin 
I assessed NETs formation in bronchiectasis and in pneumonia patients at the start 
and end of treatment with antibiotics. Although, in vitro, in the healthy volunteers 
(with no infection) lipoxin was able to reduce PMA induced NET formation in a dose 
dependent manner, there was no reduction in PMA induced NETs production in 
bronchiectasis or pneumonia patients, either at the start or at the end of infection. 
However, in unstimulated neutrophils, LXA4 100nM was able to significantly reduce 
NETs formation compared to untreated neutrophils. Additionally, as expected there 
were reduced PMA induced NETs at the end of infection in both bronchiectasis and 
pneumonia. Significantly higher NETs were detected at the start of infection in 
bronchiectasis and lesser NETs were detected at the end of bronchiectasis 
exacerbation compared to end of pneumonia treatment.  
 
3.12.7. Lipoxin and function of blood neutrophils  
I studied the behavior of peripheral blood neutrophils in mild and severe 
bronchiectasis and compared it to the behavior of peripheral blood neutrophils from 
healthy volunteers, as discussed earlier. In addition, I assessed the role of lipoxin A4 
in modulating the response of these neutrophils under various stimuli. Three groups 
were of participants were recruited for this study- 7 healthy volunteers, 6 patients with 
mild bronchiectasis and 6 patients with severe bronchiectasis. Lipoxin A4 was unable 
to increase or decrease spontaneous apoptosis in blood neutrophils from healthy 
volunteers, mild bronchiectasis and severe bronchiectasis patients. When treated with 
roscovitine, a known inducer of apoptosis, there was less apoptosis and more necrosis 
of neutrophils from bronchiectasis patients compared to healthy volunteers. 
Neutrophil activation was measured by assessing expression of CD11b and CD62L. 
Upon activation, neutrophils express more CD11b and shed CD62L. Lipoxin was able 
to reduce fMLF-induced activation and further increase in CD11b expression and 
CD62L shedding, in a dose dependent manner, in all three groups. Next I assessed 
neutrophil degranulation by measuring myeloperoxidase. Upon stimulation with 
fMLF and cytochalasin B, lipoxin was able to reduce myeloperoxidase release in all 
groups in a dose dependent manner. Reactive oxygen species generation by 
neutrophils upon stimulation with fMLF was measured. When stimulated with fMLF, 
LXA4 was able to reduce superoxide release in a dose dependent manner in healthy 
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volunteers and severe bronchiectasis patients. There was no effect of lipoxin on 
superoxide generation in mild patients.  
 
Effect of Lipoxin on neutrophil function was assessed next. Lipoxin was able to 
enhance phagocytosis and killing of GFP labeled Pseudomonas aeruginosa by blood 
neutrophils in a dose dependent manner across all three groups.  
 
Lipoxin A4 binds to the ALX/FPR2 receptor. Although this just failed to reach 
statistical significance, there was an increased expression of the ALX/FPR2 receptor 
in healthy individuals compared to bronchiectasis patients, at baseline. Upon 
treatment with LXA4, there was significant increase in ALX/FPR2 expression in 
neutrophils from healthy volunteers compared to bronchiectasis patients.  
 
In summary, pretreatment of blood and airways neutrophils with Lipoxin A4, 





Clearance of apoptotic neutrophils is one of the key functions of macrophages to 
initiate the process of resolution of inflammation. Although, other studies (Mitchell et 
al 2002) have demonstrated that lipoxin does increase efferocytosis (albeit the 
methods of assessing by Mitchell and colleagues were by electron microscopy and I 
assessed efferocytosis by flow cytometry), in this study lipoxin was not able to 
enhance clearance of apoptotic neutrophils. However, addition of the cell surface 
receptor CD44 was significantly able to increase efferocytosis. Assessing 
efferocytosis with higher doses of lipoxin is needed but has not been investigated 






IN HUMAN STUDIES 
 
Study aim:  Assess the anti-inflammatory and pro resolution effect of LXA4 on 
neutrophils during stable state in bronchiectasis. 
 
4.1. BRONCHOSCOPY STUDY 
 
55 patients meeting the study criteria were approached to take part in the study of 
which 34 bronchiectasis patients consented and completed the study. 6 healthy 
volunteers took part and completed the study. Patients were all given a bronchiectasis 
severity score by calculating their respective bronchiectasis severity index (BSI). Of 
the 34 patients, 10 were mild, 15 moderate and the remaining 9 severe bronchiectasis.  
 
 
Figure 85. Flow chart depicting the recruitment of healthy volunteers and 
bronchiectasis patients and classification of patients as per the bronchiectasis severity 





Baseline demographics of study participants are shown in table 18. Section 4.1.1.1 to 
4.1.1.5 describes the baseline demographics in further detail. 
 
Parameters  Bronchiectasis patients  
N=34 
 



















Gender (% female) 
 



















































































































Hospital admissions in 






Table 18. Baseline demographics of the study population. Data presented as mean (± 
standard deviation). 
CRP= c reactive protein; ESR= erythrocyte sedimentation rate; FEV1= forced 
expiratory volume in 1sec; FVC= forced vital capacity; KCO= transfer coefficient; 






4.1.1. STUDY PARTICIPANTS  
 
4.1.1.1. Age 
There was no statistically significant difference in the age across the groups in the 



























Figure 86. There was no significant difference in age across the group. Pooled data 




4.1.1.2. Serum inflammatory markers 
• 4.1.1.2.1. White cell counts, CRP and ESR 
Using one-way ANOVA with Bonferroni’s multiple comparison post hoc test, there 
was a statistically significant difference in the total white cell count (p=0.005), 
neutrophils (p=0.001) and c reactive protein (p=0.04). Although there was a trend, 
there was no significant difference in erythrocyte sedimentation rate; p=0.1.  Severe 
patients had higher white cell counts, neutrophil counts, c- reactive protein and a trend 
towards higher ESR compared to the other three groups. There was no statistical 
difference in the monocyte count (p=0.4) or eosinophil count (p=0.4) between the 
groups; figure 87. 
 
 
Figure 87. Significantly higher white cell counts, neutrophils, c- reactive protein 
(CRP) across the four groups. No difference in erythrocyte sedimentation rate. Pooled 
data presented as mean ± SEM. One way ANOVA was done for all comparisons.
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4.1.1.3. Lung physiology 
 
Using one-way ANOVA with Bonferroni’s multiple comparison post hoc test, there 
was a statistically significant difference in percent predicted FEV1 and FVC across 
the groups; p=0.0001 and p=0.008 respectively. Severe patients has lower % 
predicted FEV1, % predicted FVC compared to the other two groups. Unpaired t tests 
showed a p value of p=0.052, when comparing % predicted TCO between mild and 
severe patients. There was no statistically significant difference in percent predicted 
KCO; p=0.4, by one way ANOVA; figure 88.  
 
 
Figure 88. Significantly higher % predicted forced expiratory volume in 1 second,  % 
predicted forced vital capacity % predicted transfer factor in mild compared to severe 
bronchiectasis. Pooled data presented as mean ± SEM. One way ANOVA was done 











4.1.1.4. Exacerbations and hospital admissions  
 
The number of exacerbations (as defined by the British thoracic society guidelines) 
(British Thoracic Society bronchiectasis guidelines, 2010, Thorax) and hospital 
admissions secondary to bronchiectasis, in the year preceding participation in the 
study were recorded. Using one-way ANOVA with Bonferroni’s multiple comparison 
post hoc test, there was a statistically significant difference across the groups, in 
exacerbations requiring antibiotics and hospital admissions; p=0.0002 and p=0.0008 
respectively (figure 89).  Severe patients had more exacerbations requiring antibiotics 
and hospital admissions, compared to mild and moderate patients.  
 
 
Figure 89. Significantly more exacerbations requiring antibiotic therapy and hospital 
admissions secondary to bronchiectasis exacerbations, in the preceding year, in severe 











4.1.1.5. Microbiology from bronchoalveolar samples in study participants 
 
All 34 patients and 6 healthy volunteers underwent bronchoscopy. In healthy 
volunteers 33% isolated an organism from the bronchoalveolar lavage fluid. In the 
mild group 40%, moderate 43% and severe 56%, isolated an organism from the 
bronchoalveolar lavage fluid.  
Chi square analyses showed that there was a statistically significant increase in 
percentage of bacteria isolated in the severe group compared to healthy and mild 
groups; p=0.001 and p=0.03 respectively. There was no significant difference 
between the moderate and severe groups, p=0.08. The breakdowns of the organisms 
















0 1 (7%) 1 (11%) 0 
Gram negative 
organisms 
1 (10%) 2 (14%) 3 (34%) 0 
Haemophilus 
influenzae 
2 (20%) 2 (14%) 1 (11%) 1 (17%) 
Streptococcus 
pneumoniae 
0 1 (7%) 0 0 
Moraxella 
catarrhalis 
1 (10%) 0 0 1 (17%) 
Mixed normal 
flora/ no growth 
 
6 (60%) 8 (57%) 4 (44%) 4 (66%) 
Table 19. Qualitative microbiology across the groups.  
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4.1.2. BLOOD NEUTROPHIL AND LIPOXIN 
 
4.1.2.1. Phagocytosis 
Peripheral blood neutrophils were isolated and phagocytosis assays were performed 
by co incubating the pre treated neutrophils (30 minutes with LXA4) with GFP PAO1 
for 15 minutes.  Using one-way ANOVA with Bonferroni’s multiple comparison post 
hoc test, there was a statistically significant improvement in phagocytosis by LXA4 in 
a dose dependent manner in the healthy volunteers group (p=0.0001), mild 
(p<0.0001), moderate (p<0.0001) and severe bronchiectasis p=0.03; figure 90. These 




















GFP PAO1)      
38.6 (2.9) 33.3 (0.5) 34.4 (1.3) 32.3 (1.4) 
+ LXA4 1nM 
 
40.5 (2.5) 38.3 (1.5) 37.2 (1.2) 36.4 (2.9) 
+ LXA4 10nM 42.9 (2.6) 40.1 (1.7) 37.3 (1.7) 38.1 (2.9) 
+ LXA4 
100nM 
     46. 3 (2.2) 41.2 (1.7) 39.4 (1.2) 42.1 (2.3) 
Table 20. Percentage phagocytosis across the bronchiectasis groups including the 
different treatments the neutrophils were exposed to- vehicle treated, 1nM, 10nM and 





Figure 90. There was a dose dependent increase in phagocytosis with LXA4. One-way 
ANOVA with Bonferroni’s correction for multiple comparisons used; with p values 
representing the comparison of control to 1nm, 10nM and 100nM of LXA4. Pooled % 
neutrophil phagocytosis data, showing means +/- SEM. *P<0.05; ***P<0.001; 
****P<0.0001. 




4.1.2.2. Bacterial killing 
Following co incubation of the peripheral blood neutrophils with the GFP PAO1 for 
15 minutes, the cells were lysed and the suspensions were plated out on pseudomonas 
isolation agar and bacterial counts were read after 24 hours.  Data is presented as 
median (inter quartile range). 
Using one-way ANOVA with Bonferroni’s multiple comparison post hoc test, there 
was a statistically significant improvement in phagocytosis by LXA4 in a dose 
dependent manner in the healthy volunteers group (p=0.001), mild (p=0.04), moderate 









Figure 91. Lipoxin A4 significantly improved bacterial killing in a dose dependent 
manner in all 4 groups. Box plot of killing assay of GFP labelled PAO1 by peripheral 
blood neutrophils, across the groups. Scale is log bacterial load in cfu/ml. One-way 
ANOVA with Bonferroni’s correction for multiple comparisons used; with p values 
representing the comparison of control to 1nm, 10nM and 100nM of LXA4. Pooled % 
neutrophil killing data, showing means +/- SEM. *P<0.05; **P<0.01. 
















4.1.3. AIRWAYS NEUTROPHILS AND LIPOXIN  
 
Bronchoalveolar lavage was done in an area affected by bronchiectasis and in an area 
unaffected by bronchiectasis. Neutrophils were isolated and counted from the lavage 
fluid; table 21. In all three groups there was a similar return of neutrophils/ml in areas 
affected by bronchiectasis compared to unaffected areas, with no significant statistical 
difference (using unpaired t-tests); figure 92. This suggests that in bronchiectasis, 
there is an altered phenotype of neutrophils and that this is perhaps effected at the 

























































Figure 92. There was no significant difference in total cell counts between affected 
and unaffected segments in mild, moderate and severe bronchiectasis. Paired t tests 
used for comparisons. Pooled data presented as mean ± SEM.  
A= affected segment; U= unaffected segment. 
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 4.1.3.1. Phagocytosis  
 
Airways neutrophils were isolated from bronchoalveolar lavage fluid from 
bronchiectasis patients and phagocytosis assays were performed with GFP PAO1.   
Using paired t-tests, in the unaffected segments, there was no significant improvement 
in phagocytosis with LXA4 100nM in any of the groups. In the affected segments, 
there was a statistically significant improvement in phagocytosis by LXA4 100nM in 
the mild, moderate and severe bronchiectasis groups by LXA4 100nM, p=0.01, p=0.02 
and p=0.04 respectively, figure 93. The percentage phagocytosis is summarized in 
table 22. 
 




















































Figure 93. Lipoxin A4 was able to significantly increase phagocytosis by airways 
neutrophils in the segments affected by bronchiectasis in mild, moderate and severe 
disease. There was no effect of LXA4 on the unaffected segments. Paired t tests used 
for comparisons. Pooled data presented as mean ± SEM. Paired t tests used for all 
comparisons.  




















4.1.3.2. Bacterial killing 
 
Following co incubation of the airway neutrophils (isolated from bronchoalveolar 
lavage fluid) with the GFP PAO1, the cells were lysed and the suspensions were 
plated out on pseudomonas isolation agar and bacterial counts were read after 24 
hours.  Data is presented as median (interquartile range).  
Using paired t-tests, in the unaffected segments, there was a statistically significant 
improvement in bacterial killing with LXA4 100nM in the severe group of patients 
only; p=0.02. In the affected segments, there was a statistically significant 
improvement in killing by LXA4 in the mild, moderate and severe bronchiectasis 
groups by LXA4 100nM, p=0.02, p=0.0005 and p=0.04 respectively, figure 94 and 
table 23. 
 









































































Figure 94. Lipoxin A4 was able to significantly increase killing by airways neutrophils 
in the segments affected by bronchiectasis in mild, moderate and severe disease. 
However, in the unaffected segments, LXA4 was able to increase killing in severe 
disease only. Paired t tests used for comparisons. Pooled data presented as median ± 
IQR. Unpaired t tests used for all comparisons. Scale is log bacterial load cfu/ml. 
Bx= bronchiectasis; LX= Lipoxin A4. 
 
The results from the phagocytosis and killing assays and the effect of Lipoxin A4 
suggests that Lipoxin A4 predominantly has an effect on neutrophils from segments of 
the lung affected with bronchiectasis. In the unaffected segment- there is no further 
role for LXA4 to improve neutrophil function, in comparison to affected segments 
where LXA4 is able to significantly improve neutrophil phagocytosis and killing. 
Assessing neutrophil maturity and determining the ratio in which low-density and 
high-density neutrophils would be present in the unaffected and affected segments 
would be additive.  
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4.1.3.3. BALF inflammatory markers from affected airways 
 
• 4.1.3.3.1. Myeloperoxidase 
Myeloperoxidase was measured in all 4 groups from BALF.  Using one-way 
ANOVA with Bonferroni’s multiple comparison post hoc test showed a 
statistically significant increase in myeloperoxidase across the groups; 
p=0.002, with highest levels of MPO in the severe group. Comparison 
between groups (as measured by ANOVA) showed a significant difference 
between healthy and moderate group (p=0.01), between healthy and severe 
group (p=0.001). There was no statistically significant difference between 



































Figure 95. Myeloperoxidase measured was significantly higher in moderate and 
severe bronchiectasis compared to healthy volunteers. Pooled data presented as mean 
± SEM. One way ANOVA with post test used for comparisons. 




• 4.1.3.3.2. Neutrophil Elastase 
Neutrophil elastase was measured in all 4 groups from bronchoalveolar lavage fluid. 
Using one-way ANOVA with Bonferroni’s multiple comparison post hoc test showed 
a statistically significant increase in neutrophil elastase across the groups; p=0.002; 
with highest levels of neutrophil elastase in the severe group. Comparison between 
groups (as measured by ANOVA) showed a significant difference between healthy 
and severe group, p=0.01. There was no significant difference between healthy and 




































Figure 96. Neutrophil elastase was significantly higher in severe bronchiectasis 
compared to healthy volunteers. Pooled data presented as mean ± SEM. One way 
ANOVA used for comparisons. 










4.1.4. SERUM LL37 
As one of the relevant anti microbial cathelicidins, I wanted to measure serum LL37 
in all 4 groups. Although there was a trend towards increase in serum LL37 with 
disease severity, one way ANOVA with Bonferroni’s post hoc analysis for multiple 





























Figure 97. There was no difference in LL-37 measured across the groups, by one way 
ANOVA. Pooled data presented as mean ± SEM 







4.1.5. SERUM LIPOXIN A4 
Serum Lipoxin A4 was measured in all study participants. One way ANOVA showed 
that LXA4 was reduced in severe bronchiectasis compared to healthy volunteers; 
p=0.04. There was no significant difference in LXA4 levels between healthy 
volunteers and mild bronchiectasis (p=0.2) or between healthy volunteers and 






























Figure 98. Serum Lipoxin A4 was significantly reduced in severe bronchiectasis, on 
comparison to healthy volunteers, mild and moderate bronchiectasis. Pooled data 




4.1.6. SERUM LIPIDOMICS 
 
Liquid chromatography and mass spectrometry was done on all serum samples 
obtained, where available. Samples were divided into mild (9) and moderate-severe 
(15) groups, based on their score calculated by the bronchiectasis severity index.  
 
The main lipids assessed were: Lipoxin A4, Resolvins, Maresins, Prostaglandin (PG) 
E2, 5 hydroxyeicosatetranoic acid (HETE), 15 hydroxyeicosatetranoic acid (15 
HETE), LTB4 and 9-hydroxyoctadecadienoic acid (9-HODE). Lipoxin A4, Resolvins 
and Maresins were not detected in any of the samples. 15 HETE is a precursor of 
Lipoxin A4 and is a pro inflammatory mediator. LTB4 is a pro inflammatory cytokine 
and 9HODE is a pro inflammatory metabolite produced from arachidonic acid. 
Using unpaired t-tests, there were significantly higher levels of PGE2, 15 HETE and 
LTB4  in patients with moderate-severe disease compared to healthy controls, p=0.03, 
p=0.03 and p=0.02 respectively. Although there was a trend towards higher 5HETE 
and 9 HODE levels in moderate-severe disease compared to healthy volunteers, this 
failed to reach statistical significance; p=0.3 and 0.2 respectively (figure 16a&b). 
There was no difference in the PGE2, 15 HETE, LTB4 , HETE and 9 HODE levels 





Figure 99a: Significantly higher levels of PGE2, 15 HETE and LTB4 detected in 
patients with moderate- severe disease compared to mild healthy volunteers, p=0.03, 
p=0.03 and p=0.02, respectively. Lipidomics were obtained by mass spectrometry and 
liquid chromatography. Pooled data presented as mean ± SEM. One way ANOVA 
used for comparisons. 





Figure 99b: Higher levels of 5 HETE and 9 HODE detected in patients with more 
moderate-severe disease compared to mild disease, but not statistically significant. 
Lipidomics were obtained by mass spectrometry and liquid chromatography. Pooled 
data presented as mean ± SEM. One way ANOVA used for comparisons. 
5 HETE (hydroxyeicosatetranoic acid), 15 HETE hydroxyeicosatetranoic acid), 9-
HODE (hydroxyoctadecadienoic acid), LT (leukotriene) B4 and PG (Prostaglandin) 
E2. 




4.1.7. BALF LIPIDOMICS 
 
Liquid chromatography and mass spectrometry was done on all samples obtained at 
bronchoalveolar lavage, where available. In addition, samples were obtained from an 
area affected by bronchiectasis and an area unaffected by bronchiectasis; hence 
patients could act as their own internal control. As before, samples were divided into 
mild (9) and moderate-severe groups (15), based on their score calculated by the 
bronchiectasis severity index.  
PGE2 was not detectable in BALF from healthy individuals. Using unpaired t-tests, 
there were significantly higher levels of PGE2, 5HETE and 15 HETE in patients with 
moderate-severe disease compared to healthy volunteers, p<0.0001, p=0.004 and 
p=0.005 respectively. There were significantly higher levels of 9HODE and LTB4 in 
moderate-severe patients compared to healthy volunteers, p=0.04 and p<0.0001 
respectively (figure 100 a&b). There was no difference in the PGE2, 15 HETE, LTB4, 










Figure 100a: Significantly higher levels of PGE2, 5 HETE and 15 HETE detected in 
patients with moderate- severe disease compared to mild disease. Lipidomics obtained 
by mass spectrometry and liquid chromatography. Pooled data presented as mean ± 
SEM. One way ANOVA used for comparisons. 




Figure 100b: Significantly, higher levels of 9 HODE and LTB4 detected in patients 
with moderate-severe disease compared to mild disease and healthy volunteers. 
Lipidomics obtained by mass spectrometry and liquid chromatography. Pooled data 
presented as mean ± SEM. One way ANOVA used for comparisons. 
5 HETE (hydroxyeicosapentanoic acid), 15 HETE hydroxyeicosapentanoic acid), 9-
HODE (hydroxyoctadecadienoic acid), LT (leukotriene) B4 and PG (Prostaglandin) 
E2. 






4.1.8. Comparison of lipidomics in samples obtained from affected and 
unaffected areas 
Data was then analysed to compare the mediators obtained from the affected and 
unaffected area of the same patient and to assess if this there was a significant 
difference in samples obtained from an individual patient.  
Using paired t-tests, there were no significant differences between affected and 
unaffected segments in PGE2 (p=0.6 in mild and p=0.8 in mod-severe), 5HETE 
(p=0.7 in mild and p=0.9 in mod-severe), 15 HETE (p=0.5 in mild and p=0.1 in mod-
severe), and 9 HODE (p=0.5 in mild and p=0.3 in mod-severe; figure 101).  It was not 
possible to sub-analyse the results for LTB4 as there were not enough samples in 
which LTB4 was detected.  
 
 
Figure 101. No significant difference in PGE2, 5 HETE, 15 HETE and 9HODE 
obtained by lipidomics between unaffected and affected segments in the mild and 
moderate-severe groups. Pooled data presented as mean ± SEM. Unpaired t tests used 
for comparisons. 
5 HETE (hydroxyeicosapentanoic acid), 15 HETE hydroxyeicosapentanoic acid), 9-
HODE (hydroxyoctadecadienoic acid) and PG (Prostaglandin) E2. 
Healthy=6 volunteers; mild= 9 patients; moderate- severe =15 patients. 
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4.1.9. RT PCR from bronchial brushings 
 
Study aim: To investigate a potential mechanism for low levels of LXA4 in 
bronchiectasis, lipoxin biosynthetic genes expression was measured.  
Bronchial brushings were obtained from all 34 patients and 6 healthy volunteers. 
RNA was extracted from the brushings where adequate samples were obtained. There 
was insufficient samples for RNA extraction from samples that were obtained from 
healthy volunteers. RT PCR was done for the following genes: 5 Lipoxygenase 
(5LOX), Leukotriene A4 hydrolase (LTA4H), 15 Lipoxygenase A (15 LO-A) and 15 
Lipoxygenase B (15 LO-B).  The lipoxin generation pathway and the important 
biosynthetic enzymes are shown in figure 12 section 1.10. 
By quantitative PCR, the delta Ct values for these four pivotal LX biosynthetic genes 
were determined. LTA4 hydrolase was the most abundant RNA (lowest DCt) in 
bronchial brushings. In contrast, the least abundant gene (highest delta Ct) was 15 
LO-B. Using unpaired t-tests, the delta Ct values for 5-LOX and 15-LO-B were both 
significantly increased (p=0.01 and p=0.01 respectively) in subjects with moderate-
severe bronchiectasis compared with subjects with mild bronchiectasis, indicating 
decreased expression of all these regulatory genes in moderate-severe bronchiectasis. 
Unpaired t- tests showed that, delta Ct value of LTA4 hydrolase was significantly 
decreased in subjects with moderate-severe bronchiectasis compared with subjects 
with mild bronchiectasis (p=0.007), indicating increased expression of in moderate-
severe bronchiectasis. There was no significant difference in 15 LO-A gene 
expressions between mild bronchiectasis and moderate-severe bronchiectasis (p=0.2); 






















Figure 102: 5LOX and 15 Lipoxygenase B genes were significantly lower and LTA4 
hydrolase was significantly higher in moderate –severe bronchiectasis. No difference 
in 15 LO-A between the groups. Pooled data presented as mean ± SEM. Unpaired t 
tests used for comparisons. 
5 Lipoxygenase (5LOX), Leukotriene A4 hydrolase (LTA4H); 15 Lipoxygenase A (15 
LO-A) and 15 Lipoxygenase B (15 LO-B).  


















4.2. LIPOXIN FUNCTION IN HEALTHY VOLUNTEERS AND IN 
BRONCHIECTASIS PATIENTS 
 
4.2.1. Clinical parameters 
This study was done to assess the role of Lipoxin A4 on serum and airways neutrophil 
function in bronchiectasis patients, and compare it to its role on serum neutrophil 
function from healthy volunteers. A total of 40 study participants were recruited in the 
study- 34 bronchiectasis patients and 6 healthy volunteers. Of the 34 patients, 10 had 
mild, 15 had moderate and 9 had severe disease, as calculated by the bronchiectasis 
severity index. Several parameters were assessed to measure if diseases severity on 
the bronchiectasis severity index correlated to clinical and laboratory markers. There 
was no significant difference in age between the groups. There was a statistically 
significant higher values of total white cell count, neutrophil count and c- reactive 
protein, in the severe group compared to the other three groups. There was no 
difference in erythrocyte sedimentation rate across the groups, although there was a 
trend towards increasing ESR in the severe group. Lung function was measured in the 
bronchiectasis groups. There was a statistically significant lower values in the percent 
predicted forced expiratory volume in one second (FEV1), forced vital capacity (FVC)  
and transfer factor for the lung carbon monoxide (TLCO), with worsening lung 
function in the severe group. There were more antibiotic courses and hospital 
admissions required in the severe group compared to mild and moderate group. 
Analysis of the percentage of bacteria isolated in each group showed that there was a 
statistically significant difference between healthy and severe groups, mild and severe 
groups, but failed to reach statistical significance between moderate and severe 
groups. There was however no difference in the colony counts across the groups.  
 
4.2.2. Lipoxin and serum neutrophil function 
Peripheral blood neutrophils were isolated from all four groups. Phagocytosis and 
killing of GFP labeled Pseudomonas aeruginosa by peripheral neutrophils and the 
effect of Lipoxin A4 was measured. In the healthy group, there was a statistically 
significant improvement in phagocytosis by LXA4 in a dose dependent manner. There 
was a statistically significant improvement in phagocytosis by LXA4 in mild, 
moderate and severe bronchiectasis groups. In the healthy group, there was a 
statistically significant improvement in bacterial killing by LXA4 in a dose dependent 
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manner;. There was a statistically significant improvement in bacterial killing by 
LXA4 in mild, moderate and severe bronchiectasis groups.  
 
4.2.3. Lipoxin and airways neutrophil function 
Bronchoscopy was done and bronchoalveolar lavage fluid was obtained from two 
separate segments in the same patient- a segment affected by bronchiectasis and a 
segment unaffected by bronchiectasis. By this, patients were able to act as their own 
internal controls.  
 
Airway neutrophils were isolated from bronchoalveolar lavage fluid. There was no  
statistically significant difference in neutrophil counts in the bronchoalveolar lavage 
fluids obtained from the unaffected segments compared to the affected segments.  
 
In the unaffected segments, there was no statistically significant improvement in 
phagocytosis with LXA4 100nM in any of the groups. In the affected segments, there 
was a statistically significant improvement in phagocytosis by LXA4 100nM in the 
mild, moderate and severe bronchiectasis groups. 
 
In the unaffected segments, there was a statistically significant improvement in 
bacterial killing with LXA4 100nM in the severe group of patients only; p=0.02. In 
the affected segments, there was a statistically significant improvement in bacterial 
killing by LXA4 in the mild, moderate and severe bronchiectasis groups by LXA4 













4.2.4. Lipoxins, cytokines and cathelicidins in bronchiectasis 
Serum Lipoxin A4 levels were measured and statistically significant lower levels were 
detected in severe patients compared to healthy volunteers. There was no significant 
difference in lipoxin levels between mild and moderate disease and healthy 
volunteers.  
Inflammatory markers were measured in the bronchoalveolar lavage fluid. There was 
a statistically significant difference in myeloperoxidase and free neutrophil elastase 
across the groups, with higher levels detected in the severe group. There was a trend 
towards increase in the anti microbial cathelicidin LL-37 in severe patients, but this 
was not statistically significant.  
 
4.2.5. Lipidomics 
Lipidomics was done on serum and bronchoalveolar samples, as available. For 
analyzing the lipidomics- three groups were used- healthy, mild and moderate-severe 
bronchiectasis. Lipoxin A4, resolvins and maresins were not detected in any of the 
samples- in serum or lavage. In serum, significantly higher levels of PGE2, 15 HETE 
and LTB4 were detected in moderate- severe disease compared to healthy individuals. 
5 HETE land 9 HODE levels were higher in moderate to severe disease but not 
statistically significant.  
 
There were significantly higher levels of PGE2, 5-hydroxyeicosapentanoic acid 
(HETE) and 15 HETE in patients with severe disease compared to patients with mild 
disease and healthy volunteers. There were significantly higher levels of 9-
hydroxyoctadecadienoic acid (HODE) and LTB4 in severe patients compared to mild 
patients and healthy volunteers. 
 
Further sub analysis of lipidomics was done to assess if there was a difference in 
lipidomics between the affected and unaffected segments in the groups. Although, 
there was a trend towards increased levels of prostaglandin E2, 5HETE and 9HODE, 
and decreased levels of 15 HETE in the affected segments compared to the unaffected 
segments, none of these were statistically significant. LTB4 was detected in fewer 
samples and hence enough data sets were not available for a sub analysis.  
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What was very different in the levels of 5 HETE and 15 HETE detected was that there 
was an at least 100 fold higher level of these metabolites detected in serum compared 
to bronchoalveolar lavage fluid.  This indicates that these lipids are expressed in 
different quantities in different compartment of the body. Would gene expression be 
different in serum compared to bronchial cells? This needs to be explored further. 
 
4.2.6. Gene expression in bronchial brushings 
Gene expression of key lipoxin biosynthetic enzymes was measured in samples 
obtained from bronchial brushings. Statistically significantly higher ΔCt levels of 
5LOX, p=0.01 and 15LO-B, p=0.01 were detected in moderate-severe bronchiectasis 
patients compared to mild bronchiectasis, indicating decreased expression of these 
genes in bronchial brushings from moderate-severe patients. In addition, lower ΔCt 
levels of LTA4 hydrolase, p=0.007 were detected in severe bronchiectasis, compared 
to mild disease indicating higher gene expression of LTA4 hydrolase in moderate-
severe disease. There were lower levels of 15 LO-A in moderate-severe 
bronchiectasis compared to mild bronchiectasis although this was not statistically 
significant. The lowest ΔCt level was that of LTA4 hydrolase indicating it was the 
most abundant gene isolated in bronchial brushings from moderate-severe patients. 
The highest ΔCt level was of 15 LO-B indicating it was the least abundant gene 








5.1. PATIENT CHARACTERISTICS 
169 patients were included in the study. All patients were seen at baseline and one 
year later, whilst clinically stable. Patients were categorized in to mild, moderate and 
severe bronchiectasis severity, based on the BSI index. There were 61 patients with 
mild disease, 69 with moderate and 39 with severe bronchiectasis.  
 








Age 61 (1.4) 69 (1.1) 70 (1.4) 









































Asthma 23 (38%) 29 (42%) 17 (43%) 
COPD 4 (7%) 11 (16%) 9 (23%) 
IHD 13 (21%) 10 (14%) 9 (23%) 
Previous malignancy 5 (8%) 9 (13%) 3 (8%) 
Table 24. ABPA= allergic bronchopulmonary aspergillosis; COPD= chronic 




5.2. SERUM LIPOXIN A4 AND BRONCHIECTASIS  
 
5.2.1. At baseline 
Serum Lipoxin A4 from healthy volunteers was measured. The mean was 269.3 
pg/ml, with the lower 95% CI of 135 pg/ml. Based on these results, bronchiectasis 
patients in the stable state, with a serum level of LXA4 <135 pg/ml were taken as 
deficient in Lipoxin A4 and a value of ≥ 135 pg/ml was taken to be sufficient in LXA4 
(figure 103). Using unpaired t-tests (for all comparisons), at baseline, bronchiectasis 
patients deficient in serum LXA4 had more severe disease p=0.01 (as calculated by 
the Bronchiectasis severity index), had significantly higher serum levels of serum c-
reactive protein and erythrocyte sedimentation rate; p=0.04 and p=0.02 respectively. 
LXA4 deficient patients had higher levels of sputum myeloperoxidase and LTB4 
levels; p=0.01 and p=0.03 respectively, figure 104 a&b. In addition, LXA4 deficient 
patients had a worse quality of life, difference of 4units compared to LXA4 sufficient 
patients, as measured by the St. Georges Respiratory Questionnaire. Other parameters 











































































































































Table 25. Baseline inflammatory markers, quality of life and spirometry in lipoxin 
































Figure 104b.  
Figure 2. (a) CRP, ESR, LTB4 and MPO were significantly different at baseline 
between the deficient (N=95) and sufficient (N=74) patients. 
(b) BSI was significantly higher in the deficient group.  
Pooled data presented as mean ±SEM. Unpaired t –tests used for comparison. 
BSI= Bronchiectasis Severity Index; CRP= c reactive protein; ESR = erythrocyte 
sedimentation rate; LTB4 = Leukotriene B4; MPO= myeloperoxidase.  
5.2.2. Follow-up after 1 year 
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All 169 patients were followed up after 1 year and the same parameters were 
measured again to assess disease progression. Using unpaired t-tests, patients who 
were lipoxin sufficient, had lesser exacerbations requiring antibiotics (p=0.02) and 
significantly lesser amounts of LTB4 (p<0.0001) and myeloperoxidase (p<0.0001) in 
sputum, compared to lipoxin deficient patients; figure 105.  
 
 
Figure 105. Significantly lesser exacerbations, MPO and LTB4 were detected in the 
Lipoxin A4 sufficient patients after 1 year. Pooled data presented as mean ±SEM. 
Unpaired t –tests used for comparison. 
LTB4= Leukotriene B4; MPO= myeloperoxidase. 











5.3. SUMMARY OF LONGITUDINAL STUDY 
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This study was done to assess the role of lipoxin and its deficiency in bronchiectasis 
in a large cohort of bronchiectasis patients, over a year. 169 bronchiectasis patients 
were recruited into the study. All patients were reviewed at baseline and then after a 
year. Several parameters were checked at both time points including serum lipoxin 
A4, white cell count, c reactive protein, erythrocyte sedimentation rate, sputum 
inflammatory markers (myeloperoxidase, neutrophil elastase and interleukin 8), 
quality of life questionnaires and spirometry. Bronchiectasis severity index was 
calculated on all patients. Hospital admissions and antibiotic courses for 
bronchiectasis exacerbations only were also recorded. Serum lipoxin was measured in 
healthy volunteers and followed up longitudinally. Based on these results, 
bronchiectasis patients in the stable state, with a serum LXA4 level of LXA4 <135 
pg/ml were taken as deficient in Lipoxin A4 and a value of ≥ 135 pg/ml was taken to 
be sufficient in LXA4. Patients were categorized into lipoxin sufficient and deficient 
groups. At baseline, the LXA4 deficient group had more severe disease as calculated 
by the bronchiectasis severity index; significantly raised c reactive protein; 
erythrocyte sedimentation rate and sputum myeloperoxidase and LTB4 levels, 
compared to lipoxin sufficient patients. Patients with LXA4 deficiency had worse 
quality of life as measured by St. Georges Respiratory Questionnaire. There was no 
difference in forced expiratory volume in one second or forced vital capacity between 
the groups. There was no difference in hospital admissions or antibiotic courses 
required for exacerbations at baseline, between the groups.  
All patients were followed up after one year. On comparison of the two groups after 1 
year, the lipoxin sufficient group had lesser and fewer exacerbations needing 
antibiotic therapy. In addition, the lipoxin sufficient group had significantly lesser 
amounts of the pro inflammatory cytokine interleukin 8 and leukotriene B4 in sputum, 
indicating that lesser inflammation in the airways perhaps leads to fewer 








6.1. REPROGRAMMING OF BLOOD NEUTROPHILS IN 
BRONCHIECTASIS 
 
6.1.1. Are blood neutrophils reprogrammed in bronchiectasis? 
Neutrophils from bronchiectasis patients live longer and undergo less apoptosis 
compared to healthy volunteers. There was no difference in apoptosis between mild 
and severe bronchiectasis, suggesting that in bronchiectasis, peripheral blood 
neutrophils persist longer irrespective of disease severity. Given the number of 
neutrophils in bronchiectasis airways, late neutrophil apoptosis could have 
devastating consequences. Slowing neutrophil apoptosis would mean delayed removal 
by macrophages and thereby perpetuating the ongoing inflammation. To understand, 
if delayed apoptosis was a constitutive or adaptive defect, I investigated apoptosis by 
using serum from healthy volunteers. Delayed apoptosis was reversed by incubating 
neutrophils with serum from healthy volunteers- suggesting a constitutive defect 
rather than an acquired mechanism.  
 
In bronchiectasis, I have established that peripheral neutrophils have increased 
expression of CD11b, more shedding of CD62L, and increased release of 
myeloperoxidase in the stable state compared to healthy volunteers. Results from 
these neutrophil activation experiments demonstrate that in bronchiectasis, peripheral 
peripheral blood neutrophils are in a primed and pre activated state at all times, 
perhaps secondary to chronic and undetectable infection. All patients in this study had 
no infective exacerbation of bronchiectasis for at least 4 weeks prior to giving blood 
for this study. Hence, acute infection can be safely ruled out as a driver for 
inflammation in this study. Thereby, this study helps distinguish between ‘adaptive’ 
and ‘constitutive’ inflammation in bronchiectasis. I have established earlier in this 
thesis, that there is increased myeloperoxidase, interleukin 8, leukotriene B4 and 
neutrophil elastase in the airways in these patients. Do these pro inflammatory 
mediators lead to inflammatory reprogramming of neutrophils in bronchiectasis? It is 
known that inflammatory reprogramming of neutrophils lead to increased viability 
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(Chakravarti et al 2009). To my best knowledge, peripheral blood and airways 
neutrophils have not been studied in detail in the literature so far.  
 
Once I established that peripheral neutrophils are primed and pre activated in 
bronchiectasis, I wanted to assess what functional correlates this would have. These 
neutrophils showed a very characteristic profile. Super oxide generation was 
increased in both mild and severe patients compared to healthy volunteers at baseline, 
although this was not statistically significant. The ability of neutrophils to produce 
toxic oxygen radicals constitutes a major weapon against microbial intruders. This 
will be discussed in detail later in the next section. I found that neutrophils from 
healthy volunteers were able to phagocytose and kill bacteria, significantly higher 
when compared to neutrophils from bronchiectasis patients. Thus so far these 
‘reprogrammed’ neutrophils have demonstrated that despite being pre activated their 
ability to phagocytose and kill bacteria was lesser than that compared to healthy 
volunteers. This would thereby lead to persistent infection and inflammation in 
bronchiectasis.  Is there a failure in the resolution of inflammation in bronchiectasis 
leading to chronic inflammation? The neutrophils must “switch off” and be “buried” 
for the inflammation to resolve. I need to understand the biochemical pathways that 
can trigger the process of resolution of inflammation in bronchiectasis. Hence, there is 
a need for anti inflammatory and pro resolving mediators in bronchiectasis.  
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6.2. NEED FOR ANTI INFLAMMATORY AND PRORESOLUTION 
MEDIATOR IN BRONCHIECTASIS 
 
So far, I have established that in bronchiectasis, blood neutrophils are primed and are 
in a pre-activated state even in the stable state. These ‘reprogrammed’ neutrophils 
undergo delayed apoptosis, which contributes to the ongoing persistent inflammation.  
These neutrophils are more activated at baseline, with significantly higher CD62L 
shedding and CD11b upregulation. Additionally, these reprogrammed neutrophils 
degranulate to release significantly high levels of myeloperoxidase. This affects the 
functional ability of these neutrophils- lesser phagocytosis and killing of bacteria. I 
found that, airways neutrophils have lesser phagocytic and killing capacity than blood 
neutrophils. This would in part explain why there is persistent airways neutrophilic 
inflammation in bronchiectasis. Are airways neutrophils also reprogrammed in 
bronchiectasis? This is beyond the scope of this thesis and needs to be explored 
further.   
On comparing neutrophil function during exacerbations to stable state, I found that 
both in blood and airways neutrophils, there was higher bacterial phagocytosis and 
killing in the stable state than during exacerbations. Antibiotic therapy improves 
neutrophil function during exacerbations and restores it to its functional ability in the 
stable state.  
In community-acquired pneumonia, similarly, antibiotic therapy improved both 
bacterial phagocytosis and killing. However, there was significantly higher bacterial 
killing by neutrophils from healthy volunteers in community-acquired pneumonia 
than bronchiectasis, both at the start and end of infection.  
Reprogrammed neutrophils in bronchiectasis have lesser phagocytic and killing 
ability compared to healthy volunteers during exacerbations. This is perhaps 
secondary to their pre-activated state even in the stable state. I hypothesize that pro 
resolving and anti-inflammatory agents such as lipid mediators, administered in the 
stable state may improve neutrophil function during exacerbation. This would thereby 






6.2.1. Role of lipids in the inflammatory process: Oxidative lipid products 
including, notably, the products of unsaturated lipids are increasingly being 
recognized as important contributors to chronic inflammatory diseases (Bonnans and 
Levy 2007, Serhans et al 2007). The resolution of inflammation is a highly 
coordinated and active process that is controlled by endogenous ‘pro-resolving’ 
mediators (Gilroy et al 2004). Lipid mediators derived from arachidonic acid 
(lipoxins) (Serhan and Savill 2005, Serhan 2005, Samuelsson et al 2007) are known 
to regulate the inflammatory process and generate pro-inflammatory, anti-
inflammatory and pro-resolving mediators. Lipoxins display selective actions on 
leukocytes that include inhibition of polymorphonuclear neutrophils (PMN) 
chemotaxis (Levy et al 2001), inhibition of PMN adhesion to and transmigration 
through endothelial cells (Papayanni et al 1996), as well as inhibition of PMN-
mediated increases in vascular permeability. LXs are potent stimuli for peripheral 
blood monocytes, stimulating monocyte chemotaxis and adherence (Maddox and 
Serhan 1996), without causing degranulation or release of reactive oxygen species 
(Joszef et al 2002). More recently LX has been shown to attenuate release of cytokine 
[Interleukin (IL)-1β, IL-13, Interferon (IFN) gamma] and CXCL8 (Hachicha et al 
1999, Gronert et al 1998), eosinophil trafficking and stimulation of phagocytosis of 
apoptotic PMN in vitro (Godson et al 2000). 
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 6.3. LIPOXIN AND THE INFLAMMATORY PROCESS IN 
BRONCHIECTASIS 
 
6.3.1. Lipoxin and apoptosis 
Bronchiectasis is a neutrophilic condition where recurrent cough, excessive sputum 
production and recurrent chest infections are the key symptoms. Precise control of the 
neutrophil death program provides a balance between their defense functions and safe 
clearance, whereas impaired regulation of neutrophil death is thought to contribute to 
a wide range of inflammatory pathologies. Apoptosis is essential for neutrophil 
functional shutdown, removal of the emigrated neutrophils, and timely resolution of 
inflammation (Rossi et al 2006). Neutrophils receive survival and pro-apoptosis cues 
from the inflammatory microenvironment and integrate these signals through surface 
receptors and several downstream mechanisms. A complex network of intracellular 
death and survival pathways regulates neutrophil apoptosis and the balance of these 
pathways would ultimately determine the fate of neutrophils. Since neutrophils 
undergo apoptosis even in the absence of any extracellular stimuli, this type of death 
is called spontaneous or constitutive programed cell death (Savill et al 2002; Rossi et 
al 2006).  It has been demonstrated that during inflammation, extending the lifespan 
of neutrophils during transendothelial migration and at the sites of infection is critical 
for efficient destruction of pathogens (Watson et al 1997; Savill et al 2002; Nathan 
2006). Once this is achieved, neutrophils may undergo necrosis, apoptosis, NETosis 
(neutrophil extracellular trap cell death) (Brinkmann et al 2004; Fuchs et al 2007), or 
autophagy (Remijsen et al 2011) with the type of death profoundly affecting the 
outcome of the inflammatory response.  
 
Apoptotic neutrophil death in situ has multiple pro-resolution actions. In addition to 
be coming unresponsive to agonists and stopping the production of inflammatory 
mediators, apoptotic neutrophils can thereafter sequester cytokines (Ariel et al 2006; 
Ren et al 2008) and their phagocytosis by macrophages induces macrophage 
polarization from a pro-inflammatory (M1) to a pro-resolution (M2) phenotype 
(Fadok et al 1998). M2 macrophages secrete mediators, such as IL-10 and TGFb, 




In non-resolving inflammation, such as in bronchiectasis, it is speculated that 
neutrophils persist at the inflamed site and are liable to cause tissue destruction 
(Nathan and Ding, 2010; Soehnlein, 2010). Neutrophil recruitment may occur 
normally or may become excessive, but neutrophils persist as a result of delayed 
apoptosis or decreased clearance by macrophages (Haslett 1999; Savill et al 2002). 
The abnormal host response creates a persistent inflammatory microenvironment with 
ongoing release of inflammatory mediators and with it the damage-associated 
molecular patterns (Nathan and Ding 2010; Serhan 2011).  
 
6.3.2. Myeloperoxidase prolongs neutrophil life span and delays resolution of 
inflammation 
Acute elevation of plasma myeloperoxidase levels are known to prolong the life span 
of rat neutrophils by suppression of apoptosis as assayed ex vivo by Kebir et al. MPO 
also suppresses neutrophil apoptosis in a mouse model of carrageenan-induced lung 
injury and delays spontaneous self-resolution of pulmonary inflammation (El Kebir et 
al 2008). Thus, combined administration of carrageenan and MPO evokes persisting 
lung injury/inflammation with few airway neutrophil-exhibiting signs of apoptosis 
even 5 days post-injection, compared to complete resolution of pulmonary 
inflammation in the lungs of carrageenan-injected mice. The effects of MPO closely 
resemble those of zVAD-fmk, a pan-caspase inhibitor, which aggravates and prolongs 
carrageenan-elicited acute pleurisy (Rossi et al., 2006) and lung inflammation (El 
Kebir et al, 2008).  
 
Lipoxins exert multipronged actions to counter neutrophil responses to MPO. Down-
regulation of Mac-1 expression on neutrophils adhesion and transendothelial 
migration is one of the key components of the anti-inflammatory activities of LXA4 
and 15-epi-LXA4 (Serhan et al, 2008). 15- epi-LXA4 also prevents MPO-induced up-
regulation of Mac-1 expression and MPO release, thereby interrupting MPO-mediated 
autocrine/paracrine loop for perpetuation of the inflammatory response (El Kebir et 
al, 2009). Inhibition of neutrophil adhesion and transendothelial migration are 
important components of the anti-inflammatory activities of LXA4 and 15-epi-LXA4.  
 
Lipoxins themselves do not appear to interfere with the apoptotic machinery in 
neutrophils, whereas they can override the potent outside-in Mac-1-mediated survival 
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signal and redirect neutrophils to apoptosis in vitro (El Kebir et al, 2009). 15-epi-
LXA4 attenuates MPO-evoked ERK and Akt-mediated phosphorylation of the pro-
apoptotic protein Bad and decreases Mcl-1 expression, critical events in enhancing 
neutrophil apoptosis. Non-phosphorylated Bad associates with Mcl-1 and prevents its 
anti-apoptotic actions (Reed, 2006). These would aggravate mitochondrial 
dysfunction, ultimately leading to caspase-3 mediated cell death (El Kebir et al, 2009; 
Wardle et al, 2011). Treatment of mice with 15-epi-LXA4 at the peak of inflammation 
enhances resolution of carrageenan plus MPO-induced and E. coli septicemia-
associated acute lung injury and improves the survival rate (El Kebir et al, 2009). 15-
epi-LXA4 reduces pulmonary neutrophil accumulation with concomitant increases in 
the percentage of apoptotic neutrophils in the airways, facilitates recruitment of 
monocytes/macrophages and phagocytosis of apoptotic neutrophils and other cells (El 
Kebir et al, 2009), all of which is consistent with tissue repair (Godson et al, 2000; 
Mitchell et al, 2002). Furthermore, LXA4 released at sites of inflammation protects 
macrophages from apoptosis (Prieto et al, 2010). The beneficial actions of 15-epi-
LXA4 can be prevented in the presence of a pan-caspase inhibitor, thereby indicating 
the importance of neutrophil apoptosis in inflammatory resolution. 
 
In one of the sections of my study I have demonstrated the neutrophils have delayed 
apoptosis and live longer in bronchiectasis. I have also demonstrated that lipoxin was 
unable to modulate spontaneous or constitutive neutrophil apoptosis and this is in 
keeping with the current available literature. In addition, I have also demonstrated that 
there are significantly higher levels of myeloperoxidase detected in bronchiectasis 
patients. The raised myeloperoxidase levels could explain in part why there is 
prolonged survival of neutrophils in bronchiectasis and why lipoxin is unable to 
modulate spontaneous apoptosis. Is lipoxin able to modulate apoptosis in neutrophils 
isolated from bronchiectasis patients during infection, when there are several pro 
survival factors in the environment? This warrants further investigation.  
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6.4. LIPOXIN AND ITS FUNCTIONAL EFFECT ON BRONCHIECTASIS 
NEUTROPHILS 
In health, acute inflammatory responses in the lung are almost-daily occurrences that 
resolve swiftly. Most respiratory pathogens and noxious stimuli elicit an acute 
inflammatory response that again swiftly resolves. This immune response is critical 
for host defense, but it is equally important for the lung's inflammatory response to 
resolve in a timely manner. If unrestrained, acute respiratory distress syndrome can 
develop (Serhan and Savill 2005). If acute inflammation becomes chronic, then 
asthma, COPD or bronchiectasis can develop. Healthy resolution of inflammation is 
an active process that programs specific signals and cellular mechanisms to control 
the intensity and duration of acute inflammation. The past decade's discovery of 
resolution mediators and mechanisms is shining new light on the pathobiology of 
important chronic inflammatory diseases including bronchiectasis. At present, much 
more information is available on lipoxins than on other specialized pro resolving 
mediators (SPMs) such as protectins and maresins. SPM are rapidly formed and 
rapidly inactivated to serve as local autacoids to influence cellular responses (Serhan 
et al 2007).  
 
In my study, I demonstrated several key functions of lipoxins. Lipoxin A4 was not 
able to augment or inhibit spontaneous apoptosis in neutrophils from healthy 
volunteers or bronchiectasis patients. LXA4 was able to reduce fMLF induced 
activation of neutrophils in a dose dependent manner in all groups- measured by flow 
cytometry assessment of CD62L shedding and CD11b upregulation. In addition, 
LXA4 was able to reduce fMLF and cytochalasin B induced degranulation and release 
of myeloperoxidase, in a dose dependent manner. These anti-inflammatory functions 
of LXA4 have previously been demonstrated in the literature. However, this is the first 
time that the effects of lipoxins have been demonstrated on a subset of reprogrammed 
neutrophils. A head to head assessment with neutrophils from healthy volunteers has 
demonstrated that lipoxins are able to override the pre activated state in these 
neutrophils and are able to exert anti inflammatory actions. This needs to be explored 





Lipoxins have dual anti inflammatory and pro resolving functions. Key pro resolving 
actions include super oxide generation and microbial clearance. The enzyme system 
responsible for this respiratory burst, the NADPH-oxidase, functions as a transporter 
of electrons from NADPH on the cytosolic side of the membrane to oxygen on the 
other side. However, there are two pools of NADPH oxidase- one extracellular on the 
plasma membrane and the other on granules. Different agonists activate the two pools 
of NADPH oxidase differently, thereby suggesting that the signaling and molecular 
mechanisms for regulation differ depending on the localization of the oxidase 
(Dahlgren et al 1987, Watson 1991, Karlsson 1998). fMLF is a G protein coupled 
receptor and activation and activation of these receptors leads to extracellular release 
of superoxide anion. Lipoxin was able to reduce fMLF induced superoxide release in 
a dose dependent manner. In addition, neutrophils pre treated with lipoxin was able to 
increase phagocytosis of and killing bacteria. Generation of superoxide anions and 
bacterial clearance are key functions in the host defense as well as are important key 
steps in resolution of an inflammation. There is evidence from our studies that lipoxin 
is able to initiate both anti inflammatory and pro resolution activities in peripheral 
blood neutrophils from bronchiectasis patients.   
 
It might be argued that if lipoxin is able to reduce the respiratory burst and limit 
superoxide release, will this affect bacterial killing? Although ROS production is 
critical for the killing and degradation of internalized bacteria and particles, it can also 
contribute to inflammatory damage of host tissue. It is perhaps important to control 
the ‘collateral’ damage that superoxide generation does. I have assessed the effect of 
lipoxin on super oxide generation by fMLF and PMA. fMLF mimics oligopeptides 
produced by bacteria and PMA is a well known endogenous ROS producer. 
Activation of G-protein-coupled seven-transmembrane spanning cell surface 
receptors, such as the formyl peptide receptors, generates signals that lead to 
assembly of the NADPH-oxidase in the plasma membrane, releasing oxidants to the 
extracellular environment. That lipoxin is able to attenuate fMLF and PMA induced 
ROS production indicates that lipoxin perhaps attenuates only extracellular 
superoxide release. Further studies using chemiluminescense (isoluminol and 




6.5. LIPOXINS AND OTHER EICOSANOIDS IN BRONCHIECTASIS 
This is the first study where bronchoscopy has been done to study the effects of lipid 
mediators in bronchiectasis.  Lipoxin A4  has previously been studied in other airway 
diseases such as asthma and cystic fibrosis. Lipoxin A4 levels are decreased in severe 
asthma and cystic fibrosis. Bronchiectasis is characterized by recurrent chest 
infections and exacerbations. In this study, I have demonstrated that lipoxin A4 can 
modulate neutrophil phagocytosis of bacteria in a dose dependent manner, both in the 
airways and peripheral blood. In addition, lipoxin was able to enhance bacterial 
killing of GFP labeled bacteria in a dose dependent manner. In blood, lipoxin was 
able to restore phagocytosis and killing of GFP PAO1, back to levels comparable to 
healthy volunteers. This study thereby demonstrates that lipoxin A4 can potentially 
enhance bacterial clearance in bronchiectasis, when neutrophils are pre treated with 
Lipoxin A4. Perhaps, this translates into treating bronchiectasis patients with lipoxin 
in the stable state- prior to an infection to enable quicker clearance and resolution of 
infection? Lipoxin can perhaps be considered as an additive therapy to antibiotics to 
augment the process of resolution, during an infection. It is known that lipoxins 
influence host control of Mycobacterium tuberculosis, Toxoplasma gondii, 
Trypanosoma cruzi and Plasmodium berghei cerebral malaria in mice (Russell and 
Schwarze 2014). The role of lipoxin in bacterial infections needs to be explored 
further.  
 
Lipoxin A4, protectins or maresins were not detected in the bronchoalveolar lavage 
samples in bronchiectasis patients. This could be due to the volumes of samples that 
were analysed and perhaps larger volumes (lesser than 500µL that was used in this 
study) are needed for future studies. However, there were several intermediates in the 
lipoxin generation pathway that were detected in these bronchoalveolar lavage 
samples. There were statistically significant higher levels of PGE2, 15 HETE and 
LTB4 in serum and PGE2, 5HETE, 15 HETE 9-HODE and LTB4 levels 
bronchoalveolar lavage fluid, in the moderate-severe bronchiectasis group compared 
to the mild group. As all these metabolites are pro inflammatory mediators, and the 
fact that they remain high even in the stable state, these findings explain in part the 
why more moderate-severe bronchiectasis patients have a higher mortality rate and 
more hospital admissions compared to patients with mild disease. In severe disease, 
as per the bronchiectasis severity index, the 1-year outcomes are 7.6 % - 10.5 % for 
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mortality rate and between 16.7 - 52.6 % for hospitalisation rates.  The 4-year 
outcomes are between 9.9 - 29.2 % for mortality and between 41.2 - 80.4 % 
hospitalisation rates. This is almost 5-6 times higher than the mortality and hospital 
admission rates in patients with mild disease: 1 year outcomes: 0 - 2.8 % mortality 
rate, 0 - 3.4 % hospitalisation rate; 4 year outcomes: 0 - 5.3 % mortality rate, 0 - 9.2 
% hospitalisation rate (Chalmers et al 2014). LTB4 has been studied in bronchiectasis 
and is known to be one of the major chemotactic factors in the bronchial airways in 
bronchiectasis (Mikami et al 1998). Additionally, there is evidence to suggest that 
LTB4 is raised during an exacerbation and reduces with antibiotic therapy (Chalmers 
et al 2012). This is the first study demonstrating however, the role of other lipid 
mediators (including LTB4) in bronchiectasis. This part of the study suggests that 
lipid mediators play a key role in the ongoing inflammation both in the serum and in 
the airways in bronchiectasis patients and thereby necessitates further exploration in 
to the biochemical pathway of lipids and the mechanism by which they trigger the 
process of resolution.  
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 6.6. NETs AND LIPOXIN 
Increased levels of neutrophils lead to chronic neutrophilic inflammation, observed in 
bronchiectasis patients, mostly caused by chronic bacterial and viral infections 
enhanced by conditions favoring microbial growth. NET production, additionally 
promoted by bacterial infection in cystic fibrosis airways, is often ineffective in 
bacterial killing as was presented for Pseudomonas aeruginosa (Marcos et al 2010), 
and may facilitate bacterial airway colonisation and biofilm formation. In 
bronchiectasis, the liberated elastase (which I have demonstrated is significantly 
higher in bronchiectasis) as well as other proteolytic NET components can damage 
lung tissue and enhance the immune response by modulating the inflammatory 
factors. Neutrophil elastase cleaves endothelial actin cytoskeleton, E-cadherin and 
VE-cadherin, thereby increasing the permeability of the alveolar-capillary barrier. 
Moreover, neutrophil elastase induces apoptosis of epithelial cells and the release of 
proinflammatory cytokines (Saffarzadeh et al 2012). Other proteinases (PR3, 
cathepsin G) are able to regulate the inflammatory process by activating pro 
inflammatory and degrading anti-inflammatory proteins (Grommes & Soehnlein 
2011). The antimicrobial peptide LL-37, detected in NET structures (Urban et al 
2009), has cytotoxic and pro apoptotic properties directed towards endothelial and 
epithelial cells (Aarbiou et al 2006). In addition, ROS produced by MPO cause 
epithelial cell injury, which leads to apoptosis or necrosis (Grommes & Soehnlein, 
2011), besides ROS-promoted netosis (Nishinaka et al 2011). 
 
 
NETosis is a specific form of cell death different from apoptosis and necrosis. NET 
production by neutrophils plays an essential role in immune response to infection. The 
chromatin scaffold binds pathogens preventing their dissemination and limiting the 
inflammation area while the components of NETs very efficiently kill the trapped 
pathogens by oxidative and non-oxidative mechanisms (Yipp and Kubes 2013). 
Regardless of antimicrobial function, NETs participate also in many non-infectious 
diseases, autoimmune and inflammatory disorders, including chronic lung disease, 
sepsis, and vascular disorders. The increased auto reactivity towards NET constituents 
is a result of excessive netosis or diminished NET clearance (Ma and Kubes 2008). 
Although a range of biological events activating NET release is currently under 
excessive exploration, the mechanisms of its regulation are still unknown. It is 
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perhaps somewhat clear that there is excessive NETs formation in bronchiectasis and 
this in part contributes to the ongoing inflammation in this neutrophilic disease. While 
the mechanism by which lipoxin reduces NETs needs further investigation, it is 
encouraging that lipoxin is able to attenuate NETs formation in neutrophils isolated 
from individual during an infection, that have not be stimulated ex vivo.  
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6.7. REGULATION OF LIPIDS BY GENE EXPRESSION 
LTA4 hydrolase is a key enzyme in the lipoxin generation pathway. Sequential 
biosynthesis of eicosanoid classes in inflammatory exudates (termed “class 
switching”) directs the temporal progression of acute inflammation – right from 
initiation to propagation and finally to active resolution (Levy et al 2001). 
Prostaglandins initiate the inflammatory response. Leukotrienes follow and are 
typified by LTB4 which amplifies and propagates inflammation (Levy et al 2001). 
LTA4 hydrolase is a key enzyme in the class switching that metabolizes LTA4 to 
LTB4. In the absence of LTA4 hydrolase, LTA4 is metabolized to produce LXA4. 
Increased gene expression of LTA4 hydrolase in moderate-severe bronchiectasis 
patients indicates that there is higher levels of LTB4 in moderate-severe patients 
compared to LXA4. This is in keeping with our study findings where higher levels of 
LTB4 were found in serum and in bronchoalveolar lavage fluids in moderate-severe 
bronchiectasis patients.  
 
There were significantly lower levels of 15 LO-B and 5LOX genes expressed in 
moderate-severe bronchiectasis patients compared to mild patients. LXA4 is 
biosynthesised in the respiratory tract by transcellular cooperation of different cells- 
neutrophils (Chavis et al 1996), eosinophils (Serhan et al 1987), alveolar macrophages 
(Levy et al 1993) or airway epithelial cells (Claria et al 1996), each expressing 
different lipoxygenase (LO) enzymes (Haeggström JZ and Funk CD 2011). The 
neutrophil donates the LTA4 intermediate formed by the activity of 5LOX on 
arachidonic acid to the airways epithelial cells or alveolar macrophages whereby 15 
LO-A/B catalyses LXA4 formation. Additionally, airway epithelial cell or alveolar 
macrophage 15 LO-A/B activity catalyses the conversion of AA to 15(S)HETE which 
is donated to the acceptor neutrophil and converted to LXA4 by 5LOX (Levy et al 
2001, Claria et al 1996, Fiore and Serhan 1990). Hence, it is evident that 15-
Lipoxygenase plays a key role in the “eicosanoid mediator class switching.” 
Statistically significant lower levels of 15LO-B and 5 LOX genes detected in 
moderate-severe airways in bronchiectasis would mean that there are lower levels of 
15 and 5 lipoxygenase in moderate-severe airways. This would thereby lead to lesser 




Lower 15LO-B would necessarily lead to more LTA4 availability for LTA4 hydrolase 
to metabolize into LTB4 and thereby lesser production of LXA4. However, this is a 
complex system whereby a host of different enzymes produced by different cells act 
in a complex airways condition. Further studies in larger patient groups are needed to 




6.8. LONG TERM EFFECTS OF LIPOXINS 
This study elucidates that patients who are deficient in lipoxin A4 have more severe 
disease with higher levels of serum and sputum inflammatory markers compared to 
patients who are sufficient in lipoxin A4. Recent studies have established that disease 
severity in bronchiectasis, predicts mortality, hospital admissions, exacerbations, 
quality of life, respiratory symptoms, exercise capacity and lung function decline in 
bronchiectasis (McDonnell et al 2016). Lipoxin deficient patients had raised sputum 
LTB4 at the end of one year, remaining parameters remained stable. Interestingly, 
there were lesser antibiotic courses required in the lipoxin sufficient group in the one 
year follow up period and this was demonstrated in their sputum which detected lower 
levels of myeloperoxidase and interleukin 8.  This is a large study where several 
clinical parameters used to assess disease progression and severities were recorded. 
Lipoxins are the lead family in specialized pro resolving mediators, and have both 
anti inflammatory and pro resolution properties to stop acute inflammation. In 
bronchiectasis, there is chronic, unresolved and unremitting inflammation.  LXA4, 
LXB4, and their 15-epimers are active in doses ranging from picogram to nanogram. 
They are generated at sites of vascular inflammation and are known to down regulate 
neutrophil transmigration, vascular leakage, proinflammatory cytokine release and 
function, and inflammatory pain signals. When exogenous specialized pro resolving 
mediators are administered during experimental inflammation, they exert their 
protective actions in low-nanogram amounts (Serhan 2007). The capacity of these 
molecules to jump-start several aspects of resolution suggests intriguing 
pharmacological roles for them as potential biotemplates for the design of new 
therapeutics (Serhan 2007), some of which are the subject to ongoing clinical 
research. That lipoxin sufficient patients had more stable, less severe disease and 
lesser exacerbations requiring antibiotic courses can be explained in part due to the 









6.9. ANTI INFLAMMATORY AND PRO RESOLVING	
 
“Anti-inflammatory” and “pro resolving” do not have the same meaning, however. 
The definitions of these terms have important differences. Anti-inflammatory actions 
decrease granulocyte recruitment and activation, resulting in a predisposition to 
infection. Mediators with anti-inflammatory properties lead to decreased leukocyte: 
endothelial cell interactions, platelet aggregation, vascular permeability, and 
generation of reactive oxygen species from leucocytes. In sharp contrast, pro 
resolving actions activate tissue-resident cells to decrease vascular and tissue 
inflammation to restore organ function-a process termed catabasis to represent a 
return from the battle of inflammation. Mediators with pro resolving properties 
stimulate endothelial nitric oxide and prostacyclin release, mucosal epithelial 
expression of antimicrobial peptides, and macrophage phagocytosis, including 
efferocytosis, microbial clearance, removal of cellular debris and noxious stimuli such 
as antigens, and their cellular efflux to lymph nodes (Levy and Serhan 2014). These 
pro resolving actions increase tissue host defense either directly or indirectly via the 



















6.10. FUTURE DIRECTIONS 
 
In this thesis, I have addressed two important areas in bronchiectasis. I have 
demonstrated that blood neutrophils are reprogrammed in bronchiectasis and that lipid 
mediators are key regulators in the on going inflammatory process in bronchiectasis. 
Findings in this thesis suggest that lipoxin A4 can target one of the key arms of the 
vicious circle in bronchiectasis as shown in figure 106.  
The reprogrammed neutrophils remain pre activated in the stable state and are 
undergo lesser spontaneous apoptosis. These neutrophils tend to live longer. Through 
further studies, I have demonstrated that this is a constitutive defect. Why do 
neutrophils live longer in bronchiectasis? Do they inhibit caspase 3 and cause 
persistence of the neutrophils? Additionally these reprogrammed neutrophils release 
more myeloperoxidase and superoxide anions thereby contributing significantly to the 
ongoing inflammation in bronchiectasis. Persistence of these pre activated 
reprogrammed neutrophils can have deleterious effects in bronchiectasis. Despite 
being primed and activated, blood neutrophils from bronchiectasis patients had lesser 
killing ability than neutrophils from healthy volunteers. This is not desirable and 
explains in part why exacerbation in bronchiectasis need longer antibiotic therapy 
duration, compared to other infections. I also demonstrated that airways neutrophils 
have lesser phagocytic and bacterial killing ability than blood neutrophils, in 
bronchiectasis. Are airways neutrophils also reprogrammed in bronchiectasis? This 




Figure 106. Peripheral blood neutrophils are reprogrammed in bronchiectasis and 
Lipoxin A4 has key anti inflammatory and pro resolution effects in bronchiectasis.  
 
There is a dysregulation of the eicosanoids in bronchiectasis serum and airways. The 
key products studied were the omega 6 derivatives produced by the arachidonic acid 
pathway. Several mechanistic and functional studies have been done to demonstrate 
the efficacy of lipoxins in bronchiectasis. Lipoxin did not affect spontaneous or 
constitutive apoptosis. Could lipoxin affect apoptosis during an infection? Studies 
assessing the role of lipoxin on blood neutrophil apoptosis during an exacerbation 
would be interesting. Additionally, lipoxin was able to reduce superoxide generation 
from neutrophils. However, further studies are needed to assess if lipoxin affects intra 
cellular or extracellular superoxide generation. There is excessive myeloperoxidase in 
bronchiectasis and it is known that for super oxide generation, myeloperoxidase 
present in the azurophilic granules must fuse with the free radical in the same 
compartment. Does lipoxin inhibit the fusion by slowing down neutrophil 






From a clinical point of view, I was able to demonstrate that lipoxin sufficient patients 
did better and had lesser exacerbations when followed up after one year, compared to 
lipoxin deficient patients. Functionally, lipoxin was able to increase phagocytosis and 
bacterial killing across all groups of patients. This is desirable in bronchiectasis. 
Across the studies I have demonstrated the various anti inflammatory and pro 
resolving activity of lipoxin in bronchiectasis neutrophils, both in blood and in the 
airways. Should lipoxin be used as an adjunct to antibiotics during exacerbations or 
should they be administered in the stable state too? There is evidence in this thesis to 





In this thesis, I have demonstrated through different methods and techniques that there 
is failure of resolution of inflammation in bronchiectasis. There is on going persistent 
neutrophilic inflammation. Blood neutrophils are reprogrammed and persist longer in 
bronchiectasis. These reprogrammed neutrophils are the key contributors to the 
ongoing persistence of inflammation in bronchiectasis. This prolonged survival, made 
neutrophils primed and pre activated. These reprogrammed neutrophils were 
functionally different and produced higher levels of myeloperoxidase but had less 
phagocytic and bacterial killing ability. However, lipoxin was able to override the pro 
survival signals in these neutrophils. Although, lipoxin could not modulate 
spontaneous apoptosis, lipoxin was able to decrease neutrophil activation and 
degranulation and enhance their functional ability by enhancing neutrophil 
phagocytosis and bacterial killing.  
 
I have demonstrated that there is a dysregulation of lipid mediators in the blood as 
well as in the airways of bronchiectasis patients. There is more production of the pro 
inflammatory mediators and decreased production of the anti inflammatory and pro 
resolution mediators in bronchiectasis. This impairs the resolution process thereby 
perpetuating the vicious circle of infection-triggered inflammation. Decreased gene 
expression of 15 Lipoxygenase B and increased expression of LTA4 hydrolase in 
bronchial brushings demonstrated that in the airways, the direction of the arachidonic 
acid metabolism pathway is more steered towards production of leukotriene B4 and 
lesser production of lipoxin A4. Lipoxin overrides these proinflammatory signals and 
commences the resolution process by enhancing bacterial phagocytosis and killing, 
both in blood and in the airways. I demonstrated that patients that were deficient in 
lipoxin at baseline had higher levels of LTB4. LTB4 is one of the main 
chemoattractants in bronchiectasis, and key pro inflammatory signal.  
 
There is now evidence from this thesis, that blood neutrophils are reprogrammed in 
bronchiectasis and that there is an imbalance of lipids in bronchiectasis, which 
contributes to the persistence of inflammation. Further studies assessing if airways 
neutrophils are reprogrammed in neutrophils will be needed. Additionally, I need to 
investigate further, the mechanisms by which lipid mediators regulate the 
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AT A GLANCE COMMENTARY: 
 
Scientific knowledge on the subject 
Bronchiectasis is a predominantly neutrophilic airways disease and despite this, there is persistent 
airways infection leading to chronic inflammation. The are no studies that have assessed neutrophil 
phenotype and how this alters neutrophil function in bronchiectasis.  
 
What the study adds to the field 
This is the first study that demonstrates that there is a distinct subset of neutrophils that are 
reprogrammed in bronchiectasis. Bronchiectasis neutrophils have prolonged survival and delayed 
apoptosis. In stable bronchiectasis patients, blood neutrophils are pre-activated and reprogrammed 
leading to an inability to kill PAO1 as effectively as healthy controls or patients that have recovered 
from community acquired pneumonia, leading to persistent infection and inflammation. Blood 
neutrophil phagocytosis and killing of PAO1 are further impaired at start of exacerbations needing 
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Excessive neutrophilic airways inflammation is the central feature of bronchiectasis, but little is known 
about neutrophils in bronchiectasis. The aim of this study was to assess blood neutrophil phenotype in 
bronchiectasis patients both whilst stable and during exacerbations. 
 
Methods 
In the clinically-stable arm of this study were 8 healthy volunteers, 8 mild and 8 severe bronchiectasis. 
In addition, 6 severe bronchiectasis patients were compared with 6 community-acquired pneumonia 
patients at the start and end of an exacerbation. We assessed neutrophils for spontaneous apoptosis rate, 
cell surface marker expression, degranulation, reactive oxygen species generation, phagocytosis and 
killing of Pseudomonas aeruginosa (PAO1). In addition, blood neutrophil function was compared to 
airway neutrophil function in bronchiectasis. 
 
Results  
In stable bronchiectasis, compared to healthy volunteers, blood neutrophils had: significantly 
prolonged viability; delayed apoptosis; increased CD62L shedding; upregulated CD11b expression; 
increased myeloperoxidase release; impaired neutrophil phagocytosis and killing of PAO1. 
 
Bronchiectatic airway neutrophils had significantly lower bacterial phagocytosis and killing, than their 
matched autologous blood neutrophils. Both blood and airway neutrophil phagocytosis and killing was 
impaired at the start of an exacerbation and improved following antibiotic treatment.  
 
In pneumonia patients, there was a significant improvement in phagocytosis and killing after treatment 
with antibiotics. On comparing phagocytosis and killing during exacerbations in bronchiectasis to 
pneumonia patients, there was no difference in phagocytosis, but there was significantly increased 




In the stable state, in bronchiectasis, peripheral blood neutrophils are reprogrammed and have 
prolonged survival.This impairs their functional ability of bacterial phagocytosis and killing, thereby 






Excessive neutrophilic airways inflammation is the central feature of bronchiectasis. This paradoxically 
both promotes bacterial colonization and perpetuates damage to the airways creating a vicious circle of 
bacterial colonization and inflammation [1]. The acute inflammatory response is a protective 
mechanism that is evolved to eliminate invading organisms and should ideally be self-limiting and lead 
to complete resolution [2-4]. However, there is failure of resolution of inflammation in bronchiectasis, 
leading to irreversible damage and dilatation of the bronchial airways with loss of mucociliary 
function. The driver for persistent neutrophilic airways inflammation in bronchiectasis is unknown.  
 
The traditional definition of the neutrophil, is that it is an effector of acute inflammation, and is short 
lived, with lifespan being measured in hours, and having a predefined set of functions [5]. However, 
this concept has been developing primarily by studying blood neutrophils (before extravasation to the 
tissues). It is subject to challenge as evidence emerges that neutrophil lifespan is considerably 
prolonged in response to stimuli such as granulocyte-macrophage colony-stimulating factor (GM-
CSF), tumor necrosis factor-α (TNF-α), interleukins (ILs), interferons and bacterial products [6-10] 
with consequent functional significance. During inflammation, leukocytes leave the circulation, enter 
new environments, and are exposed to multiple factors, such as cytokines, endogenous growth factors 
and bacterial products. Indeed, the activity of infiltrating neutrophils has been closely linked to disease 
evolution in a variety of clinical conditions [11-12]. Thereby these cells contribute not only to acute 
inflammatory reactions, but also to the evolution of a variety of chronic inflammatory diseases.  
 
Despite being a predominantly neutrophilic disease, bronchiectasis results in patients having recurrent 
chest infections. In more severe bronchiectasis there are high levels of sputum myeloperoxidase, free 
elastase activity and chemo attractants such as interleukin 8, leukotriene B4 and C5a [7,8], contributing 
to the persistent neutrophilic airways inflammation. Watt and colleagues have shown there is prolonged 
airway neutrophil survival in bronchiectasis [10] with less airway neutrophil apoptosis. Is this 
consequent to the altered inflammatory milieu in bronchiectasis? How does this impact on neutrophil 
function? There have been no studies to date assessing and phenotyping blood neutrophil function in 
bronchiectasis. 
 
The aim of this study was to assess the phenotype of blood neutrophils in bronchiectasis patients whilst 





Three study groups were included. Study 1: all patients were in a stable state (no infective exacerbation 
of bronchiectasis for at least 4 weeks prior to giving blood for this study) and included 8 patients with 
mild bronchiectasis, 8 with severe bronchiectasis and 8 healthy volunteers. Bronchiectasis patients that 
took part in the study were not on any inhaled corticosteroids, long term antibiotics or 
immunosuppressive therapy. All participants had 60 mls of blood taken and underwent a bronchoscopy 
with a broncho-alveolar lavage targeted to the most affected segment with bronchiectasis. 
 
Study 2: Six severe bronchiectasis patients were recruited during an exacerbation requiring intravenous 
antibiotics and patients were reviewed at day 1 (start of antibiotic therapy) and day 14 (end of 
antibiotic therapy). All patients had 60 mls of blood taken and sputum induced on day 1 and day 14.  
 
Patients in study 2 were not the same patients as in study 1. 
 
Study 3: Six community acquired pneumonia patients were recruited and reviewed at day 1 (hospital 
admission) and day 5 (when stable following antibiotic therapy). All patients had blood taken at day 1 




The severity of bronchiectasis was based on the Bronchiectasis Severity Index (BSI) [13]. The BSI is a 
risk stratification tool for morbidity and mortality in bronchiectasis. The minimum score is 0 and the 
maximum score is 26. A score between 0-4 indicates mild disease; 5-8 indicates moderate disease and 
a score of >9 indicate severe disease. The BSI was calculated in all bronchiectasis patients taking part 
in the study.  
 
Consent 
Lothian Research Ethics Committee gave consent for the study, 10/S1402/33.  
 
Isolation of blood and airways neutrophils 
Freshly drawn blood was collected into 3.8% sodium citrate and granulocytes were subsequently 
isolated by dextran sedimentation and discontinuous Percoll gradient, as described [14].  
 
Sputum and bronchoalveolar lavage was washed, treated with sputolysin and airways neutrophils 
isolated (described in detail in online supplement). Anti CD16 antibodies (Abcam) were used to 
identify neutrophils by flow cytometry.  
 
Blood neutrophil apoptosis at 20 hours 
Freshly isolated blood neutrophils (at least 97% purity) was suspended at 10x106 cells/ml in Iscove's 
Modified Dulbecco's Media (IMDM) supplemented with 10% autologous serum and 
penicillin/streptomycin (1x). The assay was done on a 96 well flat-bottom plate. Following 20-hour 
incubation, apoptosis was examined by flow cytometry (Annexin-V (Roche) and propidium iodide 





Freshly isolated neutrophils were activated with N-Formyl-methionyl-leucyl-phenylalanine, (fMLF) or 
vehicle control. Anti CD62L (BD Pharmigen ™) and CD11b (Alexa Fluor®) antibodies were added and 
the samples analyzed by flow cytometry (BD FACS Calibur™) [15].  
 
Neutrophil degranulation and MPO measurement 
Neutrophils were activated with cytochalsin B (Sigma Aldrich) and fMLF (Sigma Aldrich). 
Supernatants were collected and stored at -80°C. We measured myeloperoxidase activity (Sigma 
Aldrich) [16] with a chromogenic substrate assay.  
 
Reactive oxygen species generation 
Freshly isolated blood neutrophils were loaded with dihydrorhodhamine (Sigma Aldrich). fMLF was 
added and superoxide release was measured by flow cytometry (BD FACS Calibur™) [15]. 
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Neutrophil phagocytosis of Green fluorescent protein (GFP) labeled Pseudomonas and killing 
GFP bacteria in the log phage were resuspended in PBS at a final concentration of 108 bacteria/ml. 
Following this, bacteria were opsonised with autologous serum for 1 hour at 37°C. The neutrophils 
(10x106 per condition) were then co-cultured with opsonised GFP PAO1 (1x108 bacteria per condition) 
and phagocytosis was measured by flow cytometry (BD FACS Calibur™) [17]. Cells were lysed with 
saponin (Sigma Aldrich, UK) before serial dilutions were plated out on Pseudomonas isolation agar. 




All patients in study 1 underwent a bronchoscopy. Patients were sedated with midazolam +/- fentanyl. 
Bronchoalveolar lavage was done and samples obtained for neutrophil studies. 
 
Inducing sputum 
Sputum was induced as per standard protocol using 3% saline [18]. 
 
Statistical analysis 
Flow cytometry analysis was performed using FlowJo v10.0.4 (Tree Star, Ashland, OR, USA). Results 
are presented as mean ± standard error of mean (SEM). Paired and unpaired t tests were used to 
compare two groups, where applicable. Data was analyzed by one-way ANOVA with a Bonferroni’s 
multiple comparison post hoc test (GraphPad Prism v6; GraphPad Software, La Jolla, CA, USA), when 





The groups examined, and the timepoints for collection of biological samples, in the three elements of 
this study are shown in Figure 1. 
 
Figure 1. The three groups recruited for this study.  
Study 1: All study participants – healthy volunteers, mild and severe bronchiectasis (no 
exacerbations for at least 4 weeks prior to taking part in the study) had blood obtained and 
underwent bronchoscopy.  
Study 2: Six severe bronchiectasis patients had blood and sputum obtained at the start (day 1) 
and end of antibiotic therapy (day 14). 
 Study 3: Six pneumonia patients had blood obtained at the start (day 1) and end of antibiotic 




Baseline demographics of the participants for Study 1 are shown in Table 1 (see online supplement 
Table E3 and E4, for baseline demographics of study 2&3 participants). In comparison to the patients 
with mild bronchiectasis, the severe group had significantly higher white cell counts, neutrophil counts 
and C reactive protein in blood; lower FEV1 % predicted, FVC % predicted and TLCO % predicted; 
higher rates of bacterial lung colonization; and a greater number of exacerbations and hospital 
admissions in the preceding year.  
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in the last year 
- 0 0.7 
(0.2) 
p=0.008 
Table 1. Baseline demographics of study participants. Results expressed as mean (SEM). Chronic 
colonization defined as at least two isolates of an organism whilst clinically stable, at least 3 months 
apart over 1 year [13,19]. CRP= c reactive protein; ESR= erythrocyte sedimentation rate; FEV1= 
forced expiratory volume in 1 sec; FVC= forced vital capacity; KCO= transfer coefficient; TLCO= 
transfer factor for the lung for carbon monoxide; WCC= white cell count. 
 
 
Blood neutrophil - spontaneous apoptosis  
 
Healthy blood neutrophils undergo well-described spontaneous apoptosis in culture; a process which 
can be altered by exposure to survival factors and by activation [19]. Blood neutrophils from both mild 
and severe bronchiectasis patients, in stable state, had greater viability, after 20 hours in culture, than 
healthy controls (p=0.002, p=0.005 respectively; figure 2). A correspondingly lower number of 
apoptotic neutrophils was observed (p=0.0003 for mild and p<0.0001 for severe), with no difference in 
the percentage of necrotic cells. The proportion of apoptotic neutrophils from severe bronchiectasis 
patients was reduced to ~50% of that of controls. There was no difference in the proportions of viable 
(p=0.4) or apoptotic cells (p=0.2) when comparing cells from mild and severe bronchiectasis patients. 
The effect was confirmed by light microscopic counting and assessment of total cell numbers 
demonstrated that these percentages were not skewed by an artefact of cell loss (data not shown). 
 
 
Figure 2. Blood neutrophils from mild and severe bronchiectasis patients survived longer and 
underwent less apoptosis when compared to healthy volunteers.  
Blood neutrophils from mild and severe bronchiectasis patients in a stable state and healthy volunteers 
were cultured for 20 hours and cell viability (AnnV-ve/ PI-ve), apoptosis (AnnV +ve/PI-ve) and 
necrosis (AnnV+ve PI+ve) were assessed by flow cytometry. (A) N=8 in each group; percentage of 
viable, apoptotic and necrotic neutrophils in each group; *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001. One-way ANOVA with Bonferroni’s correction for multiple comparisons used for all 3 
groups compared; comparing mild and severe bronchiectasis to healthy controls in viable, apoptotic 
and necrotic neutrophils (B)-(D) Representative flow cytometry plots and cytocentrifuge preparations 
at 20 hours (x1000 magnification). PI= propidium iodide. Black arrow: Dark pyknotic apoptotic 
nucleus. Grey arrow: multi lobulated viable nucleus. 
 
In order to determine whether disease-related factors in the autologous serum used in these cultures 
differentially impacted the rate of neutrophil apoptosis, serum swap studies were conducted 
(Supplementary Figures E1 and E2). Firstly, spontaneous apoptosis was assessed in neutrophils from 
bronchiectasis patients in the presence of serum from healthy volunteers. After 20 hours, there was a 
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significant reduction in the percentage of viable neutrophils when cultured in healthy control serum, as 
opposed to autologous serum (from 43.4% (±1.5) versus 50.7% (±3) respectively, p=0.02) and a 
significant increase in the percentage of apoptotic neutrophils (43% (±1.8) versus 38% (±2) 
respectively, p=0.02). There was no change in the percentage of necrotic neutrophils. In contrast, the 
nature of the serum used had no effect on the apoptosis of neutrophils from healthy volunteers   
These data raise that possibility that a factor in healthy serum, deficient in serum from bronchiectasis 
patients, can promote neutrophil apoptosis. However, the effect of serum was minimal compared to the 
overall disease-specific differences between the rates of spontaneous apoptosis of neutrophils, 
suggesting some level of reprogramming or activation of circulating blood neutrophils in 
bronchiectasis. 
 
Blood neutrophil  - cell surface expression of CD62L and CD11b  
To evaluate the baseline activation status of unstimulated blood neutrophils from stable bronchiectasis 
patients, surface expression of CD62L and CD11b were contrasted to heathy controls (figure 3). 
Surface expression of CD62L on neutrophils from mild and severe bronchiectasis patients was 
significantly lower than on healthy control neutrophils (p=0.04 and p=0.02 respectively). There was no 
difference between mild and severe bronchiectasis. Compatible with this, CD11b levels were 
significantly higher on neutrophils from severe bronchiectasis patients compared to healthy controls 
(p=0.01) and mild bronchiectasis (p=0.01), but in this case neutrophils from patients with mild 
bronchiectasis were unchanged compared to controls. 
 
Blood neutrophil - degranulation and reactive oxygen species generation  
To further evaluate the baseline activation status of blood neutrophils from stable bronchiectasis 
patients, myeloperoxidase (MPO) release from granules and superoxide generation were evaluated in 
unstimulated cells. A significantly higher level of MPO was detected in the supernatant of neutrophils 
from severe bronchiectasis patients, after 90 minutes in culture, compared to neutrophils from mild 
bronchiectasis patients (p=0.03) and healthy controls (p=0.04), with the latter two groups comparable. 
However, on comparison of superoxide release at baseline, there was no significant difference between 




Figure 3. Blood neutrophils from stable bronchiectasis patients are more activated in the 
unstimulated state than neutrophils from healthy volunteers.  
(A)-(B) Blood neutrophils were isolated and cell surface markers CD62L and CD11b were measured 
by flow cytometry, when unstimulated. N=8 in each group.  
(C) Blood neutrophils were isolated and MPO measured by chromogenic assay, when unstimulated. 
N=8 in each group.   
 (D) Blood neutrophils were isolated, loaded with dihydrorhodamine and spontaneous reactive oxygen 
species generation was measured by flow cytometry. N=8 in each group. 
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One-way ANOVA with Bonferroni’s correction for multiple comparisons used for all 4 experiments; 
A, C&D: comparison of severe and mild bronchiectasis to healthy volunteers (used as control); B: 
comparison of healthy volunteers and mild bronchiectasis to severe bronchiectasis (used as control). 
Pooled data expressed as mean ± SEM. 
 
Blood neutrophil - phagocytosis and killing of Pseudomonas aeruginosa 
Having determined baseline differences in parameters that suggest differential activation of blood 
neutrophils from stable bronchiectasis patients, their functional efficacy in uptake and killing of 
pathogens was evaluated using a GFP P. aeruginosa strain PAO1 (Figure 4). Cells were spun at 300g 
for 5 minutes, supernatants discarded to remove free bacteria, and then cells lysed before plating. 
Phagocytosis was confirmed with z-stacking using confocal microscopy. In separate experiments 
phagocytosis was blocked by doing the experiments at 4°C, which demonstrated that at 4°C bacteria 
were still bound to cells but not internalized (data not shown).  
Data was analysed by gating the overall phagocytosis first (figure 4a). There was no difference in the 
overall phagocytosis between the groups. Next, we gated the neutrophils that had taken up much higher 
number of bacteria, as indicated by the mean fluorescence (MFLI). This was done at 50% of the total 
phagocytosis and we called this high MFLI phagocytosis.  There was significantly higher phagocytosis 
(comparing only the high MFLI and not total phagocytosis) by blood neutrophils from healthy 
volunteers compared to those from bronchiectasis patients, both the mild and severe groups (p=0.04; 
p=0.02 respectively). There was no difference between mild and severe groups, p=0.4. Comparison of 
the subsequent neutrophil-mediated bacterial killing showed significantly lower numbers of bacteria 
following exposure to healthy control neutrophils when compared to neutrophils from patients with 
mild or severe bronchiectasis (p=0.006; p=0.0003 respectively). There was no difference between mild 
and severe groups, p=0.1. These data demonstrate that despite increased activation, neutrophils from 
the blood of bronchiectasis patients have impaired phagocytosis and killing capacity (figure 4). 
 
Figure 4. Impaired bacterial phagocytosis and killing by blood neutrophils from bronchiectasis 
patients compared to in healthy controls. 
Blood neutrophils were isolated and co cultured with autologous serum-opsonized GFP-labelled P. 
aeruginosa PAO1 (at a concentration of 108/ml) for 15 minutes. Bacterial phagocytosis was measured 
by flow cytometry and serial dilutions of lysed cells were plated on Pseudomonas isolation agar, with 
colony forming units (cfu) counted 24 hours after plating to assess killing. 
(A) Representative flow cytometry plot of phagocytosis, with high MFLI. Gates distinguish total cells 
having phagocytosed GFP-labelled bacteria, with “High MFL1 Phagocytosis”, indicating cells that had 
phagocytosed the most bacteria. (B) Pooled % neutrophil phagocytosis data, showing means +/- SEM 
of n=8 per group for Hi MFL1 gating. (C) Pooled bacterial killing in log scale units cfu/ml, data, 
showing median with IQR of n=8 per group. (B)-(C) One-way ANOVA with Bonferroni’s correction 
for multiple comparisons used for both experiments; with p values representing the comparison of 





Comparison of antibacterial function of blood and airways neutrophils from patients with 
bronchiectasis 
 
Having established differential function of blood neutrophils isolated from bronchiectasis patients as 
compared to healthy controls, the antibacterial function of bronchoalveolar lavage-derived airway 
neutrophils from these patients was then evaluated (figure 5). Significantly lower levels of bacterial 
phagocytosis were observed for bronchoalveolar lavage-isolated neutrophils, when compared to donor-
matched blood neutrophils, both from patients with mild and severe bronchiectasis (p<0.0001; 
p=0.0004 respectively). Comparison of the bacterial killing capacity showed a compatible significantly 
lower antibacterial function of bronchoalveolar lavage derived neutrophils compared to autologous 
blood neutrophils from the same patient, both in patients with mild and severe bronchiectasis (p=0.003; 
p=0.001 respectively). No differences between the antimicrobial functions of neutrophils from patients 
with mild and severe bronchiectasis was observed.  This demonstrates that bronchoalveolar lavage 
neutrophils have impaired function compared to blood neutrophils in bronchiectasis.  
 
Figure 5. Impaired antibacterial function of bronchoalveolar lavage (BAL) derived neutrophils 
compared to matched blood neutrophils from patients with mild and severe bronchiectasis.  
Neutrophils were isolated from BAL and blood from patients with mild and severe bronchiectasis, and 
co-cultured with serum-opsonized GFP PAO1 for 15 minutes (blood neutrophils) or 60 min (BAL 
neutrophils). Bacterial phagocytosis was measured by flow cytometry, and serial dilutions of lysed 
cells were plated on Pseudomonas isolation agar, with colony forming units (cfu) counted to assess 
killing. (A) Mild and (B) Severe bronchiectasis: Matched neutrophil phagocytosis data in blood and 
BAL derived neutrophils in the same patient; n=8 per group. (C) Mild and (D) Severe bronchiectasis: 
Matched bacterial killing in log scale units cfu/ml, in blood and BAL derived neutrophils in the same 
patient; n=8 per group. 2 way ANOVA showed no significant difference in the antibacterial activity 
between mild and severe bronchiectasis; p=0.2. **P<0.01; ***P<0.001; ****P<0.0001. 
 
Comparison of antibacterial function of blood neutrophils from patients with bronchiectasis in 
stable and exacerbation states 
 
The observation that blood neutrophils from patients with bronchiectasis had a higher baseline level of 
activation, with impaired antibacterial function, raised the question of the extent to which this might be 
further modulated by disease exacerbations. Matched samples collected from the same individuals at 
the beginning and end of an exacerbation were analysed, and compared to unmatched stable state 
controls. There was significantly higher bacterial phagocytosis by neutrophils collected at the end of an 
exacerbation compared those from the beginning of exacerbation (p=0.02). There was significantly 
more phagocytosis in the stable state compared to start of exacerbation, p=0.01. There was no 
difference in phagocytosis between the stable state and the end of exacerbation, p=0.9 (figure 6). 
	 325	
There was significantly higher killing at the end of exacerbation compared to beginning of 
exacerbation, p=0.03. There was significantly more killing in the stable state compared to start of 
exacerbation, p=0.02. There was no difference in bacterial killing between the stable state and the end 
of exacerbation, p=0.3. This demonstrates that blood neutrophil function is restored to levels 
comparable to the stable state in bronchiectasis, at the end of treatment of exacerbations.  
	
Figure 6. Phagocytosis and killing of bacteria by blood neutrophils significantly improves after 
antibiotic therapy in bronchiectasis. 
(A)-(B) N=8 in stable state and N=6 at the start and end of exacerbation. Blood neutrophils isolated 
and phagocytosis and killing of GFP PAO1 assessed as previously described. Unpaired t-tests for 
comparison of stable state to start and end of exacerbation and paired t-tests for comparison of start to 
end of exacerbation. Pooled data presented as mean ± SEM for phagocytosis data and median (IQR) 
for bacterial killing data.  
 
Phagocytosis and killing by sputum derived neutrophils during exacerbations and comparison to 
stable state  
 
Having established that blood neutrophil function improved after treatment with antibiotics, the extent 
to which sputum-derived neutrophils had a similar response was assessed. There was significantly 
higher phagocytosis at the end of exacerbation compared to cells from the same donor taken at the 
beginning, p=0.008. There was more phagocytosis in the stable state compared to start of exacerbation 
although this observation, between unmatched donors, failed to reach statistical significance, p=0.08. 
There was no difference in phagocytosis between the stable state and the end of exacerbation, p=0.1.	
There was significantly higher bacterial killing at the end of exacerbation compared to the beginning, 
p=0.02. There was more killing in the stable state compared to start of exacerbation p=0.02. There was 
no significant difference in killing between stable state and end of exacerbation, p=0.06, demonstrating 
that sputum neutrophil function is restored to stable state after treatment with antibiotics in 
exacerbations (figure 7). 
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Figure 7. Phagocytosis and killing of bacteria by airways neutrophils significantly improves after 
antibiotic therapy in bronchiectasis. 
(A)-(B) N=8 in stable state and N=6 at the start and end of exacerbation. Airway neutrophils isolated 
and phagocytosis and killing of GFP PAO1 assessed as previously described. Unpaired t-tests for 
comparison of stable state to start and end of exacerbation and paired t-tests for comparison of start to 
end of exacerbation. Pooled data presented as mean ± SEM for phagocytosis data and median (IQR) 
for bacterial killing data. 
 
 
COMMUNITY ACQUIRED PNEUMONIA 
 
Comparison of bronchietasis versus pneumonia 
In order to determine the disease specificity of the neutrophil phenotypes determined for individuals 
with bronchiectasis, 6 pneumonia patients (with no comorbidities) who were admitted to hospital, were 




Phagocytosis and killing of GFP PAO1 by blood neutrophils  
The phagocytic and antibacterial properties of matched blood neutrophils collected at the beginning 
and day 5 of treatment of pneumonia, from the same patients, were compared. There was significant 
improvement in phagocytosis (p=0.03) and killing (p=0.03) at the end of treatment in pneumonia 
patients.  
 
Comparison of phagocytosis by blood neutrophils collected in CAP and bronchiectasis exacerbation 
showed no statistically significant difference at the beginning (p=0.7) or end of infection (p=0.1), 
between the two conditions. This suggested that the phagocytosis phenotype may not be disease 
specific, but a more general consequence of severe infection. In contrast, there was significantly lower 
bacterial killing in patients with bronchiectasis both at the start (p=0.0007) and end of exacerbation 
(p=0.003). These data demonstrate a bronchiectasis-specific neutrophil bacterial killing defect, that 
may be exacerbated by impaired phagocytosis. Furthermore, at the end of bronchiectasis exacerbations 
treated with antibiotics, this remains highly impaired in comparison to neutrophils from healthy 
volunteers with a recent pneumonia 
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Figure 8. There is significantly higher bacterial killing at the start and end of pneumonia 
compared to bronchiectasis.  
(A)-(B) N=6 in each group. Blood neutrophils isolated and phagocytosis and killing of GFP PAO1 
assessed as previously described. Unpaired t-tests for all comparisons. Pooled data presented as mean ± 
SEM for phagocytosis data and median (IQR) for bacterial killing data. Bx= bronchiectasis; CAP = 




We studied the functional phenotype of blood neutrophils in mild and severe bronchiectasis and 
compared it to the activity of blood neutrophils isolated from healthy volunteers. In bronchiectasis 
patients, we also assessed the function of airways neutrophils and compared it to blood neutrophil 
function from the same patient. In addition, we studied neutrophil function during bronchiectasis 
exacerbations and compared it to neutrophil function in healthy patients admitted with community-
acquired pneumonia. The authors chose experiments with Pseudomonas aeruginosa, as this organism 
is associated with a worse outcome in bronchiectasis [13]. Future work investigating other pathogens in 
bronchiectasis is warranted.  
 
Blood neutrophils from bronchiectasis patients (both in mild and severe groups) had prolonged survival 
and delayed apoptosis when compared to healthy volunteers. Further studies demonstrated that when 
blood neutrophils from bronchiectasis patients were treated with serum from healthy volunteers, there 
was a reduction in viability and increased apoptosis in bronchiectasis neutrophils. However, the reverse 
was not true when treating healthy volunteers neutrophils with bronchiectasis serum. The overall effect 
of delayed apoptosis and prolonged survival of bronchiectasis neutrophils was more pronounced than 
the effect of serum swap. The reason for this remains to be determined, but the effect	was	minimal 
compared to the overall disease-specific differences between the rates of spontaneous apoptosis of 
neutrophils, suggesting some level of reprogramming or activation of circulating blood neutrophils in 
bronchiectasis. There was more CD62L shedding in mild and severe bronchiectasis compared to 
healthy volunteers. There was higher CD11b expression and myeloperoxidase release in severe 
bronchiectasis compared to healthy volunteers and mild bronchiectasis. There was no difference in 
reactive oxygen species generation in the three groups. There was significantly higher phagocytosis 
and bacterial killing of PAO1 in healthy volunteers compared to mild and severe bronchiectasis. 
Although the significantly higher proportion of females in the healthy volunteers group, compared to 
bronchiectasis patients, could be considered a minor limitation of this study, we have no reason to 
believe that this had any impact on the results of the study [20]. Studies have shown that older adults 
have impaired neutrophil migration that contributes to poorer outcomes during infection [21,22]. In this 
study, both in the stable state (healthy volunteers and bronchiectasis patients) and during exacerbations 
(pneumonia patients and severe bronchiectasis patients), there was no significant difference in the age 
of the study groups. 
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Having established that blood neutrophil phagocytosis and killing is impaired irrespective of disease 
severity, we wanted to explore whether airway neutrophil function was impaired. We demonstrated 
that phagocytosis and killing of PAO1 is impaired in airways neutrophils compared to blood 
neutrophils in both mild and severe bronchiectasis. Although the etiology of bronchiectasis is 
heterogeneous, to address this as a confounding factor, for the purpose of this study we included 
patients with idiopathic bronchiectasis only. Despite the neutrophils being preactivated, the phagocytic 
and bactericidal ability of blood and airways neutrophils is impaired (more marked in the airways) 
which suggests that the inflammatory milieu with myeloperoxidase and proteinase excess in patients 
with bronchiectasis is perhaps a contributory factor for this [8] leading to impaired function. It is 
known that inflammatory reprogramming of neutrophils leads to increased viability [23]. To the 
authors best knowledge airways neutrophil function in other disease such as COPD and cystic fibrosis 
conditions remain limited. Studies on broncho-alveolar lavage fluid neutrophils from other chronic 
lung diseases is warranted in the future. We hypothesize that airway neutrophils are also reprogrammed 
in bronchiectasis.  
 
In acute infective exacerbations of bronchiectasis, phagocytic and bactericidal activity of blood and 
airways neutrophil function improved with antibiotic therapy and was restored to levels comparable to 
the stable state. On comparison of bronchiectasis exacerbations and patients admitted with community-
acquired pneumonia, there was no difference in blood neutrophil phagocytosis between the two groups; 
there was however significantly higher bacterial killing of PAO1 at the start and end of infection in 
community-acquired pneumonia patients compared to bronchiectasis exacerbations. Indeed, even at the 
end of treatment with antibiotics during bronchiectasis exacerbations, although phagocytosis and 
killing ability of neutrophils are restored to stable state, it was still lesser than in patients recovered 
from community acquired pneumonia suggesting that even at the end of exacerbation, there is failure of 
resolution of inflammation in bronchiectasis. This is important, as reduced functional activity of 
neutrophils would mean slower and lesser clearance of bacteria in bronchiectasis. Reduced 
phagocytosis and killing was not secondary to anti-pseudomonal antibodies as only 25% were positive 
for P aeruginosa in the severe group and in sub-group analysis excluding P aeruginosa, killing was 
still impaired (data not shown). We hypothesize that this failure of resolution could be secondary to 




Bronchiectasis is a predominantly neutrophilic condition, where despite excess neutrophils, patients 
suffer daily cough, chronic sputum production and recurrent chest infections. The lung is continuously 
exposed to inhaled pathogen and it is the primary and secondary defense of the lung that maintains the 
microbiome of the lung. The excessive neutrophilic airways inflammation leads to damage of the 
bronchial wall and paradoxically promotes more airways inflammation and bacterial infection creating 
a vicious cycle [24, 1]. During natural resolution, polymorphonuclear neutrophils are required for 
antimicrobial defense [3], but these cells must then apoptose and are removed from the inflammatory 
site by macrophages [25]. Is this natural resolution impaired in bronchiectasis? There are no studies 
exploring the resolution mechanism in bronchiectasis or perhaps the lack of it, in the literature to date. 
 
Apoptotic neutrophil death in situ has multiple pro-resolution actions [26-28]. Bronchiectasis 
neutrophils live longer and undergo delayed apoptosis compared to healthy volunteers. Given the 
number of neutrophils in bronchiectasis airways, late neutrophil apoptosis could have devastating 
consequences. Slowing neutrophil apoptosis would mean delayed removal by macrophages and 
delaying the process of resolution, thereby perpetuating the ongoing inflammation. Vandivier and 
colleagues had previously demonstrated that neutrophil elastase cleaves phosphatidylyserine receptor 
on neutrophils in cystic fibrosis and bronchiectasis, thereby impairing its clearance by macrophages 
[29]. This along with the data from our study suggest that bronchiectasis neutrophils undergo an 
alternative method of cell death. Could this be  NETosis or secondary necrosis? It is known that 
inefficient clearance of apoptotic cells results in secondary necrosis of cells and exacerbation of the 
inflammatory response [30]. Recent studies have demonstrated that in cystic fibrosis, there is increased 
NETosis as these neutrophils engage less in apoptosis [31]. This needs to be studied further in 
bronchiectasis.    
 
  
Our studies demonstrate that bronchiectasis neutrophils are reprogrammed. There is emerging evidence 
of subpopulations of mature and immature neutrophils coexisting in the circulation performing 
	 329	
immunosuppressive or proinflammatory functions [32]. These have been identified as low-density 
neutrophils (LDNs) and are known to have phenotypic and functional heterogeneity [32]. LDNs have 
not been investigated in this study. Is there a release of chronic immature neutrophils in bronchiectasis 
or is there an imbalance between mature and immature neutrophils released? Antibiotics improve 
neutrophil function during exacerbations. However, neutrophils are preactivated even in the stable 
state. Do anti inflammatory or pro resolution mediators have a role as a long-term treatment in 
bronchiectasis? This needs to be investigated further.  
 
Overall, there was higher c-reactive protein, CD11b and myeloperoxidase generation in severe disease 
compared to mild disease. For the rest of the other parameters measured- there was no difference in 
viability, apoptosis, CD62L, reactive oxygen species generation, phagocytosis and killing between 
mild and severe groups. These suggest that the effect of the disease on peripheral blood neutrophil 
activity and function is more pronounced than disease severity. However, we accept that a limitation of 
the study is the size of the study and therefore further differences may have been found with a larger 
sample size. We accept that exacerbation data from the same patients in study 1 would be ideal but this 
is a technical difficulty. It was difficult to predict exacerbations in the stable patients and hence we 
recruited consecutive patients who had an exacerbation and presented to hospital. The data remains a 
valuable addition despite this. Another limitation is we assessed patients following 14 days of 
antibiotic therapy in bronchiectasis patients. A different time point was chosen for patients with 
pneumonia at day 5. All patients with pneumonia, were however clinically improved at day 5.  These 
time points were chosen to reflect end of antibiotic therapy.  
 
To the authors’ best knowledge, this is the first study demonstrating that peripheral blood neutrophils 
are reprogrammed in bronchiectasis. This is important preliminary work and would lead to further 
research in the area. Key future work would be to assess the airway neutrophil function. In this study, 
we have shown that in the vicious circle of infection and inflammation, the dynamics of cell death and 
clearance are not altered leading to overwhelming neutrophilic inflammation and thereby cytokine 





In the stable state, peripheral blood neutrophils are reprogrammed and persist longer in bronchiectasis. 
This impairs their functional ability of bacterial phagocytosis and killing, thereby perpetuating the 
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